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Abstract 
 Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized 
by deficits in social interaction and communication, and repetitive behavior and 
stereotypical interests. First we describe what is known about ASD risk factors, including 
genetic variants and environmental exposures, particularly during gestation (Chapter 1). 
Then we tested the hypothesis that prenatal exposure to maternal immune activation 
(MIA) increases the risk of ASD. In a prospective birth cohort (Boston Birth Cohort, 
BBC), we found that prenatal exposure to maternal fever, and not maternal genitourinary 
infections or influenza, is associated with an increased risk of ASD (Chapter 2). 
Electronic medical records (EMR) were used to identify children in the BBC with ASD 
or typical development. While reliance on EMR enables us to increase sample size 
compared to a traditional study that requires extensive research contact, it could lead to 
outcome misclassification. Here, we explored using Random Forests, a data mining and 
machine learning technique, and Latent Class Analysis, a probabilistic clustering method, 
to identify other EMR diagnosis codes that help predict a child’s ASD status (Chapter 3). 
These techniques were able to identify children with typical and atypical development in 
the BBC. 
 Finally, to further explore the potential biological consequences of prenatal 
exposure to MIA, we analyzed DNA methylation in the whole blood of 2-5 year old 
children in the Study to Explore Early Development (Chapter 4). We found one site in an 
intergenic region that was differentially methylated in children whose mothers contracted 
!ii
an infection shortly before they were conceived, and two sites in the genome (IQSEC1, 
EPS8L3) that were differentially methylated in children whose mother had an infection 
during her third trimester. While the differences in percent methylation were small in 
magnitude (<1% mean or median absolute difference), they were statistically significant 
after accounting for technical and biological sources of variation, including ancestry and 
ASD case status. 
 This dissertation contributes to our understanding of the role of MIA exposure 
during pregnancy in ASD risk, biological changes identified in early childhood associated 
with prenatal exposure to MIA, and suitable methods for conducting EMR-based 
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Chapter 1: Introduction 
1.1     Autism Spectrum Disorder  
1.1.1 Definition  
 Autism spectrum disorder (ASD) is characterized by deficits in social interaction 
and communication (both verbal and nonverbal), and repetitive behavior or stereotypical 
interests. ASD is increasingly common, with a prevalence in the United States of 1 in 68 
children (1 in 42 boys and 1 in 189 girls) as of 2012 (Christensen, Baio et al. 2016). ASD 
is by definition a heterogeneous disease, with communication deficits and repetitive 
behaviors existing on a spectrum; the causes of ASD may be as diverse as its different 
presentations, with evidence for strong genetic and environmental contributions to 
disease risk (Hallmayer, Cleveland et al. 2011, Persico and Napolioni 2013, Sandin, 
Lichtenstein et al. 2014). 
1.1.2 Etiology: genetics 
 The strong familial risk of ASD was first established through twin studies, 
comparing the autism concordance rate of dizygotic twins to monozygotic twins (Folstein 
and Rutter 1977, Steffenburg, Gillberg et al. 1989, Bailey, Le Couteur et al. 1995, 
Papadakis, Baltzis et al. 2011). Additionally, a high sibling recurrence risk has been 
demonstrated in families who already have a child diagnosed with ASD; the recurrence 
risk exists for a confirmed diagnosis of ASD, but also extends to a broader quantitative 
ASD phenotype. The sibling recurrence risk for a diagnosed ASD ranges from 10-20%, 
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but inheritance of quantitative traits related to ASD (primarily related to language or 
social communication) may extend to another 20% of siblings (Constantino, Zhang et al. 
2010, Ozonoff, Young et al. 2011).  
 The strong genetic risk for ASD may be due to inherited common variants, 
inherited rare variants, or de novo rare variants. In some cases, de novo genetic mutations, 
particularly those that disrupt a protein-coding gene, or de novo copy number variants 
appear to explain the genetic risk for an individual (Sebat, Lakshmi et al. 2007, Glessner, 
Wang et al. 2009, Sanders, Ercan-Sencicek et al. 2011, Iossifov, Ronemus et al. 2012, 
Neale, Kou et al. 2012, Sanders, Murtha et al. 2012). There may be particular sites across 
the genome, or “hot spots,” where rare de novo variants related to ASD risk 
independently arise more frequently than would be expected (Weiss, Shen et al. 2008). 
While in a few cases a specific genetic cause can be identified, ASD generally appears to 
be a polygenic disorder (Neale, Kou et al. 2012, O'Roak, Vives et al. 2012).  
 Although individually rare variants, particularly de novo variants, may be strongly 
associated with ASD, the additive effects of common variation probably explain much of 
the risk across a population, even though each common variant confers little risk by itself 
(Wang, Zhang et al. 2009, Anney, Klei et al. 2012, Klei, Sanders et al. 2012, Gaugler, 
Klei et al. 2014, Robinson, St Pourcain et al. 2016). One recent estimate suggests that the 
narrow-sense heritability (the ratio of additive genetic variance to the overall phenotypic 
variance) of ASD is approximately 50%, while the variance in liability due to rare, de 
novo variation is only 2.6% (Gaugler, Klei et al. 2014). Our understanding of the 
contribution of common variation to genetic ASD risk will improve as large 
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collaborations, such as that between the Psychiatric Genomics Consortium autism group 
(PGC-ASD) and the Danish iPsych project, increase our power to detect the common 
variants contributing to ASD risk (Robinson, St Pourcain et al. 2016). 
 While early twin studies estimated the genetic heritability of ASD to be as high as 
90%, work that has taken into account shared and non-shared environmental factors 
suggests that the variance in ASD liability is substantially affected by both environment 
and genetics (Taniai, Nishiyama et al. 2008, Hallmayer, Cleveland et al. 2011, Sandin, 
Lichtenstein et al. 2014). Environmental exposures may explain more than 50% of the 
individual variance in disease risk, and might be particularly important in settings with a 
low prevalence rate, such as in sporadic or simplex families with only one ASD case 
(Tick, Bolton et al. 2016). Indeed, even early twin studies noted significant differences in 
the rate of obstetric complications between ASD affected and unaffected twins; the 
incidence of complications could be related to abnormal fetal development and placental 
dysfunction, or may represent an early environmental exposure to perinatal stress 
(Steffenburg, Gillberg et al. 1989, Bailey, Le Couteur et al. 1995). 
1.1.3 Etiology: environment 
 Several demographic factors are strongly associated with ASD risk. Males are 
more commonly affected than females, at a ratio of approximately 4:1, though females 
with ASD are more likely to be severely affected and intellectually disabled (Werling and 
Geschwind 2013, Christensen, Baio et al. 2016). Ethnicity or ancestry may be related to 
ASD risk, with the highest prevalence observed among white rather than black or 
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Hispanic Americans as of 2012 (Christensen, Baio et al. 2016). In the US, foreign born 
mothers are also more likely to have children with ASD, as are more educated mothers 
(Guinchat, Thorsen et al. 2012, Dickerson, Rahbar et al. 2016). However, it is possible 
that the association with both race and education in the United States is related to 
socioeconomic status and services availability; social factors can influence the probability 
of ASD diagnosis (Mazumdar, Winter et al. 2013, Dickerson, Rahbar et al. 2016).   
 Increasing parental age (both maternal and paternal) is significantly associated 
with increased risk of ASD, as is being a young mother (Sandin, Schendel et al. 2016). 
There are several other pre- or peri-conception exposures that might be related to ASD 
risk. Studies have found that a short (<12 months between births) or long (≥72 months 
between births) inter-pregnancy interval is significantly associated with increased ASD 
risk in the child (Zerbo, Yoshida et al. 2015, Conde-Agudelo, Rosas-Bermudez et al. 
2016), while the use of folic acid supplements prior to conception and early in pregnancy 
is protective (Smith, Strutton et al. 1990, Schmidt, Tancredi et al. 2012, Gao, Sheng et al. 
2016). Maternal obesity and diabetes prior to pregnancy are also significantly associated 
with increased risk for ASD in the child (Li, Fallin et al. 2016). 
 A number of exposures during pregnancy have been implicated as potential risk 
factors for ASD later developing in the exposed fetus. These include dietary factors, such 
as folic acid supplementation as above or maternal vitamin D deficiency, which increases 
the risk of ASD with co-occurring intellectual disability (Magnusson, Lundberg et al. 
2016). Toxicant exposures during pregnancy that have been implicated in ASD risk 
include air pollution (Volk, Lurmann et al. 2013, Flores-Pajot, Ofner et al. 2016, Lam, 
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Sutton et al. 2016) and pesticides (Roberts, English et al. 2007, Shelton, Geraghty et al. 
2014, Lyall, Croen et al. 2017), while further work is needed to assess the risk associated 
with endocrine disrupting chemical exposure during pregnancy (Schmidt, Lyall et al. 
2014). The use of medications during pregnancy, such as acetaminophen (Avella-Garcia, 
Julvez et al. 2016, Liew, Ritz et al. 2016) and SSRIs (Croen, Grether et al. 2011, Rai, Lee 
et al. 2013, Harrington, Lee et al. 2014) has also been linked to ASD risk, though this 
research is complicated by the possibility of confounding by indication when assessing 
risk associated with medication use.   
 Pregnancy complications such as preeclampsia are also associated with increased 
ASD risk (Getahun, Fassett et al. 2017). Neonatal ASD risk factors include preterm birth 
or being born small for gestational age, planned cesarean section, low Apgar scores, or 
hyperbilirubinemia (neonatal jaundice) (Guinchat, Thorsen et al. 2012, Logan, Dammann 
et al. 2017). In particular, the risk for ASD increases as a child is born at a lower 
gestational age (Joseph, Korzeniewski et al. 2017). Respiratory stress and hypoxia at 
birth have also been identified as ASD risk factors (Froehlich-Santino, Londono Tobon et 
al. 2014).  
 There may also be postnatal factors related to ASD risk, though fewer significant 
associations have been found compared to preconception or prenatal exposures. Early life 
exposure to air pollution has been implicated in ASD risk (Volk, Lurmann et al. 2013, 
Flores-Pajot, Ofner et al. 2016). Respiratory infections may be increased in children with 
ASD, though this was not assessed prospectively (Hadjkacem, Ayadi et al. 2016); it is, 
however, consistent with animal models that have shown early postnatal inflammation to 
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be associated with ASD-like behavior and brain overgrowth (Pang, Dai et al. 2016). 
While childhood vaccinations were once postulated to be an early life exposure that 
increased ASD risk, extensive research has demonstrated that this is not the case 
(Peterson and Barbel 2013, American Academy of Pediatrics 2017).     
1.1.4 Prenatal exposures 
 Many of the identified environmental risk factors for ASD appear to act prior to or 
during pregnancy. It is plausible that exposures during pregnancy may alter 
neurodevelopment and increase disease risk (Rodier, Ingram et al. 1996, Rice and Barone 
2000, Schlotz and Phillips 2009, Marques, O'Connor et al. 2013, Lyall, Schmidt et al. 
2014), in part because children who will go on to be diagnosed with ASD may show 
differences in their behavioral and physical development very early in life. Children who 
will go on to be diagnosed with ASD may start to have an excessive increase in head 
circumference—evidence of brain overgrowth—as early as 1-2 months of age 
(Courchesne, Carper et al. 2003). Brain imaging directly shows this brain volume 
overgrowth, while a hyperexpansion of the cortical surface area can also be seen between 
6 and 12 months of age (Hazlett, Gu et al. 2017). Children with ASD may show 
differences in fine motor and grasping skills as early as six months old, as well as head 
lag, an indicator of poor postural control (Libertus, Sheperd et al. 2014, Flanagan, Landa 
et al. 2012). There may be differences in gene expression in young children who will later 
be diagnosed with ASD (Glatt, Tsuang et al. 2012, Pramparo, Pierce et al. 2015). Primary 
health care professionals can be trained to accurately recognize potential signs of ASD, 
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related to social attention and communication, as early as 8 months of age (Barbaro and 
Dissanayake 2010).  
 In summary, current evidence indicates that ASD is a developmental disease that 
begins very early in life, and likely during gestation, as a result of genetic liability, 
environmental exposures, and the interaction between the two (Bakulski, Singer et al. 
2014). Notably, because the prenatal period is a time where environmental exposures are 
most likely to influence later ASD development (Barouki, Gluckman et al. 2012, Stoner, 
Chow et al. 2014), this immediately suggests a population where timely interventions on 
environmental risk factors may act to decrease ASD incidence.  
 As described above, there are many potential prenatal exposures that could 
increase risk of autism in offspring (Gardener, Spiegelman et al. 2009). However, there is 
one significant risk factor that we have yet to mention: currently, a body of work from 
animal models and human epidemiological studies is coalescing to provide strong 
evidence that prenatal exposure to maternal immune activation (MIA) increases the risk 
of many different types of neurodevelopmental disorders (NDD), including autism. 
1.2     Maternal Immune Activation 
 Maternal Immune Activation (MIA) is a construct representing increased maternal 
immune activity during pregnancy, as the result of an infection, inflammatory symptoms 
such as fever, or autoimmune activity. In particular, this dissertation focuses on MIA from 
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infection and fever exposure during gestation, primarily because they are common 
exposures (Collier, Rasmussen et al. 2009), likely with a high population attributable risk 
for ASD. 
1.2.1 Congenital infections 
 One line of evidence is based on case reports of neurodevelopmental disease 
developing after congenital infections; autism was noted in some patients with congenital 
rubella (Chess 1971, Chess 1977, Chess, Fernandez et al. 1978, Chauhan, Sen et al. 
2016), cytomegalovirus (Yamashita, Fujimoto et al. 2003, Garofoli, Lombardi et al. 
2017), and herpes simplex virus (Ghaziuddin, Tsai et al. 1992). These early reports of 
increased prevalence of ASD in children with congenital infections led to further 
examination of the consequences of in utero infection exposure.   
1.2.2 Analogy to schizophrenia 
 There are a number of ecological studies showing association between 
schizophrenia and winter/spring birth, when pregnancy would overlap with flu season; 
this potential association has been validated in studies that more specifically looked at 
serologically confirmed influenza during pregnancy and schizophrenia development in 
the offspring (Brown, Begg et al. 2004). Several different birth cohort studies have 
demonstrated associations between schizophrenia and maternal infections with 
Toxoplasma gondii (Brown, Schaefer et al. 2005, Mortensen, Norgaard-Pedersen et al. 
2007) and herpes simplex virus type 2 (Buka, Tsuang et al. 2001a, Buka, Cannon et al. 
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2008). Elevated levels of maternal inflammatory mediators during pregnancy such as 
interleukin-8 (IL-8, renamed CXCL8) and tumor necrosis factor alpha (TNF-alpha) and 
the acute phase reactant C-reactive protein (CRP) are also associated with an increased 
risk of the exposed child developing schizophrenia (Buka, Tsuang et al. 2001b, Brown, 
Hooton et al. 2004, Canetta, Sourander et al. 2014). This work with maternal immune 
activation and schizophrenia serves as a proof of principle: in utero inflammation can 
alter neurodevelopment in ways that may not become clinically apparent until years after 
birth. Given the overlap of genetic and environmental risk factors for schizophrenia and 
autism (Meyer, Feldon et al. 2011), we are interested in the possibility that some of these 
same processes are involved in autism development. Evidence to support this hypothesis 
is accumulating from animal and human studies, as summarized below. 
1.2.3 Animal models 
 Animal models of maternal immune activation generally rely on either direct 
injection of infectious antigens or induction of a generalized inflammatory response, and 
show behavioral, hormonal, neuropathologic, and transcriptional abnormalities in 
exposed offspring in species from mice to monkeys (Iwata, Matsuzaki et al. 2010, Harvey 
and Boksa 2012). Behavioral abnormalities noted in mice after exposure to prenatal 
inflammation include decreased vocalizations when separated from their mother or in 
social interactions as adults; decreased sociability; and increased repetitive behaviors in 
marble-burying and self-grooming tests (Malkova, Yu et al. 2012, Schwartzer, Careaga et 
al. 2013). Behavioral abnormalities have also been seen in rhesus monkeys who were 
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exposed to MIA by experimentally triggered systemic inflammation. MIA exposed 
monkeys exhibited increased repetitive behaviors, decreased social affiliative behaviors, 
and abnormal gaze patterns in response to faces (Bauman, Iosif et al. 2014, Machado, 
Whitaker et al. 2015). Abnormalities in immune function, hormonal differences, and 
altered neurotransmitter levels have also been noted in mice exposed to MIA (Hsiao, 
McBride et al. 2012, Miller, Zhu et al. 2013, Ohkawara, Katsuyama et al. 2015). 
Impaired neuronal growth has been observed after exposure to MIA (Straley, Togher et al. 
2014). Cerebellar abnormalities or mild brain overgrowth after MIA exposure, closely 
mirroring what is seen in humans with ASD, have been detected as well (Shi, Smith et al. 
2009, Le Belle, Sperry et al. 2014). It appears that elevated levels of interleukin-6, a pro-
inflammatory cytokine, are required for the pathologic effects of MIA to manifest in 
exposed offspring (Smith, Li et al. 2007); this work has been extended to demonstrate 
that IL-6 works upstream of IL-17a, an effector cytokine that is released from specific T 
helper cells (TH17 cells) and is responsible for the abnormal cortical phenotype in MIA-
exposed mouse pups (Choi, Yim et al. 2016). The ability to induce MIA in experimental 
models independent of particular infectious antigens demonstrates that the negative 
effects of prenatal MIA are not directly caused by the infectious organism itself, but by 
the maternal immune response and systemic inflammation. In general, data derived from 
animal models consistently points to deranged neurodevelopment after exposure to MIA, 
in ways that are causally related to behavioral and pathologic changes seen in 
schizophrenia and autism. 
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1.2.4 Epidemiologic studies 
 Human observational studies have also demonstrated a relationship between 
inflammatory biomarkers during pregnancy and autism risk in the offspring. Amniotic 
fluid obtained during pregnancy was shown to differ in chemokine and cytokine levels 
between children who went on to develop ASD and those who did not; particularly 
striking is that even when controlling for maternal autoimmunity and history of infections 
during pregnancy, fetuses that went on to develop ASD after birth were exposed to 
significantly higher levels of TNF-alpha and TNF-beta (Abdallah, Larsen et al. 2012, 
Abdallah, Larsen et al. 2013). In a case-control study with access to archived maternal 
serum samples, mothers of children with ASD had significant elevations in mid-
pregnancy levels of interferon-gamma, IL-4, and IL-5 (Goines, Croen et al. 2011). A 
recent study found that mothers whose children developed ASD with intellectual 
disability had higher mid-gestational levels of granulocyte macrophage colony-
stimulating factor, interferon-gamma, interleukin-1alpha, and IL-6, compared to the mid-
gestational levels of mothers whose children were typically developing (Jones, Croen et 
al. 2017).  
 C-reactive protein (CRP) is an acute phase reactant that is often used as a clinical 
marker of significant systemic inflammation; a study of 677 ASD cases and 677 matched 
controls derived from the Finnish Maternity Cohort found a significant association 
between CRP during pregnancy and risk of the offspring developing ASD. Mothers in the 
highest quintile of CRP values had an OR of 1.43 [1.02-2.01] of their child developing 
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ASD as compared to mothers in the lowest quintile of CRP values (Brown, Sourander et 
al. 2014).  
 A study of all children born in Denmark from 1980 to 2005 (n = 1,612,342) took 
advantage of the ability to link the Danish Medical Birth Register, Danish Psychiatric 
Central Register, and Danish National Hospital Register to identify children whose 
mother was hospitalized with an infection while pregnant with them. A mother's 
admission to a hospital with a viral infection in her first trimester or a bacterial infection 
in her second trimester was significantly associated with ASD risk in the offspring 
(adjusted hazard ratio of 2.98 [95% CI 1.29-7.15] for viral infection in first trimester, and 
adjusted hazard ratio of 1.42 [1.80-1.87] for bacterial infection in the second trimester) 
(Atladottir, Thorsen et al. 2010). A study from the Danish National Birth Cohort (n = 
101,033) had self-reported infection, fever, and antibiotic use data, prospectively 
collected at 17 and 32 weeks gestation. They reported a significantly increased risk of 
ASD in children exposed to a prolonged period of maternal fever in utero (adjusted 
hazard ratio, 3.2 [1.8-5.6]). Similar to the 2010 study, they also found that maternal self-
report of influenza (a viral infection) during the first trimester was significantly 
associated with early-onset autism in the children (Atladottir, Henriksen et al. 2012). 
However, an HMO-based case-control study found no association between maternal 
influenza—defined by a medical record diagnosis of influenza or a positive influenza 
laboratory result—and risk of ASD (Zerbo, Iosif et al. 2013). A large autism case-control 
study in California with rigorously validated ASD outcomes confirmed the association 
between self-reported maternal fever during pregnancy and autism (OR 2.12 [1.17-3.84]) 
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and other developmental disabilities (OR 2.5 [1.20-5.20]). This association was 
attenuated in mothers who took anti-pyretic medications to control their fever, but 
remained elevated in mothers who did not (OR 2.55 [1.30-4.99]) (Zerbo, Iosif et al. 
2013). A nested case-control study using the Kaiser Permanente Northern California 
database found an association between hospitalization with an infection during pregnancy 
and increased ASD risk (adjusted OR 1.48 [1.07-2.04]), with the risk elevated to almost 
60% above baseline for those women hospitalized with a bacterial infection. This study 
also noted that having multiple hospitalizations for infections was associated with 
increased ASD risk (adjusted OR 1.36 [1.05-1.78]) (Zerbo, Qian et al. 2013). A large 
Swedish registry study (n = 2,371,403) demonstrated an association between maternal 
inpatient diagnosis of infection any time during pregnancy and ASD in the offspring (OR 
1.37 [1.28-1.47]). This analysis was robust to an assumption of residual confounding and 
persisted for all infection categories regardless of organism, infection site, or trimester of 
infection (Lee, Magnusson et al. 2014). A study in Taiwan using incident ASD cases and 
matched controls from a health insurance database found that two or more maternal 
outpatient visits for a genital infection (aOR 1.34 [1.12-1.60]) or bacterial infection (aOR 
1.25 [1.06-1.43]) during the third trimester of pregnancy was significantly associated 
with increased ASD risk (Fang, Wang et al. 2015). In a Norwegian birth cohort, high 
levels of IgG antibodies against herpes simplex virus-2 during midpregnancy was 
significantly associated with an increased risk of ASD, but only in male offspring (aOR 
2.07 [1.05-4.06]) (Mahic, Mjaaland et al. 2017). Finally, a recent meta-analysis found 
that any maternal infection during pregnancy was modestly associated with an increased 
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risk of ASD, and that this may be a stronger association in those hospitalized for an 
infection during pregnancy (Jiang, Xu et al. 2016). 
 There is also evidence that prenatal infections appear to increase autism severity 
in individuals who are otherwise genetically susceptible by virtue of pathologic copy 
number variations (Mazina, Gerdts et al. 2015). This is in concordance with earlier 
evidence that familial liability and exposure to prenatal infection interact to increase 
schizophrenia risk (Clarke, Tanskanen et al. 2009), suggesting that there may be classes 
of individuals who are particularly susceptible to the effects of prenatal MIA. 
1.3     Focus of this dissertation 
 With strong evidence for an association between MIA and neurodevelopmental 
disabilities in general and ASD specifically, further work to understand the biological 
consequences of prenatal exposure to MIA in humans is required. Infection and fever are 
both very common in pregnancy, with a prevalence of self-reported infection of 63.6% in 
one US cohort, and a prevalence of fever of 20.5% (Collier, Rasmussen et al. 2009). 
Understanding the consequences of prenatal infection and fever and their role in 
neurodevelopmental deficits is thus of clear public health importance. We are particularly 
interested in the role that epigenetics might play in either mediating or marking 
gestational infection exposure.  
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 Epigenetics is the study of DNA regulation that is mitotically heritable, or passed 
from one cell to its daughter cell; one type of epigenetic control is DNA methylation, 
where a methyl group added to a specific DNA nucleotide can influence the expression of 
a gene either locally or at-a-distance. These methyl marks on DNA can differ over time, 
across cell types, and in response to the environment. DNA methylation can be assayed 
across the genome with an affordable platform, the Illumina Infinium 
HumanMethylation450 BeadChip methylation array ("450k platform"), which queries the 
degree of methylation at 485,512 genetic loci (Bibikova, Barnes et al. 2011). Using this 
platform allows us to test for association of methylation at any measured locus with a 
phenotype of interest, in our case history of prenatal exposure to MIA (Chadwick, Sawa 
et al. 2015). Previous work using this technology has shown that prenatal insults can 
epigenetically alter offspring. For example, prenatal exposure to tobacco smoke changes 
a newborn's DNA methylation in a set of locations across the genome, which forms an 
epigenetic signature reflecting prior exposure (Breton, Byun et al. 2009, Joubert, Haberg 
et al. 2012). This epigenetic signature of prenatal smoking exposure actually persists 
through the first few years of childhood, and can be detected in children 3-5 years of age 
(Ladd-Acosta, Shu et al. 2016). Prenatal exposure to infection may also lead to 
observable epigenetic changes in exposed children.  
 There are already tantalizing clues that epigenetics will be able to explain aspects 
of autism etiology. Epigenetic differences have been observed in the brains of individuals 
with ASD compared to normal controls (Schanen 2006, Shulha, Cheung et al. 2012, 
Ladd-Acosta, Hansen et al. 2014, Nardone, Sams et al. 2014, Loke, Hannan et al. 2015). 
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These differences have been detected and replicated with independent technologies and 
across relevant neuroanatomic regions, including those associated with language and 
movement. Additionally, evidence demonstrating epigenetic differences in the brains of 
adolescent mice exposed to inflammation in utero has emerged (Basil, Li et al. 2014). 
Epigenetic differences were also present in the medial prefrontal cortex of adult mice 
who had been exposed to MIA during gestation, in both a candidate region and genome-
wide approach (Labouesse, Dong et al. 2015, Richetto, Massart et al. 2017). Similar 
changes might arise in the human brain, and lead to changes that are detectable in blood.  
 In summary, there is extensive evidence indicating that prenatal exposure to 
maternal immune activation (MIA), as a consequence of infection or fever, can play a 
role in the development of Autism Spectrum Disorder (ASD). In this dissertation, we 
estimate the association between MIA and ASD in a prospective birth cohort (Chapter 2) 
and a case-control study (Chapter 4), both in the United States. We also explore ways to 
improve ASD case identification in electronic medical records to assist future 
epidemiological studies of ASD risk factors (Chapter 3). We then conduct an Epigenome 
Wide Association Study (EWAS) to detect differential methylation in the peripheral blood 
of 2-5 year old children who were prenatally exposed to maternal infection (Chapter 4). 
Taken together, the work presented here extends research on the relationship between 
ASD risk and exposure to maternal immune activation. 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Chapter 2: Prenatal exposure to fever is associated 
with Autism Spectrum Disorder in the Boston 
Birth Cohort 
 This chapter describes work currently under revision at Autism Research, with 
contributions from co-authors Christine Ladd-Acosta, Mengying Li, Deanna Caruso, 
Xiumei Hong, Jamie Kaczaniuk, Elizabeth A. Stuart, M. Daniele Fallin, and Xiaobin 
Wang.  
2.1     Abstract 
 Autism Spectrum Disorder (ASD) is phenotypically and etiologically 
heterogeneous, with evidence for genetic and environmental contributions to disease risk. 
Research has focused on the prenatal period as a time when environmental exposures are 
likely to influence risk for ASD. Epidemiological studies have shown significant 
associations between prenatal exposure to maternal immune activation (MIA), caused by 
infections and fever, and ASD. However, due to differences in study design and exposure 
measurements no consistent patterns have emerged revealing specific times or type of 
MIA exposure that are most important to ASD risk. As well, no prior studies have 
examined prenatal MIA exposure and ASD risk in a predominantly under-represented 
minority population. To overcome these limitations we estimated the association between 
prenatal exposure to fever and maternal infections and ASD in a prospective birth cohort 
!17
of an understudied urban minority population in the United States. No association was 
found between prenatal exposure to genitourinary infections or influenza and the risk of 
ASD in a nested sample of 116 ASD cases and 988 typically developing controls in crude 
or adjusted analyses. Prenatal exposure to fever was associated with increased ASD risk 
(aOR = 2.02 [1.04 – 3.92]) after adjustment for educational attainment, marital status, 
race, child sex, maternal age, birth year, gestational age and maternal smoking. This 
effect may be specific to fever during the third trimester (aOR 2.70 [1.00 – 7.29]). Our 
findings provide a focus for future research efforts and ASD prevention strategies across 
diverse populations. 
2.2     Introduction 
 Autism spectrum disorder (ASD) is characterized by deficits in social interaction 
or communication and repetitive behavior or stereotypical interests. ASD is increasingly 
common, with a prevalence of 1 in 68 children (1 in 42 boys and 1 in 189 girls) as of 
2012 (Christensen et al. 2016). ASD is phenotypically and etiologically heterogeneous, 
with evidence for both genetic and environmental contributions to disease risk 
(Hallmayer et al. 2011, Persico et al. 2013, Sandin et al. 2014). Converging evidence 
points to the prenatal period as a time when environmental exposures are most likely to 
influence ASD risk (Rodier et al. 1996, Rice et al. 2000, Schlotz et al. 2009, Barouki et 
al. 2012, Marques et al. 2013, Lyall et al. 2014, Stoner et al. 2014). Identification of 
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modifiable ASD risk factors can lead to preventative intervention strategies that may 
reduce overall ASD burden. Studies to examine a broad range of environmental risk 
factors for ASD during this critical time window are now emerging.  
 There is a growing body of evidence suggesting prenatal exposure to maternal 
immune activation (MIA) and/or systemic inflammation increases the risk of many 
different types of neurodevelopmental disorders (NDD), including autism. Animal 
models of MIA have shown behavioral, hormonal, and neuropathologic differences 
among prenatally exposed offspring relative to their unexposed counterparts (Malkova et 
al. 2012, Miller et al. 2013, Schwartzer et al. 2013, Bauman et al. 2014, Machado et al. 
2015). In addition, MIA-associated differences in immune function (Hsiao et al. 2012), 
hormone and neurotransmitter levels (Miller et al. 2013, Ohkawara et al. 2015), neuronal 
and whole brain growth (Shi et al. 2009, Le Belle et al. 2014, Straley et al. 2014), as well 
as microglial neurodevelopmental regulatory patterns (Miller et al. 2013, Matcovitch-
Natan et al. 2016) have been found in animal models and are consistent with observations 
in humans with ASD. 
 Human studies have identified associations between prenatal exposure to maternal 
infection and ASD risk. Two European registry-based population studies and one US 
HMO-based case-control study have identified associations between maternal infection, 
bacterial or viral, during pregnancy and increased ASD risk in her offspring (Atladottir et 
al. 2010, Lee et al. 2015), with the highest elevated risk among women with multiple 
hospitalizations for infections or those with bacterial infections (Zerbo et al. 2015). One 
case-control study in Taiwan using medical record data found an elevated risk for ASD 
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after genital or bacterial infections (Fang et al. 2015). In addition, a study that assessed 
maternal exposure to infection by self-report, rather than medical records, showed 
potential risk effects for influenza (Atladottir et al. 2012), although a recent HMO-based 
cohort analysis did not observe such an association (Zerbo et al. 2017). A meta-analysis 
of 15 studies found an increase in ASD risk after any type of maternal infection (Jiang et 
al. 2016). 
 Fewer studies have examined the potential impact of fever specifically, rather than 
infection broadly, on ASD risk. One study found that prolonged febrile episodes were 
associated with increased risk (Atladottir et al. 2012). A retrospective case-control study 
based on maternal self-report showed association between fever during pregnancy and 
increased ASD risk (Zerbo et al. 2013). That study further showed that risk was 
attenuated in mothers who took anti-pyretic medications to control their fever, but 
remained elevated in mothers who did not (Zerbo et al. 2013). Fever exposure has also 
been shown to adversely influence developing fetal health more generally (Dreier et al. 
2014).   
 Effect sizes for associations between MIA exposure and ASD have been relatively 
modest; however, infection during pregnancy is common and thus can have a major 
impact on disease burden. The prevalence of self-reported infection during pregnancy in 
the US has been reported to be as high as 63.6%, and 20.5% for fever (Collier et al. 
2009). While studies to date suggest prenatal MIA as an important environmental risk 
factor for ASD, there remain several limitations with respect to study design, 
generalizability, time resolution, ability to examine specific infectious agents or organ 
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systems, and lack of inclusion of minority groups. While we were not able to address all 
of the limitations of the literature, here we overcome concerns associated with non-
diverse samples and retrospective exposure assessment by performing a prospective 
analysis of prenatal exposure to MIA and ASD risk in an under-represented minority birth 
cohort in the US.  
2.3     Methods 
2.3.1 Boston Birth Cohort (BBC) Study Description 
 Mother-child pairs were from the Boston Birth Cohort (BBC), a prospective birth 
cohort with pregnancy exposure, early life factors, and phenotypic data available for over 
8,000 mother-child dyads recruited at the Boston Medical Center (Wang et al. 2002, 
Wang et al. 2014). The BBC enrolls predominantly urban, low-income minority mothers 
and their children; the representative subsample examined in this study is approximately 
38% black/African American, 22% Hispanic, 19% Haitian, and 8.5% white (see Table 
2.1). The majority of BBC mothers are receiving health care through public assistance 
based insurance programs, e.g. Medicaid or MassHealth. The Boston Birth Cohort was 
established as the Molecular Epidemiology of Preterm Delivery in 1998 with the 
recruitment of women delivering at the Boston Medical Center (BMC), with 
oversampling for preterm birth. Women with a singleton live birth at the BMC are 
eligible for recruitment, with exclusions for IVF, multiple gestations, chromosomal 
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abnormalities, major birth defects, and preterm deliveries due to maternal trauma. As 
described in detail in Wang et al. (2002), participants are contacted 24-72 hours after birth 
to obtain consent and initiate study enrollment. Starting in 2002, child development was 
followed through electronic medical records for the subset of BBC children who received 
pediatric care at the Boston Medical Center (n=2992). At the time of recruitment into the 
BBC, each mother-child dyad is given a unique study ID that is linked to the electronic 
medical record identifiers for both the mother and child. 
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Table 2.1: Characteristics of the ASD case-control study sample 






Gravidity, M (SD) 2.79 (1.79) 2.85 (1.93) 0.701
Parity, M (SD) 1.04 (1.20) 0.96 (1.22) 0.491
Maternal agea, M (SD) 28.25 (6.55) 30.11 (6.24) 0.004*
Education, n (%) 0.281
Elementary school 41 (4.3) 4 (3.5)
Secondary school 238 (24.7) 21 (18.6)
High school/GED 333 (34.6) 40 (35.4)
Some college 203 (21.1) 33 (29.2)
College degree and above 148 (15.4) 15 (13.3)
Marital status, n (%) 0.570
Married 327 (34.0) 42 (37.5)
Not Married 661 (66.0) 74 (62.5)
Race or Ethnicityb, n (%) 0.472
Black 615 (62.2) 73 (62.9)
White 83 (8.4) 6 (5.2)
Hispanic 214 (21.7) 31 (26.7)
Asian 20 (2.0) 2 (1.7)
Other 56 (5.7) 4 (3.4)
Maternal smokingc, n (%) 0.179
Never 817 (85.1) 88 (78.6)
Some 48 (5.0) 9 (8.0)
Continuous 95 (9.9) 15 (13.4)
Child sex, n (%) <0.001*
Female 585 (59.2) 31 (26.7)
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ASD, autism spectrum disorder; BBC, Boston Birth Cohort; M, mean; SD, standard deviation 
a Maternal age at time of delivery  
b Black includes self reported Black, African American, Haitian, Cape Verdean, and Caribbean 
race and ethnicities. Asian includes Asian and Pacific Islander races. The Other category 
includes individuals with a mixed or other racial background. 
c Never smokers were defined as mothers with no history of smoking 6 months prior to 
conception or during pregnancy; some smoking includes mothers that smoked at some point in 
the window of 6 months prior to conception and through delivery but did not smoke throughout 
that window; continuous is defined as mothers that smoked starting 6 months prior to and 
throughout pregnancy.  
d Defined by sonogram 
* Denotes statistically significant 
2.3.2 Analytic Sample & Outcome Classification 
 We performed a case-control analysis of children with Autism Spectrum Disorder 
(ASD) and with neurotypical development. We used electronic medical record ICD-9-
CM diagnosis codes for pediatric inpatient, outpatient, and emergency room visits to the 
Boston Medical Center, between 1 October 2003 and 30 September 2015 (the last date 
before transition from ICD-9-CM to ICD-10-CM), to define ASD cases and neurotypical 
controls. Specifically, individuals were classified as an ASD case if their medical records 
contained any of the following ICD-9-CM codes, at least once: 299.00, 299.01, 299.80, 
299.81, 299.90, or 299.91. We classified individuals as neurotypical controls if they were 
Male 403 (40.8) 85 (73.3)
Gestational age, mean (SD)d 38.4 (2.7) 36.5 (4.6) <0.001*
Child Year of birth, M (SD) 2006.0 (3.8) 2006.4 (3.5) 0.279
Birth weight, n (%) 0.072
>2500 grams 763 (78.9) 81 (71.1)
<2500 grams  204 (21.1) 33 (28.9)
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never diagnosed with any of the following conditions: ASD, attention deficit 
hyperactivity disorder (ADHD), intellectual disability (ID), developmental delay (DD), 
oppositional defiant disorder (ODD) or other "emotional disturbances of childhood," 
conduct disorder (CD), or congenital anomalies (based on ICD-9-CM codes; see Table 
2.2).  
Table 2.2: ICD-9-CM code based definitions for ASD cases and 
typically developing controls in the Boston Birth Cohort, 2003 – 
2015 
2.3.3 Exposure Definitions 
 Enrolled BBC mothers were interviewed 24-72 hours after delivery using a 
standardized postpartum questionnaire to gather information about her pregnancy (Wang 
et al. 2014). Data on prenatal exposure to influenza, fever (excluding intrapartum), and 
ICD-9-CM codes N
ASD case definition 120
Inclusion criteria (any one of these codes): 299.0, 299.01, 299.8, 299.81, 
299.9, 299.91
Neurotypical control definition 1033
Exclusion criteria (any one of these codes):
ADHD 314.0 - 314.9
Conduct Disorder 312.0 - 312.9
Emotional disturbances of childhood 
or adolescence including 
Oppositional Defiant Disorder 313.0 - 313.9
Developmental Delay 315.0 - 315.9
Intellectual Disability 317 - 319
Congenital Anomalies 740 - 759.9
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genitourinary tract infections were obtained from self-report based on the questionnaire. 
In addition, history of an intrapartum fever (>38C) was abstracted from electronic 
medical record data by trained study personnel using a standardized form.  
 For each type of exposure examined, including prenatal genitourinary (GU) 
infections, prenatal influenza infection, maternal fever during pregnancy, and intrapartum 
maternal fever, we generated a dichotomous categorical variable representing “exposed” 
or “unexposed.” Children whose mothers responded ‘yes’ to having any vaginal or genital 
tract or urinary tract infections during this pregnancy (including yeast infections), any 
fever during this pregnancy, and any flu during this pregnancy were defined as “exposed” 
for GU, fever, and flu variables, respectively (Table 2.3). Similarly, dichotomous 
trimester-specific variables were derived for flu and fever exposures using trimester-
specific information among the subset of mothers that positively responded to having an 
exposure at any point during pregnancy. For intrapartum fever exposure, individuals were 
categorized as “exposed” if their mother had an intrapartum temperature > 38C, obtained 
via abstracted labor and delivery electronic medical records. 
!26
Table 2.3: Study questions about flu, fever, and infection exposure 
during pregnancy from the BMC Maternal at Postpartum 
questionnaire  
2.3.4 Covariate Definitions 
 Covariates used for adjustment included characteristics of the mother (educational 
attainment, marital status, race, pregnancy smoking status, age at delivery) and child (sex, 
birth year, gestational age at birth according to ultrasound dating). Educational 
attainment, marital status, race, and smoking during pregnancy were all self-reported in 
the postpartum questionnaire. Child sex was self-reported and confirmed in the abstracted 
medical records. Maternal age at the time of delivery was self-reported and confirmed 
based on mother’s date of birth recorded in her medical records. We defined gestational 
Question Answer
Did you have any flu during this pregnancy? Yes/no
a. First trimester Yes/no
b. Second trimester Yes/no
c. Third trimester Yes/no
Did you have any fever during this pregnancy? Yes/no
a. First trimester Yes/no
b. Second trimester Yes/no
c. Third trimester Yes/no
Did you have any vaginal or genital tract or 




Chlamydia, Gonorrhea, Syphilis, 
Trichomonas, GBS, BV, Yeast, Herpes, 
HPV, Other GT, Unknown GTI, 
Urinary Tract
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age at birth using dating from the first available ultrasound in the medical records (Wang 
et al. 2014). 
 We defined mothers’ educational attainment as a categorical variable (elementary 
school, secondary school, high school/GED, some college, or college/postgraduate 
degree) using the self-reported questionnaire data. Marital status was self-reported as 
married, single, divorced, separated, or widowed; this was dichotomized to “married” or 
“not married” for our analyses. Race was self-reported by checking one of the 9 
following categories that best reflected the respondent’s background: Black/African 
American; Asian; Pacific Islander; White; Haitian; Hispanic; Cape Verdean; Other; and 
Unknown. For our analyses, we then collapsed these responses into five categories to 
generate the race covariate: (1) Black, (2) White, (3) Hispanic, (4) Asian, and (5) all 
others. Black includes self-reported Black, African American, Haitian, Cape Verdean, and 
Caribbean race and ethnicities. White includes all individuals that reported white. Asian 
includes Asian and Pacific Islander races. The Other category includes all other 
backgrounds. Maternal smoking was a categorical covariate defined using self-reported 
data; never smokers were defined as mothers with no history of smoking 6 months prior 
to conception or during pregnancy. Mothers that smoked at any point in the 6 months 
prior to conception or at any point during their pregnancy were coded as “some 
smoking.” Continuous smokers were defined as mothers that smoked 6 months prior to 
conception and throughout their pregnancy.  
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2.3.5 Statistical Analyses 
 All data cleaning and analysis was performed with R-3.1.3. Summary tables of 
characteristics of ASD cases and controls, as well as exposed and unexposed, were 
created with the R package tableone (https://CRAN.R-project.org/package=tableone). 
Descriptive statistics for categorical variables were obtained with the function chisq.test() 
with continuity correction, and the function oneway.test() for continuous variables with 
an assumption of equal variance.  
 ASD odds ratios for MIA exposures were estimated via unadjusted and adjusted 
binomial logistic regression using R-3.1.3. For each of the 4 exposures (prenatal fever, 
flu, GU infection, and intrapartum fever) we performed independent analyses. Our final 
model was adjusted for socioeconomic status as represented by mothers’ educational 
attainment, marital status, and race, as well as for child sex, maternal age, child birth year 
and gestational age at birth, and maternal smoking during pregnancy. Beta coefficients 
from the logistic regression were transformed to obtain odds ratios for association with 
ASD outcome. A p-value < 0.05 was taken to be evidence for a statistically significant 
association. Forest plots were generated with the R package metafor (https://CRAN.R-
project.org/package=metafor). 
 To allow a cleaner comparison of exposed and unexposed groups and to better 
take confounding into account, we also conducted a propensity score analysis for 
exposure to fever. We matched individuals who were exposed to maternal fever any time 
during their gestation with those who were not exposed to fever by their propensity for 
exposure to fever, conditional on maternal age, smoking status, race, and educational and 
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marital status, as well as child sex, gestational age at birth, and year of birth, using the R 
package MatchIt (Ho et al. 2007, Ho et al. 2011); exposed individuals were matched to 
their nearest unexposed, with a caliper of 0.08 and a case:control ratio of 1:8.  
 Probabilistic sensitivity analyses for the effect of exposure misclassification were 
performed using the R package episensr (https://CRAN.R-project.org/package=episensr) 
and the function probsens(), which implements the quantitative bias methods described in 
Lash et al. 2009. We explored various prior probability distributions of the sensitivity and 
specificity for fever, including uniform and logit-normal. We also used the functions 
misclassification() and boot.bias() to empirically derive, with bootstrapping, estimates of 
the uncertainty in the OR for different models of sensitivity and specificity, including 
differential and non-differential exposure misclassification. 
2.4     Results 
2.4.1 Sample Description 
 Electronic medical records for 121,457 inpatient, outpatient, and emergency room 
visits to the Boston Medical Center (BMC) were available for children enrolled in the 
Boston Birth Cohort follow-up study. After 2,436 visits contributed by siblings were 
removed from the dataset, 118,939 records from 2,992 index children remained; these 
visits occurred between 1 October 2003 and 30 September 2015. On average each child 
had 39.8 visits to the BMC, with a range of 1 to 463 visits. 
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 120 ASD cases and 1033 neurotypical controls were identified in the dataset 
based on ICD-9-CM diagnoses, as described above. Mother-child pairs were constructed 
by linking maternal demographic data to child EMR data via a unique family-level study 
ID; 2 ASD cases and 22 controls were dropped at this stage. Then each mother-child pair 
was linked to questionnaire data on prenatal exposures via study ID. 23 controls and 2 
cases were removed, leaving 988 neurotypical controls and 116 cases before listwise 
deletion.  
 There was only limited correlation between the exposure variables (Table 2.4). 
The highest correlation was seen between reported exposure to influenza and reported 
exposure to fever (r = 0.31). 
 At this stage, there was a low prevalence of missing data in the covariates 
(ranging from 0% for maternal age and child sex and birth year, to 2.1% for maternal 
race, and 4.3% for gestational age) and exposures of interest (1.4% missing for 
genitourinary infections, 2.6% for fever any time during pregnancy, 2.7% for flu any time 
during pregnancy, and 8.4% for intrapartum fever). We handled missingness by listwise 
deletion—removing a subject from further analysis if they were missing data—for each 
exposure and the set of covariates included in the final model (maternal education, 
marital status, race, age, and pregnancy smoking status; child sex, birth year, and 
gestational age at birth) (Table 2.5). 
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Table 2.4: Pearson's product-moment correlation between exposure 
variables 
Table 2.5: Sample sizes remaining after listwise deletion for each 
exposure model 







(I, T1) 0.027 0.48 1
Trimester 2 
(I, T2) 0.022 0.60 0.092 1
Trimester 3 
(I, T3) -0.038 0.65 0.14 0.095 1
Intrapartum 
fever 0.037 0.013 0.015 0.0023 0.041 1
Fever 0.034 0.31 0.18 0.17 0.13 -0.021 1
Trimester 1 
(F, T1) 0.029 0.13 0.32 -0.052 0.018 -0.022 0.58 1
Trimester 2 
(F, T2) 0.033 0.24 -0.016 0.39 -0.016 -0.045 0.57 0.029 1
Trimester 3 
(F, T3) 0.029 0.16 0.055 -0.052 0.24 0.031 0.58 0.058 -0.0014 1
exposure categories neurotypical controls ASD cases
GU infections 890 101
Influenza, any time during pregnancy 884 101
Influenza, trimester-specific 881 101
Fever, any time during pregnancy 884 101
Fever, trimester-specific 881 101
Intrapartum fever 843 95
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 Individuals in the final analytic sample and those removed by listwise deletion 
differed significantly by average year of birth. Specifically, for analysis of prenatal 
exposure to fever at any time during gestation, those retained in our analytic sample were 
born in 2006, on average, and those removed from the final analytic dataset were born in 
2004, on average (p = 0.001). Otherwise, there were no significant differences between 
individuals retained for further analysis and those removed due to missing data (Table 
2.6). 
 As expected, we observed significant associations between known autism 
spectrum disorder (ASD) risk factors including child male sex, increased maternal age, 
and lower gestational age in the Boston Birth Cohort (BBC) sample (Table 2.1). No 
significant ASD case-control differences were observed for maternal gravidity, parity, 
education, marital status, race/ethnicity, smoking status, or child birth weight or birth year 
(Table 2.1). 
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Table 2.6: Characteristics of mother-child pairs in the Boston Birth 
Cohort (BBC) who were missing data for prenatal exposure to 
fever at any time during pregnancy; 2.6% of the sample was 








ASD diagnosis, n (%) 0% 0.528
no 884 (89.7) 104 (87.4)
yes 101 (10.3) 15 (12.6)
Maternal agea, M (SD) 0% 28.46 (6.54) 28.29 (6.59) 0.780
Child year of birth, M (SD) 0% 2006.18 (3.52) 2004.93 (5.48) 0.001*
Education, n (%) 2.5% 0.853
Elementary school 40 (4.1) 5 (5.5)
Secondary school 240 (24.4) 19 (20.9)
High school/GED 339 (34.4) 34 (37.4)
Some college 215 (21.8) 21 (23.1)
College degree and above 151 (15.3) 12 (13.2)
Marital status, n (%) 2.6% 0.138
Married 640 (65.0) 66 (73.3)
Not Married 345 (35.0) 24 (26.7)
Race or Ethnicityb, n (%) 2.1% 0.563
Black 605 (61.4) 60 (62.5)
White 84 (8.5) 5 (5.2)
Hispanic 219 (22.2) 26 (27.1)
Asian 21 (2.1) 1 (1.0)
Other 56 (5.7) 4 (4.2)
Maternal smokingc, n (%) 2.9% 0.788
Never 833 (84.6) 72 (82.8)
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ASD, autism spectrum disorder; BBC, Boston Birth Cohort; M, mean; SD, standard deviation 
a Maternal age at time of delivery  
b Black includes self reported Black, African American, Haitian, Cape Verdean, and Caribbean 
race and ethnicities. Asian includes Asian and Pacific Islander races. The Other category 
includes individuals with a mixed or other racial background. 
c Never smokers were defined as mothers with no history of smoking 6 months prior to 
conception or during pregnancy; some smoking includes mothers that smoked at some point in 
the window of 6 months prior to conception and through delivery but did not smoke throughout 
that window; continuous is defined as mothers that smoked starting 6 months prior to and 
throughout pregnancy.  
d Defined by sonogram 
* Denotes statistically significant 
Some 51 (5.2) 6 (6.9)
Continuous 101 (10.3) 9 (10.3)
Child sex, n (%) 0% 0.984
Female 549 (55.7) 67 (56.3)
Male 436 (44.3) 52 (43.7)
Gestational age, mean (SD)d 4.3% 38.22 (3.03) 37.97 (3.13) 0.504
Birth weight, n (%) 2.1%
>2500 grams 215 (21.8) 22 (22.9) 0.907
<2500 grams  770 (78.2) 74 (77.1)
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2.4.2 Prenatal Exposure to Genitourinary Infection and ASD Risk 
 No association was found between self-reported maternal history of genitourinary 
(GU) infections at any time during pregnancy and risk of ASD development in the 
offspring in an unadjusted model (OR 0.83 [95% confidence interval 0.52 – 1.32]; Table 
2.7). Similarly, no significant association was observed after adjusting for child sex, 
maternal age, child birth year, maternal smoking status, maternal education, marital 
status, maternal race, and gestational age (aOR 0.69 [0.42 – 1.14]; Figure 2.1 and Table 
2.7). Our findings in the BBC sample are consistent with three prior studies (Atladottir 
2010, Lee 2015, Fang 2015) that also examined prenatal exposure to GU infections and 
ASD risk (Figure 2.2). 
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Table 2.7: Odds ratios and 95% confidence intervals for the 
association between all tested exposures and ASD in the Boston 
Birth Cohort 
Odds ratios and 95% confidence interval for the association between prenatal GU 
infection, flu (overall and by trimester), and fever (overall, by trimester, and intrapartum 
only) exposure for unadjusted and fully adjusted models (adjusted for child sex, 
maternal age, birth year, maternal smoking, education, marital status, race, gestational 
age). All exposure information was obtained by maternal self report 24-72 hours after 
delivery; with the exception of intrapartum fever > 38C, which was extracted from labor 
and delivery records. 
exposure categories OR [95% CI]
GU infections, unadjusted 0.83 [0.52 - 1.32]
GU infections, adjusted 0.69 [0.42 - 1.14]
Influenza, unadjusted 1.14 [0.69 - 1.89]
Influenza, adjusted 1.17 [0.67 - 2.05]
in first trimester, unadjusted 0.88 [0.34 - 2.27]
in first trimester, adjusted 0.93 [0.33 - 2.59]
in second trimester, unadjusted 1.69 [0.88 - 3.25]
in second trimester, adjusted 1.34 [0.65 - 2.77]
in third trimester, unadjusted 0.83 [0.39 - 1.76]
in third trimester, adjusted 0.95 [0.42 - 2.12]
Intrapartum fever, unadjusted 0.52 [0.16 - 1.69]
Intrapartum fever, adjusted 0.60 [0.18 - 2.02]
Any fever, unadjusted 1.80 [0.99 - 3.27]
Any fever, adjusted 2.02 [1.04 - 3.92]
in first trimester, unadjusted 1.21 [0.42 - 3.52]
in first trimester, adjusted 1.86 [0.61 - 5.73]
in second trimester, unadjusted 2.26 [0.90 - 5.66]
in second trimester, adjusted 1.62 [0.58 - 4.52]
in third trimester, unadjusted 2.00 [0.80 - 4.96]
in third trimester, adjusted 2.70 [1.00 - 7.29]
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Figure 2.1: Forest plot showing adjusted odds ratio (OR) and 95% confidence intervals 
for the association between prenatal GU infection, flu (overall and trimester-specific), 
and fever (overall, trimester-specific, and intrapartum) and autism in the Boston Birth 
Cohort (BBC). Sample sizes are shown for those who were exposed or unexposed for 
each variable, with the number with the ASD outcome (n) over the total who were in that 
category, including both ASD cases and neurotypical controls (N). 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Figure 2.2: Forest plot comparing the BBC results to previously reported results. The 
plot shows effect estimates and 95% confidence intervals for the association between 
infection or fever (at any point during pregnancy and by trimester) and autism. 
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2.4.3 Prenatal Exposure to Influenza and ASD Risk 
 We assessed risk for ASD among children prenatally exposed to influenza at any 
point during gestation or during a specific trimester, including trimesters 1, 2, and 3. We 
observed no association between prenatal influenza exposure at any point during 
gestation and risk of ASD in either unadjusted (OR of 1.14 [95% confidence interval 0.69 
– 1.89]) or adjusted analyses (aOR 1.17 [0.67 – 2.05]; Figure 2.1 and Table 2.7). 
Furthermore, neither adjusted nor unadjusted analyses showed an association between 
ASD risk and prenatal influenza exposure specific to any trimester (Figure 2.1 and Table 
2.7). This is consistent with prior studies that reported no association between influenza 
infection, at any time during pregnancy, and risk of the offspring developing ASD (Figure 
2.2).  
2.4.4 Fever during pregnancy is associated with increased ASD risk in offspring 
 No association between exposure to fever at any time during pregnancy and risk 
of ASD was found in unadjusted analyses (OR 1.80 [0.99 - 3.27]; Table 2.7). However, a 
significant association between child ASD diagnosis and maternal fever at any time 
during her pregnancy was found after adjustment for child sex, maternal age, child birth 
year, maternal smoking status, maternal education, marital status, maternal race, and 
gestational age (aOR 2.02 [1.04 – 3.92]; see Figure 2.1 and Table 2.7). We also observed 
a significant association between maternal fever during the third trimester of pregnancy 
and child ASD diagnosis (aOR 2.70 [1.00 – 7.29]; Figure 2.1 and Table 2.7). No 
association between child ASD status and exposure to maternal fever during the first 
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(aOR 1.86 [0.61 – 5.73]) or second trimesters (aOR 1.62 [0.58 – 4.52]) was found (Figure 
2.1 and Table 2.7).  
 Despite different covariate choices, the association between prenatal fever 
exposure and ASD was consistent in magnitude and direction across all regression 
models tested (Table 2.8). However, because we observed differences in the strength of 
association among the adjusted models we also estimated the fever association using 
propensity score matching. Eighty-nine individuals exposed to fever were matched to 540 
unexposed individuals; good balance on all covariates was achieved after propensity 
score matching (see Table 2.9 for characteristics of mother-child pairs by prenatal fever 
exposure status and Figure 2.3). Consistent with our regression models, matching by 
propensity score showed a similar association between gestational exposure to maternal 
fever and ASD risk (Table 2.8).  
 Because fever and influenza may be correlated, as fever is a potential symptom of 
influenza, we sought to further tease apart the relationship between prenatal exposure to 
fever/flu and ASD. We generated a categorical variable with four levels: neither flu nor 
fever (reference category; n = 753); fever only (n = 36); flu only (n=137); or both flu and 
fever (n = 56). We performed a logistic regression with ASD as the outcome and this 
derived categorical variable as the exposure, with adjustment for additional covariates as 
in our other models. No exposure category was significantly associated with ASD risk 
when compared to the reference category: fever (aOR 2.11 [0.75 – 5.94], p = 0.16), flu 
only (aOR 0.94 [0.47 – 1.90], p = 0.87), or fever and flu (aOR 2.05 [0.90 – 4.65], p = 
0.09). 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Table 2.8: Comparison of effect size and significance for association 
between ASD and prenatal fever exposure using different analytic 
models 
GA, gestational age; LBW, low birth weight 
Bold values represent statistically significant ORs 
a low birth weight is defined as weighing less than 2500 grams at birth 
b conditional probability of exposure to fever modeled as a function of child sex, maternal age, 
birth year, maternal smoking, education, marital status, race, gestational age 
* All main text references to “fully adjusted model” refer to this model 
Analytic 









1 1.80 [0.99 - 3.27] 0.053
2 1.72 [0.93 - 3.19] 0.085
3 1.80 [0.96 - 3.38] 0.068
4 1.86 [0.97 - 3.58] 0.062
5* 2.02 [1.04 - 3.92] 0.037
6 1.98 [1.02 - 3.86] 0.045
7 1.95 [1.01 - 3.77] 0.046
8 1.89 [0.995 - 3.59] 0.051
9 propensity score matchingb 1.54 [0.80 - 2.95] 0.195
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Table 2.9: Characteristics of mother-child pairs in the Boston Birth 







ASD diagnosis, n (%) 0.075
no 806 (90.4) 78 (83.9)
yes 86 (9.6) 15 (16.1)
Maternal agea, M (SD) 28.55 (6.53) 27.63 (6.59) 0.196
Child year of birth, M (SD) 2006.22 (3.53) 2005.83 (3.40) 0.312
Education, n (%) 0.055
Elementary school 34 (3.8) 6 (6.5)
Secondary school 221 (24.8) 19 (20.4)
High school/GED 316 (35.4) 23 (24.7)
Some college 186 (20.9) 29 (31.2)
College degree and above 135 (15.1) 16 (17.2)
Marital status, n (%) 0.483
Married 316 (35.4) 29 (31.2)
Not Married 576 (64.6) 64 (68.8)
Race or Ethnicityb, n (%) <0.001*
Black 568 (63.7) 37 (39.8)
White 75 (8.4) 9 (9.7)
Hispanic 181 (20.3) 38 (40.9)
Asian 16 (1.8) 5 (5.4)
Other 52 (5.8) 4 (4.3)
Maternal smokingc, n (%) 0.336
Never 765 (84.8) 77 (82.8)
Some 48 (5.4) 3 (3.2)
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ASD, autism spectrum disorder; BBC, Boston Birth Cohort; M, mean; SD, standard deviation 
a Maternal age at time of delivery  
b Black includes self reported Black, African American, Haitian, Cape Verdean, and Caribbean 
race and ethnicities. Asian includes Asian and Pacific Islander races. The Other category 
includes individuals with a mixed or other racial background. 
c Never smokers were defined as mothers with no history of smoking 6 months prior to 
conception or during pregnancy; some smoking includes mothers that smoked at some point in 
the window of 6 months prior to conception and delivery but did not smoke throughout that 
window; continuous is defined as mothers that smoked starting 6 months prior to and 
throughout pregnancy.  
d Defined by sonogram 
* Denotes statistically significant 
Continuous 88 (9.9) 13 (14.0)
Child sex, n (%) 0.609
Female 500 (56.1) 49 (52.7)
Male 392 (43.9) 44 (47.3)
Gestational age, mean (SD)d 38.21 (3.09) 38.28 (2.49) 0.831
Birth weight, n (%) 0.635
>2500 grams 695 (77.9) 75 (80.6)
<2500 grams  197 (22.1) 18 (19.4)
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 To further test the association between exposure to fever during gestation and risk 
of ASD, we also performed a sensitivity analysis for potential outcome misclassification. 
We used a more stringent ASD case definition of 2 or more 299 ICD-9-CM diagnoses. 
When the logistic regression models were repeated for ASD cases with at least 2 
diagnosis codes (n=82) and neurotypical controls (n=884), the unadjusted OR for ASD 
risk after fever exposure at any time during pregnancy was 1.95 [1.03 – 3.68] and the 
adjusted OR was 2.11 [1.03 – 4.32]. Using a more stringent ASD case definition did not 
change the estimated strength of the association between prenatal fever exposure and 
ASD risk or its significance. 
 Finally, we compared our findings to two prior studies that examined the 
association between prenatal exposure to maternal fever and ASD risk. Zerbo et al. saw 
an association between fever and ASD risk at any time during pregnancy, consistent with 
the current study (Figure 2.2) (Zerbo 2013a). For exposure to maternal fever during 
pregnancy (prior to 32 weeks) or specifically during trimester 1 or 2, Aladottir et al. did 
not find an association with ASD risk (Aladottir 2012).  
2.4.5 Intrapartum fever is not associated with ASD risk 
 Because of the association we observed between maternal fever during the third 
trimester and the risk of ASD in her child, we wanted to examine intrapartum fever 
exposure. This variable represents fever in the peripartum period (labor and delivery) 
only, as opposed to the third trimester. No association was seen between intrapartum 
fever and child ASD status in unadjusted (OR 0.52 [0.16 - 1.69], Table 2.7) or adjusted 
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analyses (aOR 0.60 [0.18 - 2.02]; Figure 2.1 and Table 2.7). Because there were only four 
individuals with both intrapartum fever and fever at any prior point during pregnancy (as 
measured by a structured interview based on the standardized postpartum questionnaire), 
we were not able to assess the joint effect. 
2.4.6 Effect of exposure misclassification  
 Because our study relies on self-reported exposure data collected shortly after 
delivery, we were concerned about the possibility of exposure misclassification biasing 
our results. We used two strategies for quantitative bias estimation with our three main 
exposure categories (infection, flu any time during pregnancy, fever any time during 
pregnancy): a probabilistic or Monte Carlo sensitivity analysis (MCSA) and 
bootstrapping, as implemented in the R package episensr (Lash et al. 2009). Briefly, these 
methods use estimates of the sensitivity and specificity of the exposure test (in this case, a 
structured interview based on a questionnaire) to reassign false negatives and false 
positives in a 2x2 table. The corrected 2x2 table is then used to calculate a crude odds 
ratio; the distribution of this OR over many replicates, either with randomly drawn 
sensitivity and specificity and the actual study sample per the MCSA approach or on a 
particular bootstrapped sample, is then used to generate an empirical corrected OR 
estimate and 95% confidence interval. 
 For the MCSA, we chose to model the prior probability of the sensitivity for both 
cases and controls as a uniform distribution between 0.5 and 1, while the specificity was 
a uniform distribution between 0.912 and 1. We note here that because the correction 
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method for exposure misclassification involves subtracting false positive subjects, we are 
unable to assess for dramatic overreporting of exposure (very low specificity) because it 
would result in negative cells in the corrected 2x2 table. Because the exposure data is 
collected prior to the ASD outcome, we are less concerned about differential exposure 
misclassification by ASD status. We thus set the sensitivity and specificity draws for the 
cases and controls to be tightly correlated (r = 0.9) and ran 10,000 replicates. For GU 
infection, the OR corrected for systematic exposure misclassification and random error 
was 0.78 [95% CI 0.43 - 1.38]. For flu, the OR corrected for systematic exposure 
misclassification and random error was 1.21 [0.67 - 2.17]. For fever, the OR corrected for 
systematic exposure misclassification and random error was 2.68 [1.17 - 9.59].  
 In our second approach, we first performed a bootstrap resampling of the dataset 
(10,000 bootstraps) and then conducted a simple sensitivity analysis for misclassification 
on each bootstrap. This allows us to model different ways that bias could affect the 
sensitivity and specificity of the test for exposure (Table 2.10). We believe there is low 
risk of differential exposure misclassification because of the study's prospective data 
collection, and so the sensitivity and specificity for ASD cases and controls are the same.  
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Table 2.10: Results of simple sensitivity analysis for 
misclassification with 10,000 bootstraps for each exposure-bias 
combination 
2.5     Discussion 
 We examined the prospective relationship between prenatal maternal immune 
activation and Autism Spectrum Disorder (ASD) risk in an understudied, predominantly 
urban minority population. Our results support previous suggestions of maternal immune 
Exposure Sensitivity Specificity Adjusted OR [95% CI]
GU infection
Under-reporting 0.5 0.99 0.73 [0.33 - 1.57]
0.6 0.99 0.77 [0.40 - 1.49]
0.7 0.99 0.79 [0.45 - 1.44]
0.8 0.99 0.81 [0.48 - 1.40]
Good test performance 0.95 0.95 0.80 [0.46 - 1.44]
Over-reporting 0.95 0.90 0.77 [0.39 - 1.65]
Under- and over-reporting 0.6 0.90 0.72 [0.31 - 1.76]
Flu
Under-reporting 0.5 0.99 1.21 [0.58 - 2.54]
0.6 0.99 1.18 [0.62 - 2.29]
0.7 0.99 1.17 [0.65 - 2.17]
0.8 0.99 1.16 [0.67 - 2.09]
Good test performance 0.95 0.95 1.19 [0.63 - 2.35]
Over-reporting 0.95 0.90 1.27 [0.52 - 3.47]
Under- and over-reporting 0.6 0.90 1.30 [0.48 - 4.00]
Fever
Under-reporting 0.5 0.99 2.07 [0.96 - 4.67]
0.6 0.99 2.01 [0.98 - 4.33]
0.7 0.99 1.96 [0.98 - 4.09]
0.8 0.99 1.93 [1.00 - 3.96]
Good test performance 0.95 0.95 2.77 [1.02 - 8.14]
Over-reporting 0.95 0.92 1.80 [0.99 - 3.27]
Under- and over-reporting 0.6 0.92   9.43 [1.47 - 86.28]
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activation as a risk factor for ASD, and specifically implicate fever. Our results do not 
provide evidence for an association between exposure to genitourinary infections or 
influenza during gestation and later diagnosis of ASD. However, we did observe a 
significant association between prenatal exposure to fever at any time during pregnancy 
as well as during the third trimester, and ASD.  
 This result is consistent with most prior studies showing ASD risk is not related to 
prenatal exposure to genitourinary or influenza infection (Figure 2.2). Only two prior 
studies have specifically examined prenatal exposure to fever, at any point in pregnancy 
or during specific trimesters, and ASD risk, with conflicting results. Our result showing 
increased ASD risk associated with fever (without regards to length of the febrile 
episode) is consistent with Zerbo et al. (Figure 2.2) (Zerbo et al. 2013) but not Atladottir 
et al. (Atladottir et al. 2012). The prenatal exposure definition used by Atladottir et al. 
included only data through week 32; however, our BBC study and the Zerbo et al. report 
used fever exposure for the entire pregnancy period (week 1 to birth). Thus, the Atladottir 
et al. definition did not include a large portion of the third trimester, shown to be 
significantly associated with ASD in our BBC data (Figures 2.1 and 2.2). Although the 
overall findings between Zerbo et al. and our study were consistent, their study identified 
a significant association with fever in the second trimester while we observed a 
significant association with fever in the third trimester. It is possible that this difference 
could be due to recall bias and/or exposure misclassification due to the difference in 
study design.  
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 Our study sample was derived from an enriched risk cohort, where children were 
initially recruited with oversampling for preterm birth, a known ASD risk factor. BBC 
exposure data was collected at birth, prior to ASD diagnoses, allowing for a relatively 
short recall time and prospective analysis for ASD. In contrast, Zerbo et al. (Zerbo et al. 
2013) used a retrospective case-control design in which the exposure data was 
ascertained up to 60 months after birth (longer recall) and after ASD diagnosis. 
Additionally, our study population has a different racial and economic make-up (Table 
2.1) than the population in Zerbo et al., which was approximately 50% white (Zerbo et al. 
2013). 
 Our findings were specific to fever, which could indicate that fever itself 
contributes to ASD risk. There is evidence that exposure to fever during pregnancy can 
lead to several different suboptimal developmental outcomes including oral clefts, neural 
tube defects, and congenital heart defects (Dreier et al. 2014). In support of this, Zerbo et 
al. (Zerbo et al. 2013) found an attenuation of the fever-ASD development association 
with the use of antipyretics such as acetaminophen. However, rather than fever itself 
being in the causal ASD pathway, it is also possible that fever is merely acting as a 
marker of a specific infection that is associated with increased ASD risk but that is not 
captured by our questionnaire data. The BBC prenatal infection exposure data is collected 
soon after birth with a structured questionnaire designed to ascertain exposures in a 
reliable manner. Nonetheless, the questionnaire is retrospective with respect to the 
exposure and it is possible that mothers remember fever better than infections generally. 
Finally, it is possible that the pathology of ASD begins during gestational development 
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and leads to increased maternal infections and fever through immunocompromise, 
although there is little evidence to support this. 
 We observed relatively large confidence intervals in our study compared to prior 
work (Figure 2.2). This is likely due to the relatively small number of individuals in our 
study and thus imprecision in these estimates. Because our study relied on the extraction 
of ASD outcomes from electronic medical records, specifically ICD-9-CM codes, there 
may be some outcome misclassification. However, we would not expect any outcome 
misclassification to be differential by exposure status, and a sensitivity analysis using a 
more stringent ASD case definition continued to show a significant association between 
fever exposure at any time during gestation and ASD. Additionally, there is significant 
co-morbidity among the ASD cases in our sample for developmental delay; of our 116 
ASD cases, 111 also have a diagnosis for a developmental delay (ICD-9-CM codes 
between 315.0 and 315.9). Prior research in a similar EMR data set has found this to be 
true among validated ASD cases (Dodds et al. 2009), and so we believe there is limited 
outcome misclassification.  
 We did not perform an adjustment for multiple comparisons. We examined ten 
total exposures (GU infections; flu, overall and by trimester; fever, overall and by 
trimester; and intrapartum fever), and the significant association we found between 
prenatal exposure to fever and ASD risk would not survive a conservative Bonferroni 
correction. Additional research with larger samples is necessary to clarify the role of 
prenatal exposure to fever in the development of ASD.  
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 Future studies in urban, low-income, minority populations are needed to replicate 
our findings. In addition, future work to evaluate potential clinical interventions is 
needed. One previous study from the Danish National Birth Cohort did assess the 
association between anti-pyretic medications and ASD (Liew et al. 2016). Unexpectedly, 
the results showed an increased risk for ASD with hyperkinetic symptoms and maternal 
use of acetaminophen during pregnancy (Liew et al. 2016), which contradicts the results 
from Zerbo et al. To help resolve these differences in the literature, future studies should 
collect and evaluate information on prenatal exposure to fever, including (1) timing 
during pregnancy, (2) severity, or degree of temperature elevation, (3) duration of fever, 
(4) the probable etiology, including specific infections, and (5) use of anti-pyretics, 
including timing and dose.  
 There has been limited prior research on the relationship between prenatal fever 
exposure and ASD risk, particularly among underrepresented and minority populations. 
Our findings expand upon past work, and provide evidence supporting prenatal exposure 
to fever as a risk factor for ASD in an urban, low income, minority population, adding to 
our knowledge of a highly prevalent modifiable risk factor that may inform public health 
strategies for primary and secondary prevention. 
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Chapter 3: Developing methods utilizing Machine 
Learning and Latent Class Analysis to identify 
children with ASD in administrative health data 
 This chapter describes work currently in preparation for submission for peer 
review, with contributions from co-authors Rashelle Musci, M. Dani Fallin, Xiaobin 
Wang, Elizabeth A. Stuart, and Christine Ladd-Acosta. 
3.1     Introduction  
3.1.1 Electronic medical record-based research 
 The increase in the availability of EHR data has accelerated since the Health 
Information Technology for Economic and Clinic Health (HITECH) Act of 2009, which 
mandated the adoption and meaningful use of EHR across the US (Roden and Denny 
2016). Until September 30, 2015, medical billing data in the United States used the 
International Classification of Diseases (ICD) code, ninth edition, clinical modification 
(ICD-9-CM) (O'Malley, Cook et al. 2005). The ICD classification system is frequently 
used for a diverse range of purposes including insurance reimbursement, health 
administration, and epidemiological research. It is necessary to find the best way to 
utilize these existing medical billing records. Electronic medical records are a potentially 
rich source of information for research on medical diagnoses, treatment, and disease 
course, but there are several challenges that need to addressed. In particular, a need for 
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improved sensitivity and specificity of case identification from electronic medical records 
has been identified by researchers working in a variety of fields.  
 The electronic MEdical Records & Genomics (eMERGE) network was created in 
2007 by the National Human Genome Research Institute to establish the utility of 
electronic medical records in genetic research; this has led to the development of 
phenome-wide association studies (PheWAS) to explore multiple EMR phenotype-to-
genetic variant associations (Denny, Bastarache et al. 2013, Crawford, Crosslin et al. 
2014, Verma, Basile et al. 2016). eMERGE and PheWAS “phecodes” aggregate 
individual ICD-9-CM diagnoses into code groups and major disease concept paths, but 
largely rely on a simple algorithm based on the presence or absence of individual codes 
(Namjou, Marsolo et al. 2014) (https://phewascatalog.org). There may be additional 
information within the medical record that can be used to inform phenotype construction 
and improve it beyond current strategies. 
 We are interested in the ways that EMR, and specifically billing or administrative 
health data rather than free-text clinical notes, can be optimized for the use of autism 
researchers. Research on ASD risk factors increasingly utilizes large datasets derived 
from electronic medical records or medical claims data; ensuring the validity of ASD 
phenotypes derived from these records is essential (Dodds, Spencer et al. 2009). Because 
ASD is still a relatively rare disease, despite its increased prevalence in the United States, 
EMR may be particularly useful for autism research. A traditional prospective birth 
cohort of a general population sample would require massive recruitment to generate 
reasonable sample sizes with an expected ASD prevalence of approximately 1.5% among 
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offspring (Christensen, Baio et al. 2016). With EMR, we can generate case-control 
samples from hospital-based data and dramatically improve sample size and power for 
examining ASD risk factors.   
 It is often standard to use the simple presence or absence of an ICD code to 
identify cases and controls in administrative health databases. While the US currently 
uses ICD-10-CM, and ICD-10 has been used in most other countries since the mid 1990s 
(Bowman, Cleland et al. 2015), most US-based research studies use historical data and 
will continue to have a need to identify ASD cases from ICD-9-CM codes. ASD 
diagnosis codes in ICD-9-CM are based on the DSM-IV definitions of disease: 299.0 
(autistic disorder), 288.8 (Asperger's syndrome), and 299.9 (pervasive developmental 
disorder not otherwise specified, PDD-NOS). Some studies may require that a patient be 
assigned an ASD code twice or by a pediatric neurodevelopmental specialist, while others 
allow for any provider to assign the code even once (Dodds, Spencer et al. 2009, Wang 
and Leslie 2010, Peacock, Amendah et al. 2012, Zerbo, Qian et al. 2013, Connolly, Anixt 
et al. 2016; also see above, Chapter 2, section 2.3.2 Analytic Sample & Outcome 
Classification). 
 Requiring the presence of two ASD-category ICD-9-CM codes, rather than just a 
single ASD code, may optimize the sensitivity and specificity (Coleman, Lutsky et al. 
2015). However, there are social factors, including hospital resources, that may influence 
the likelihood of a child with ASD receiving a diagnosis (Mazumdar, Winter et al. 2013). 
We also know that electronic medical records are subject to both random and systematic 
error: this may be due to the quality of information available to the provider, 
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communication errors between patient and provider or between providers, clinician 
experience and skill with the diagnosis, coder training and experience, facility practices, 
or strategies that may manipulate what is billable for a particular visit, including 
misspecification, unbundling, and upcoding (O'Malley, Cook et al. 2005). Error in EMR, 
driven both by coding practices and social factors related to receiving the appropriate 
diagnosis, complicates attempts to conduct epidemiologic research on ASD risk factors.  
 Straightforward use of these ICD-9-CM codes—even when requiring two 
diagnoses of ASD at separate visits—may not be the best way to derive valid phenotypes 
for epidemiologic research. Prior work showed a sensitivity of only 69.3% compared to a 
gold standard clinical diagnosis when the presence of one ASD code was used to define 
case status; sensitivity dropped significantly, to 36.9%, when two ASD codes were 
required to be present in the medical record to define a case (Dodds, Spencer et al. 2009). 
Either strategy for identifying children with ASD in an administrative health database 
would result in a number of false negative cases, which could bias the results of an 
association analysis. 
 One particular way to approach this problem would be to utilize the full array of 
development, behavioral, and language-related diagnoses that a child may receive from a 
medical provider. We know that false negative ASD cases are likely to carry diagnoses of 
related behavioral and developmental disorders, as well as certain psychiatric and 
medical conditions that are known to co-occur with ASD (Dodds, Spencer et al. 2009, 
Levy, Giarelli et al. 2010, Doshi-Velez, Ge et al. 2014). It may be possible to use these 
other diagnoses to improve the sensitivity (identify false negative ASD cases) and 
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specificity (identify false positives, or children incorrectly coded as having ASD) of case 
identification in electronic medical records.   
3.1.2 Co-occurring conditions in Autism Spectrum Disorder 
 There is an extensive body of literature examining the prevalence and patterns of 
co-occurring conditions in individuals with Autism Spectrum Disorder, over both secular 
time and developmental age, by sex, and by intellectual disability status (Close, Lee et al. 
2012, Kohane, McMurry et al. 2012, Stacy, Zablotsky et al. 2014). The majority of 
children with ASD have at least one non-ASD developmental diagnosis (83%), and a 
sizable fraction have at least one other psychiatric diagnosis (10%) or neurologic 
diagnosis (16%) (Levy, Giarelli et al. 2010). The non-ASD developmental diagnoses in 
this study included ADHD, language disorder, learning disability, intellectual disability, 
nonverbal learning disabilities, and sensory integration disorder; the clustering of these 
diagnoses along with ASD is so consistent that it is recommended children with any one 
of them be comprehensively evaluated (Gillberg 2010). Additionally, children and young 
adults with ASD are more likely than hospital-based controls to have epilepsy, 
schizophrenia, inflammatory bowel disease, other bowel disorders, CNS/cranial 
anomalies, diabetes mellitus type I, muscular dystrophy, and sleep disorders (Kohane, 
McMurry et al. 2012). The frequency of co-occurring conditions may actually be 
increased in children who meet ASD criteria but have yet to receive the appropriate 
diagnosis, indicating that co-occurring conditions complicate the diagnostic odyssey for 
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ASD and may be particularly useful in identifying false negative ASD cases in EMR 
(Levy, Giarelli et al. 2010).  
 It is possible that reproducible clusters of specific co-occurring conditions exist in 
children with autism; these clusters may reflect disease etiology or subtype. For example, 
a child with ASD and gastrointestinal disease is likely to also have sleep problems; and 
the severity of behavioral problems can be predicted by the number of co-occurring 
medical conditions a child with ASD has (Aldinger, Lane et al. 2015). The observation of 
clustering of particular symptoms and co-occurring conditions in individuals with ASD 
has begun to be formalized with statistical methods that can perform unsupervised 
clustering on the basis of comorbidity patterns. One study using hierarchical clustering of 
subgroups of children with ASD found a group characterized by seizures, a group with 
multisystem disorders including GI disorders and infections, and a group with psychiatric 
disorders (Doshi-Velez, Ge et al. 2014). There are other potential approaches that have 
yet to be applied to ASD. 
3.1.3 Random Forests 
 Data mining techniques may prove useful in understanding patterns in child 
development as captured by administrative health data. One particular method is Random 
Forests, an extension of Classification and Regression Trees or CART, in which 
observations or “features” are partitioned to predict a particular outcome (Breiman 1984). 
Random Forests (RF) is an ensemble method, where multiple trees are constructed and 
then allowed to vote on the optimal partitioning of the data for outcome prediction 
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(Breiman 2002). RF can be performed with classification trees, where the predicted 
outcome is class membership; or with regression trees, in which the predicted outcome is 
some value of a continuous variable. One advantage of RF is that information about the 
predictive utility or importance of individual features can be obtained from the model; 
this may assist in developing an algorithm that “boosts” case identification on the basis of 
co-morbid conditions.  
 RF has previously been shown to work well in disease prediction from electronic 
medical records (Khalilia, Chakraborty et al. 2011). It has been successfully used to 
predict chronic diseases such as diabetes (Zheng, Xie et al. 2017), hypertension (Khalilia, 
Chakraborty et al. 2011), and fibromyalgia (Emir, Masters et al. 2015), though its use is 
not yet widespread and translation into clinical management has been limited (Clifton, 
Niehaus et al. 2015). To our knowledge, RF has yet to be applied to medical claims data 
for the purpose of distinguishing normal and abnormal child neurodevelopment, though 
two other machine learning techniques, Support Vector Machine and Generalized Low 
Rank Modeling, have previously been applied to ASD cohorts to distinguish phenotypic 
subtypes (Lingren, Chen et al. 2016, Schuler, Liu et al. 2016), and RF has been applied to 
text phrases from developmental evaluations (Maenner, Yeargin-Allsopp et al. 2016). 
 Here we use the results of ASD screening performed in the Boston Birth Cohort's 
Children's Health Study (CHS) to construct a regression tree with random forests, as well 
as the presence of a 299 group code to construct a classification tree. We determine the 
variable importance of specific ICD-9-CM codes present in the medical record for 
predicting performance on an ASD screening questionnaire or the presence of a 299 
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diagnosis. We then use the most important ICD-9-CM codes in a latent class analysis of 
the CHS cohort. 
3.1.4 Latent Class Analysis 
 Latent class analysis (LCA) is a probabilistic method for clustering individuals 
based on their observed characteristics or “indicators;” individuals are grouped based on 
an unknown (latent) variable—class membership—that explains the correlation between 
their observed characteristics (Collins and Lanza 2010). This technique has been applied 
to administrative health datasets to identify patients with asthma (Prosser, Carleton et al. 
2008), systemic autoimmune diseases (Bernatsky, Lix et al. 2011), and sepsis (Shahraz, 
Lagu et al. 2014). Here we use LCA to identify clusters of children with ASD and 
distinguish disease severity and co-morbidity; the observed characteristics are the ICD-9-
CM diagnoses recorded in the child’s medical record. 
3.1.5 Study Hypothesis 
 We hypothesized that LCA could be used in the BBC to identify children with 
probable ASD on the basis of related behavioral and developmental diagnoses, as well as 
frequent medical co-morbidities such as epilepsy. Latent class analysis requires choosing 
the relevant observations or indicators; in this case, ICD-9-CM diagnosis or diagnosis 
categories served as indicators. We used machine learning, specifically Random Forests, 
to best classify the CHS population and determine which ICD-9-CM diagnosis codes best 
identify the children with abnormal ASD screening results. These predictive ICD-9-CM 
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diagnoses were then used as indicators in the generation of latent classes. Our methods 
may reveal additional cases who do not yet have an ASD diagnosis in their medical 
record, or identify the children who are most severely affected. 
3.2     Methods 
3.2.1 Boston Birth Cohort (BBC)  
 The Boston Birth Cohort is a prospective birth cohort, established as the 
Molecular Epidemiology of Preterm Delivery in 1998 with the recruitment of women 
delivering at the Boston Medical Center (BMC), with oversampling for preterm birth 
(Wang, Zuckerman et al. 2002). Women with a singleton live birth at the BMC are 
eligible for recruitment, with exclusions for IVF, multiple gestations, chromosomal 
abnormalities, major birth defects, and preterm deliveries due to maternal trauma. They 
are contacted by the research team 24-72 hours after birth. Written informed consent is 
obtained and mothers are interviewed using a standardized questionnaire (Maternal at 
Postpartum Questionnaire) to gather information about her pregnancy. Maternal and 
infant medical records are reviewed and data on ultrasound findings, placental pathology, 
laboratory reports, pregnancy complications, labor and delivery course, and birth 
outcomes are extracted. Biospecimens from mother and child are obtained and banked for 
future research. The Children's Health Study (CHS) was established in 2002 to enable 
follow-up of child developmental outcomes. Research staff approach mothers at 
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scheduled pediatric clinic visits and obtain informed consent for the CHS follow-up 
study. There are no exclusions for participation in CHS if the mother consents. Medical 
records are then obtained, including type and date of visits, clinical diagnosis, 
medications, and growth and development parameters.  
 The BBC serves as an enriched-risk cohort for Autism Spectrum Disorders. At its 
establishment, mother-child pairs were oversampled for preterm births, a known risk 
factor for ASD. Consequently there is an estimated ASD prevalence of 4.0% in the entire 
CHS cohort, compared to the general population prevalence of 1.1-1.5% (Christensen, 
Baio et al. 2016). The BBC thus serves as an excellent resource for the prospective study 
of the causes, risk factors, and disease course of ASD, which is otherwise still relatively 
rare in the general population. Information about child development is primarily available 
through the Boston Medical Center's administrative health data. These records include 
information on visit date and location, insurance, and the patient's medical diagnoses. 
However, a growing subset of children have been given an ASD screening questionnaire, 
the Social Communication Questionnaire (SCQ) (Rutter 2003, Chandler, Charman et al. 
2007); and a quantitative measure of autistic traits, the Social Responsiveness Scale 
(SRS) (Constantino, Davis et al. 2003). 
 We used R package tableone (https://CRAN.R-project.org/package=tableone) for 
the construction of tables demonstrating population characteristics in the BBC. 
Descriptive statistics for categorical variables were obtained with the function chisq.test() 
with continuity correction, and the function oneway.test() for continuous variables with 
!63
an assumption of equal variance. Annotation of ICD-9-CM codes was performed with the 
R package icd (https://CRAN.R-project.org/package=icd). 
3.2.2 Standard ASD identification algorithm 
 A simple ICD-9-CM code-based algorithm for identifying children with ASD 
(cases) and children with neurotypical development (controls) was carried out in the CHS 
(Table 3.1). As is standard in the literature, ASD cases were identified as any one 
occurrence of ICD-9-CM codes 299.0 (autism), 298.8 (Asperger's syndrome), and 299.9 
(pervasive developmental disorder not otherwise specified), including both active (.00) 
and residual (.01) disease states. We classified individuals as neurotypical controls if they 
were never diagnosed with any of the following conditions: ASD, attention deficit 
hyperactivity disorder (ADHD), intellectual disability (ID), developmental delay (DD), 
oppositional defiant disorder (ODD) or other "emotional disorders of childhood," conduct 
disorder (CD), or congenital anomalies. We also determined the number of times a child 
was given a particular diagnosis and the clinic type (specialist or general pediatric) in 
which ASD was diagnosed. 
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Table 3.1: ICD-9-CM code based definitions for ASD cases and 
typically developing controls in the Boston Birth Cohort, 2003 – 
2015 
3.2.3 Random Forests 
 There is a widely used R package for implementing Random Forests called 
randomForest (Wiener 2002) (https://CRAN.R-project.org/package=randomForest ). This 
package allows the construction of both classification and regression trees using the 
function randomForest(), and the ranking of input features based on the extent to which 
their removal from the model increases predictive error, using the function importance() 
and varImpPlot() for plotting. We used three sets of input features in the construction of 
regression trees for the prediction of child score on the SCQ: (1) all codes included, 
including 299 group codes; (2) all codes except 299 group codes, which are removed; and 
ICD-9-CM codes N
ASD case definition 120
Inclusion criteria (any one of these codes): 299.0, 299.01, 299.8, 299.81, 
299.9, 299.91
Neurotypical control definition 1033
Exclusion criteria (any one of these codes):
ADHD 314.0 − 314.9
Conduct Disorder 312.0 − 312.9
Emotional disturbances of childhood 
or adolescence including 
Oppositional Defiant Disorder 313.0 − 313.9
Developmental Delay 315.0 − 315.9
Intellectual Disability 317 − 319
Congenital Anomalies 740 − 759.9
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(3) all codes except for 299, V, and E codes, which are removed. V and E codes are 
supplemental ICD-9 codes; V codes are used to classify non-illness related visits to a 
medical professional, such as a well-child visit, while E codes are used to classify injury 
or poisoning. We then used the second feature matrix (all codes except for 299 codes) to 
generate a classification tree for predicting the presence of 299.00 (autism, current state) 
based on the presence of other ICD-9-CM codes. Variable importance was extracted to 
determine which ICD-9-CM diagnoses provided the most information for predicting the 
score on the SCQ, or for predicting the presence of a 299.00 diagnosis. We used the R 
package icd (https://CRAN.R-project.org/package=icd) for the annotation of ICD-9-CM 
codes. 
3.2.4 Latent Class Analysis  
 LCA can be implemented with a dedicated software program Mplus (https://
www.statmodel.com), which is the standard in the field. Observed characteristics of the 
sample or “indicators” are used to identify latent subgroups within a particular 
population. One limitation of LCA is that you are restricted to a relatively small number 
of indicators in the construction of latent classes; while RF can handle feature matrixes 
with thousands of input features, LCA requires careful choice of not more than 10-15 
indicators. Here we used as LCA indicators the ICD-9-CM codes identified by Random 
Forests as being most relevant to outcome prediction. We thus ran analyses in Mplus 
(with option Type=Mixture, and increasing random starts to ensure model convergence) 
of four different sets of indicators (3 from regression trees, and 1 from the classification 
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tree); within each indicator set, iterations with different class sizes were run and then 
model fit statistics (Bayesian Information Criteria (BIC), sample size adjusted BIC, Lo-
Mendell-Rubin) compared to determine the class size of the best solution. 
3.3     Results 
3.3.1 Sample Description 
 CHS electronic medical records (covering the time span from 1 October 2003 to 
30 September 2015, the last day in the US before the transition to ICD-10) include 
118,939 pediatric inpatient, outpatient, and emergency room records from 2,992 children 
after removing records from siblings of index children and removing duplicate records. 
Each child contributes on average 39.8 visits to the dataset, with a range of 1 to 463 
visits. Demographic information about children in the CHS was determined by linking 
pediatric EMR records to demographic information from postpartum maternal 
questionnaires, which could be done for 2932 children out of the 2992 children in the 
CHS cohort (Table 3.2). 
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Table 3.2: Characteristics of mother-child pairs in the Boston Birth 
Cohort (BBC)’s CHS, 2003 - 2015
Overall 
(n= 2932)
Maternal agea, M (SD) 28.5 (6.5)
Child year of birth, M (SD) 2006.4 (3.7)
Education, n (%)
Elementary school 128 (4.6)
Secondary school 684 (24.5)
High school/GED 1002 (35.8)
Some college 611 (21.8)
College degree and above 372 (13.3)
Marital status, n (%)
Married 928 (33.2)
Not Married 1866 (66.8)










Child sex, n (%)
Female 1447 (49.4)
Male 1485 (50.6)
Gestational age, mean (SD)d 37.7 (3.5)
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M, mean; SD, standard deviation 
a Maternal age at time of delivery  
b Black includes self reported Black, African American, Haitian, Cape Verdean, and Caribbean 
race and ethnicities. Asian includes Asian and Pacific Islander races. The Other category 
includes individuals with a mixed or other racial background. 
c Never smokers were defined as mothers with no history of smoking 6 months prior to 
conception or during pregnancy; some smoking includes mothers that smoked at some point in 
the window of 6 months prior to conception and delivery but did not smoke throughout that 
window; continuous is defined as mothers that smoked starting 6 months prior to and 
throughout pregnancy.  
d Defined by sonogram 
3.3.2 Standard ASD identification algorithm 
 Using simple ICD-9-CM based ASD case and neurotypical control definitions, we 
identified 120 ASD cases and 1,033 neutrotypical controls from the full CHS cohort 
(n=2992). We classified individuals as neurotypical controls if they were never diagnosed 
with any of the following conditions: ASD, attention deficit hyperactivity disorder 
(ADHD), intellectual disability (ID), developmental delay (DD), oppositional defiant 
disorder (ODD) or other "emotional disturbances of childhood," conduct disorder (CD), 
or congenital anomalies (Table 3.1). Likely because of the oversampling for preterm birth 
in the design of the BBC and CHS, there was a large proportion of children with 
competing developmental and behavioral diagnoses that disqualified them from serving 
as a typically developing control. 
Birth weight, n (%)
>2500 grams 2063 (73.3)
<2500 grams  751 (26.7)
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 Twenty-six subjects (out of 120) identified as ASD cases with a relaxed definition 
(≥ 1 ASD diagnosis) only had a single 299 group diagnosis; though notably, all of these 
children were also diagnosed with other developmental diagnoses that are known to 
commonly co-occur with ASD, including developmental delay, delayed milestones, or 
abnormal physiological development, speech or language disorders, attention deficits 
with or without hyperactivity, and behavioral or conduct disorders. In eight of these 
subjects, the ASD diagnosis was made by a specialist, either a developmental behavioral 
pediatrician (n=5), pediatric neurologist (n=2), or child psychiatrist (n=1). 
3.3.3 Social Communication Questionnaire 
 Once a week, trained research staff pull upcoming appointments at the Boston 
Medical Center for research participants. Study personnel will meet the family in the 
waiting room of their scheduled appointment, and ask them to complete the Social 
Communication Questionnaire and/or Social Responsiveness Scale. Through 9 October 
2016, 888 total SCQs were completed. If a child was administered the SCQ more than 
once, we retained the first score and discarded replicates. After removing duplicate exams 
and linking scores to pediatric electronic medical records through a family-level study 
ID, 771 unique subjects had both EMR and SCQ data, while 745 have EMR, SCQ, and 
demographic information (Table 3.3). Compared to other children in the CHS who did 
not receive the SCQ, children with a recorded SCQ were less likely to be low birth 
weight (p = 0.018), more likely to identify as black and less likely to identify as white (p 
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= 0.002), younger (born on average in 2007, rather than 2005, p < 0.001), with mothers 
who were less likely to have smoked during their pregnancy (p = 0.019). 
 We used the raw score of the SCQ; in our dataset, this ranged from 0 to 24 (out of 
40 yes/no questions), with a mean score of 6.67 and standard deviation of 4.26 (Figure 
3.1). While some studies use an SCQ cutoff of 15 to indicate a positive screen for ASD, 
other studies have used a cutoff of 11 to improve sensitivity (Eaves, Wingert et al. 2006, 
Schendel, Diguiseppi et al. 2012). Ninety-six children had an SCQ score greater than 11, 
while 32 had an SCQ greater than 15. 
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Table 3.3: Characteristics of mother-child pairs with child SCQ 
data in the CHS, 2003 - 2015
Overall 
(n= 745)
Maternal agea, M (SD) 28.9 (6.6)
Child year of birth, M (SD) 2007.9 (3.2)
Education, n (%)
Elementary school 32 (4.6)
Secondary school 151 (21.8)
High school/GED 248 (35.8)
Some college 167 (24.1)
College degree and above 95 (13.7)
Marital status, n (%)
Married 220 (31.8)
Not Married 471 (68.2)










Child sex, n (%)
Female 355 (47.7)
Male 390 (52.3)
Gestational age, mean (SD)d 37.3 (3.8)
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M, mean; SD, standard deviation 
a Maternal age at time of delivery  
b Black includes self reported Black, African American, Haitian, Cape Verdean, and Caribbean 
race and ethnicities. Asian includes Asian and Pacific Islander races. The Other category 
includes individuals with a mixed or other racial background. 
c Never smokers were defined as mothers with no history of smoking 6 months prior to 
conception or during pregnancy; some smoking includes mothers that smoked at some point in 
the window of 6 months prior to conception and delivery but did not smoke throughout that 
window; continuous is defined as mothers that smoked starting 6 months prior to and 
throughout pregnancy.  
d Defined by sonogram 
 
Figure 3.1: Distribution of SCQ scores in the Children’s Health Study (n = 771).  
Birth weight, n (%)
>2500 grams 485 (69.8)
<2500 grams  210 (30.2)
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3.3.3 Random forests 
 In the 771 patients with SCQ data, we extracted the unique ICD-9-CM codes that 
were associated with any of their medical visits in their electronic medical records and 
used the presence or absence of a single ICD-9-CM code to generate a dichotomous yes/
no variable for each child. A child was given a ‘1’ if their record contained a particular 
code at any point in time, and a ‘0’ if the code was never associated with their medical 
record. This generated 2355 unique features per child, and a feature matrix with 771 rows 
and 2355 columns. We then used Random Forests as implemented in the R package 
randomForest to identify the specific ICD-9-CM codes most predictive of the continuous 
SCQ score with regression trees. Parameters included ntree=500 and importance=TRUE 
so that we could later assess the variable importance of each ICD-9-CM code-derived 
feature. We used three different sets of ICD-9-CM codes for the regression trees: (1) all 
codes included, including 299 group codes (features = 2355); (2) all codes except 299 
group codes (features = 2351) and (3) all codes except for 299, V, and E codes (features = 
1957). Next, we used the same set of features from our second regression tree (all codes 
except 299 group codes, features = 2351) to predict the presence or absence of the ICD-9-
CM code 299.00, which is "autism, current state." As ICD-9-CM is based on DSM-IV 
diagnostic criteria, this diagnosis reflects the most severe form of ASD. In the subset of 
children with SCQ scores, 50 of them had at least one diagnosis of 299.00 in their 
medical record.  
 The first set of features (all codes included, including 299 group codes) best 
explained the variance in the SCQ scores (Table 3.4). After each model, we used the 
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varImpPlot() and importance() functions to identify the ICD-9-CM codes most predictive 
of SCQ score (Figures 3.2 - 3.5; Tables 3.5 - 3.8). The variable importance plots show the 
model performance when each feature is removed from the model; while the model 
performance is complex and can rely on the network of predictors, the increase in mean 
squared error and impact on node purity when a feature is removed from the model 
provides some measure of its function in the model. 
 To determine if the predictive utility of these diagnoses was specific to ASD, we 
also built a classification tree to predict diagnosis with 466.19 ("Acute bronchiolitis due 
to other infectious organisms"). We found that the ICD-9-CM diagnoses most predictive 
of 466.19 do not overlap with those codes predictive of either SCQ score or the presence 
of a 299.00 diagnosis (Figure 3.6, Table 3.9).  
Table 3.4: Random Forests model performance for regression and 
classification trees 
 





set 1: all codes 15.22 16.21
set 2: no 299 codes 16.13 11.2
set 3: no 299, V, or E codes 16.05 11.65
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Table 3.5: ICD-9-CM codes with highest variable importance, 
based on percent increase in mean squared error when each is 
removed from the feature matrix derived from all codes (including 
299) 
Top 14 predictive features in bold. These are used as indicators in downstream Latent 
Class Analysis. 
299.00 Autistic disorder, current or active state
315.8 Other specified delays in development
314.9 Unspecified hyperkinetic syndrome
299.90 Unspecified pervasive developmental disorder, current or active 
state
784.60 Symbolic dysfunction, unspecified
984.9 Toxic effect of unspecified lead compound
995.27 Other drug allergy
V21.30 Low birth weight status, unspecified
345.00 Generalized nonconvulsive epilepsy, without mention of 
intractable epilepsy
781.2 Abnormality of gait
771.7 Neonatal Candida infection
708.0 Allergic urticaria
744.42 Branchial cleft cyst
919.4 Insect bite, nonvenomous, of other, multiple, and unspecified sites, 
without mention of infection
995.52 Child neglect (nutritional)
327.23 Obstructive sleep apnea (adult)(pediatric)
V06.1 Need for prophylactic vaccination and inoculation against diphtheria-
tetanus-pertussis, combined [DTP] [DTaP]
703.8 Other specified diseases of nail
9.1 Colitis, enteritis, and gastroenteritis of presumed infectious origin
V49.9 Unspecified problems with limbs and other problems
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Table 3.6: ICD-9-CM codes with highest variable importance, 
based on percent increase in mean squared error (feature matrix 
derived from codes excluding 299) 
Top 14 predictive features in bold. These are used as indicators in downstream Latent 
Class Analysis. 
315.8 Other specified delays in development
784.60 Symbolic dysfunction, unspecified
314.9 Unspecified hyperkinetic syndrome
345.00 Generalized nonconvulsive epilepsy, without mention of 
intractable epilepsy
315.32 Mixed receptive-expressive language disorder
301.3 Explosive personality disorder
995.27 Other drug allergy
V06.1 Need for prophylactic vaccination and inoculation against 
diphtheria-tetanus-pertussis, combined [DTP] [DTaP]
38.9 Unspecified septicemia
348.30 Encephalopathy, unspecified
771.7 Neonatal Candida infection
984.9 Toxic effect of unspecified lead compound
315.39 Other developmental speech or language disorder
780.02 Transient alteration of awareness
V21.30 Low birth weight status, unspecified
781.2 Abnormality of gait
780.52 Insomnia, unspecified
744.42 Branchial cleft cyst
41.49 Other and unspecified Escherichia coli [E. coli]
779.84 Meconium staining
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Table 3.7: ICD-9-CM codes with highest variable importance, 
based on percent increase in mean squared error (feature matrix 
derived from codes excluding 299, V, and E) 
Top 14 predictive features in bold. These are used as indicators in downstream Latent 
Class Analysis. 
315.8 Other specified delays in development
784.60 Symbolic dysfunction, unspecified
314.9 Unspecified hyperkinetic syndrome
301.3 Explosive personality disorder
345.00 Generalized nonconvulsive epilepsy, without mention of 
intractable epilepsy
38.9 Unspecified septicemia
775.9 Unspecified endocrine and metabolic disturbances specific to the 
fetus and newborn
995.27 Other drug allergy
771.7 Neonatal Candida infection
315.32 Mixed receptive-expressive language disorder
41.49 Other and unspecified Escherichia coli [E. coli]
919.4 Insect bite, nonvenomous, of other, multiple, and unspecified sites, 
without mention of infection
780.02 Transient alteration of awareness
781.2 Abnormality of gait
703.8 Other specified diseases of nail
216.9 Benign neoplasm of skin, site unspecified
348.30 Encephalopathy, unspecified
779.84 Meconium staining
259.1 Precocious sexual development and puberty, not elsewhere classified
331.4 Obstructive hydrocephalus
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Figure 3.5: Variable importance plot of the classification tree: predict presence of 299.00 
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Table 3.8: ICD-9-CM codes with highest variable importance, 
based on percent increase in mean squared error (from the 
classification tree predicting 299.00 as outcome) 
Top 14 predictive features in bold. These are used as indicators in downstream Latent 
Class Analysis. 
315.8 Other specified delays in development
784.6 Symbolic dysfunction, unspecified
315.32 Mixed receptive-expressive language disorder
315.9 Unspecified delay in development
348.3 Encephalopathy, unspecified




780.51 Insomnia with sleep apnea, unspecified
783.4 Lack of normal physiological development, unspecified
758.5 Other conditions due to autosomal anomalies
787.03 Vomiting alone
754.79 Other deformities of feet
681.02 Onychia and paronychia of finger
314.9 Unspecified hyperkinetic syndrome
780.97 Altered mental status
752.65 Hidden penis
784.69 Other symbolic dysfunction
282.7 Other hemoglobinopathies
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Figure 3.6: Variable importance plot for the prediction of a diagnosis with 466.19 (Acute 
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Table 3.9: ICD-9-CM codes with highest variable importance for 
the prediction of a diagnosis with 466.19 (Acute bronchiolitis due to 
other infectious organisms) 
Top 14 predictive features for the presence of a 466.19 diagnosis in bold. These do not 
overlap with features predictive of SCQ score or the presence of a 299.00 diagnosis. 
786.07 Wheezing
493.92 Asthma, unspecified type, with (acute) exacerbation
466.11 Acute bronchiolitis due to respiratory syncytial virus (RSV)
493.1 Intrinsic asthma, unspecified
493.9 Asthma, unspecified type, unspecified
493.91 Asthma, unspecified type, with status asthmaticus
V49.89 Other specified conditions influencing health status
996.62 Infection and inflammatory reaction due to other vascular device, 
implant, and graft
V15.03 Allergy to eggs
780.61 Fever presenting with conditions classified elsewhere
E94.57 Antiasthmatics causing adverse effects in therapeutic use
466 Acute bronchitis
486 Pneumonia, organism unspecified
493 Extrinsic asthma, unspecified
607.83 Edema of penis
480.1 Pneumonia due to respiratory syncytial virus
832.2 Nursemaid's elbow
E92.08 Accidents caused by other specified cutting and piercing instruments 
or objects  
V18.0 Family history of diabetes mellitus
701.4 Keloid scar
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3.3.4 Latent class analysis 
 The codes with the highest importance criteria in the RF models were used as 
indicators in four separate latent class analyses (LCA) of the full dataset (n=2992). In the 
first analysis, we used 14 indicators from the full set of ICD-9-CM codes: dichotomous 
variables representing the presence or absence of any one diagnosis of 299.00 (Autistic 
disorder, current or active state), 315.8 (Other specified delays in development), 314.9 
(Unspecified hyperkinetic syndrome), 299.90 (Unspecified pervasive developmental 
disorder, current or active state), 784.60 (Symbolic dysfunction, unspecified), 984.9 
(Toxic effect of unspecified lead compound), 995.27 (Other drug allergy), V21.30 (Low 
birth weight status, unspecified), 345.00 (Generalized nonconvulsive epilepsy, without 
mention of intractable epilepsy), 781.2 (Abnormality of gait), 771.7 (Neonatal Candida 
infection), 708.0 (Allergic urticaria), 744.42 (Branchial cleft cyst), and 919.4 (Insect bite, 
nonvenomous, of other, multiple, and unspecified sites, without mention of infection). 
 LCA indicated a four class solution (Table 3.10), with a high entropy of 0.972, 
which demonstrates that assignment of the subjects to one of the four classes has little 
uncertainty. One class (93% of the sample) had a low probability of a 299 code or other 
developmental diagnoses (normal class), while one class (4% of the sample) had a high 
probability of carrying a 299 diagnosis (ASD-type class) (Figure 3.7). When compared to 
the ASD cases identified in the same dataset using standard definitions (n=120), the 
ASD-type class derived from LCA was smaller (n=113). There were 9 children who 
carried a 299 code but did not cluster with other children who did; and there were 2 
children who did not carry a 299 code but were assigned to the ASD-type class on the 
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basis of other characteristics. While only a few of these children were tested with the 
SCQ, one of the children who clustered outside of the ASD class despite having a 299 
diagnosis had an SCQ of 8, which is below even a relaxed cutoff of 11. The children in 
this group carried a number of diagnoses related to ADHD or hyperkinetic symptoms. Of 
the 113 children who clustered in the ASD class, 57 children received the SCQ, with a 
mean score of 12.4 (SD 5.4). The children who cluster outside of the ASD class may 
represent false positive ASD cases when using the standard ICD-9-CM-based 
identification, while children who cluster with the ASD class despite not having an ASD 
diagnosis of record may represent false negative ASD cases.   
Table 3.10: Criteria evaluating the model fit for different class 
solutions, using the ICD-9-CM codes most predictive of SCQ score, 
including 299.00; this represents an effort to "boost" the utility of 









Class 1 -3913.175 7938.402 7893.919 14
Class 2 -3611.78 7455.668 7363.523 29 597.811 0
Class 3 -3586.73 7525.622 7385.817 44 49.687 0.0006
Class 4 -3572.007 7616.231 7428.765 59 29.203 0.0341
Class 5 13.803 0.3106
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Figure 3.7: Illustrating the four class solution among the full set of 2992 children with 
electronic medical records from the BBC. ICD-9-CM diagnostic indicators were chosen 
based on their ability to predict SCQ score and have been pruned to those that distinguish 
the four classes. 
 When using the other two sets of indicators derived from the regression trees (299 
codes removed from the predictors; and 299, V, and E codes removed), LCA indicated a 2 
class solution. These were a normal class and smaller, atypical class with a higher 
prevalence of developmental diagnoses. However, the set of indicators derived from the 
classification tree predicting the presence of the most severe ASD diagnosis (299.00) 
indicated a four class solution (Table 3.11) with an entropy of 0.827. These indicators 
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unspecified), 315.32 (Mixed receptive-expressive language disorder), 315.9 (Unspecified 
delay in development), 348.3 (Encephalopathy, unspecified), 312.9 (Unspecified 
disturbance of conduct), 298.9 (Unspecified psychosis), 780.52 (Insomnia, unspecified), 
367.32 (Aniseikonia), 780.51 (Insomnia with sleep apnea, unspecified), 783.4 (Lack of 
normal physiological development, unspecified), 758.5 (Other conditions due to 
autosomal anomalies), 787.03 (Vomiting alone), and 754.79 (Other deformities of feet). 
Only 315.8 and 784.6 overlapped with the list of indicators used in the first LCA analysis. 
The 4 class solution indicated one typically developing class (75% of the population), and 
then three smaller classes with different types of developmental or medical diagnoses 
(Figure 3.8). Class 1 (15%) was distinguished by abnormal physiological development, 
Class 2 (3%) by encephalopathy and unspecified developmental delay in addition to 
abnormal physiological development, and Class 3 (7%) by psychosis and unspecified 
developmental delay.  
Table 3.11: Criteria evaluating the model fit for different class 
solutions, using the ICD-9-CM codes most predictive of a 299.00 
diagnosis 
* model did not converge 






Class 1 -7765.969 15643.99 15599.507 14
Class 2 -7077.807 14387.72 14295.576 29 1364.956 0
Class 3 -7020.154 14392.471 14252.666 44 114.353 0
Class 4 -6988.127 14448.473 14261.007 59 63.524 0
Class 5* -6973.036 14538.346 14303.219 74 29.415 0.2375
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Figure 3.8: Illustrating the four class solution among the full set of 2992 children with 
electronic medical records from the BBC. ICD-9-CM diagnostic indicators were chosen 
based on their ability to predict a 299.00 diagnosis and have been pruned to those that 
distinguish the four classes. 
3.4     Discussion
 Here we were interested in ways to identify probable but undiagnosed ASD cases 
with latent class analysis in an administrative health dataset to assist epidemiologic 
research on ASD risk factors. We were also interested in the possibility of identifying 
homogenous, etiologically relevant clusters of children with abnormal neurodevelopment 
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ASD screening test, the Social Communication Questionnaire, with any ICD-9-CM code, 
including 299 and related codes, we found that in fact ASD diagnosis was the strongest 
predictor of SCQ performance. This is promising for two reasons: it suggests that the 
machine learning algorithm Random Forests (RF) is a valid method for understanding the 
patterns in EMR diagnoses that might predict a child's ASD status; and it provides a 
group of related ICD-9-CM diagnoses that may be used to "boost" or reinforce an ASD 
diagnosis, entirely based on information readily available in claims datasets. While RF in 
developmental or education records that have been parsed with natural language 
processing has promising utility for identifying children with ASD for surveillance 
(Maenner, Yeargin-Allsopp et al. 2016), this kind of data is generally less available, and 
with smaller sample sizes, than claims data. 
 We believe machine learning and Latent Class Analysis show promise in 
identifying children with typical or atypical neurodevelopment, leveraging the large 
amount of information available in the electronic medical records about a child's medical 
diagnoses over time. Because of the high degree of co-morbidity between ASD and other 
physical and psychiatric diagnoses, such as epilepsy or conduct disorder, we potentially 
can identify children who may have ASD but not yet carry a diagnosis in their EMR, or 
distinguish children on the basis of their disease severity. 
 This work was conducted in a single clinical cohort, using EMR from one medical 
institution. Further validation in a separate claims data set from another hospital or city 
will be necessary to understand the generalizability of the current findings. While our 
dataset covers twelve years of secular time, not all children contributed equal person-time 
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to the dataset; we have not yet taken into account child age or developmental stage into 
our models. While the CHS represents an opportunity to compare extensive EMR data 
with research-generated outcomes, we are also constrained by the smaller sample size 
available through the CHS. We hope to next extend these methods to an independent, 
larger administrative health dataset. 
 Future directions also include using random forests to predict scores in the Social 
Responsiveness Scale (SRS); SRS score itself can represent a broad, quantitative autistic 
phenotype that is distributed normally in the population (Constantino 2011). Currently, 
over 400 SRS questionnaires have been given to children in the BBC; as this sample size 
grows, we will begin to use the SRS data in addition to the SCQ. 
3.5     Conclusion 
 Machine learning and latent class analysis show promise in improving ICD-9-
CM-based ASD case identification. They may also help in identifying subgroups of 
children with ASD based on their clinical heterogeneity. 
 This work demonstrates a method for leveraging co-morbidity patterns in ASD for 
case and developmental subtype identification. It also raises the possibility that diagnostic 
patterns present in the medical record may improve early detection in clinical settings. 
Future extension of this work to larger samples in a variety of clinical settings will clarify 
its utility for improving research phenotypes and serving as a clinical tool. 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Chapter 4: An epigenome-wide association study 
to detect epigenetic alterations reflecting prior 
exposure to infections in utero, amongst 2-5 year 
old children in the Study to Explore Early 
Development 
4.1     Introduction 
4.1.1 What is epigenetics? 
 Epigenetics is the study of DNA regulation that is mitotically heritable, or passed 
from one cell to its daughter cell (Allis and Jenuwein 2016). These are aspects of genetic 
regulation that do not change the underlying DNA code, but allow for differential gene 
expression in different cell types or for dynamic response to the environment. The 
expression of DNA can be regulated through histone modifications; histones are the 
protein cores that genomic DNA is wrapped around, like beads connected by string. 
Histones have a modifiable tail, where particular amino acids can be enzymatically 
altered to increase or decrease transcription of the local DNA sequence. In addition to 
histone modification, there is another well-studied form of epigenetic regulation: DNA 
methylation. 
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4.1.2 DNA methylation 
  In DNA methylation, a methyl group (or, less commonly, a hydroxymethyl group) 
added to a specific DNA nucleotide can influence the expression of a gene either locally 
or at-a-distance. In humans, most DNA methylation changes involve the enzymatic 
addition or removal of a methyl group to the carbon in the fifth position of the cytosine 
ring (resulting in 5-methylcytosine) at a cytosine-guanine dinucleotide (CpG site). These 
methyl marks on DNA can differ over time, across cell types, and in response to the 
environment (Ladd-Acosta 2015). In humans, DNA methylation is important in 
regulating development (Iurlaro, von Meyenn et al. 2017), has been implicated in cancer 
as either a part of the pathogenic pathway or as a biomarker (Juodzbalys, Kasradze et al. 
2016), and reflects prior environmental exposures to toxicants (Huen, Yousefi et al. 2014) 
or even psychosocial stressors (Mehta, Klengel et al. 2013, Cecil, Smith et al. 2016).  
4.1.3 Techniques for measuring DNA methylation  
 There are numerous strategies for detecting and localizing differential DNA 
methylation (Callinan and Feinberg 2006). Many of the techniques for detecting DNA 
methylation rely on the chemistry of cytosine and 5-methylcytosine (Olkhov-Mitsel and 
Bapat 2012, Kurdyukov and Bullock 2016). In the presence of sodium bisulfite, 
unmethylated cytosines will deaminate to uracil, while methylated cytosines will remain 
unchanged; downstream sequencing or array-based hybridization tools can determine 
which sites were converted to uracil, and hence were unmethylated, by comparison of the 
degenerate sequence with either the sequenced untreated input DNA or with genomic 
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references. If a researcher is interested in the DNA methylation at specific regions, a low 
throughput technique such as bisulfite pyrosequencing could be appropriate (Bassil, 
Huang et al. 2013). Genome-wide technologies include whole genome bisulfite 
sequencing. However, these strategies generally require more input DNA and are more 
expensive than array-based technologies, which have become the standard for large 
epidemiologic studies of epigenetic changes in humans.  
4.1.4 Array-based DNAm measurement 
 DNA methylation can be assayed across the genome with an affordable platform, 
the Illumina Infinium HumanMethylation450 BeadChip methylation array ("450k 
platform" or "450k array"), which queries the degree of methylation at 485,512 genetic 
loci chosen to cover areas of biological interest, including genes, CpG islands, CpG 
island shores, FANTOM 4 promoters, predicted enhancers, and MHC regions (Bibikova, 
Barnes et al. 2011). This BeadChip methylation array evolved from an initial 27k 
platform (Bibikova, Le et al. 2009); a new platform with over 850,000 loci called 
MethylationEPIC is now available as well (Moran, Arribas et al. 2016). In the present 
study, we used the 450k array; to use this technology, input genomic DNA is first treated 
with sodium bisulfite, which converts unmethylated cytosines to uracil, as described 
above. The DNA is then denatured, neutralized, amplified, fragmented, and prepared for 
hybridization with the array BeadChips. Twelve samples are applied in separate wells to a 
single BeadChip, and hybridize to the 50mers covalently linked to the beads.   
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 The 450k array uses two different types of probes to assay the degree of 
methylation at specific CpG sites across the genome. Type I probes actually use two bead 
types for a specific CpG locus; one is specific to the sequence expected if the CpG site is 
methylated, while another is specific to the sequence expected if it is unmethylated. 
Methylation state is detected by a single-base extension after hybridization of the probe 
to the target sequence; depending on whether the CpG site is methylated or unmethylated, 
that beadtype will fluoresce. In contrast, Type II probes have a single beadtype that can 
differentiate methylated and unmethylated CpG sites; it will fluoresce in the red channel 
if the CpG was unmethylated, while it will fluoresce in the green channel if the CpG was 
methylated. The complex chemistry and design of the 450k array presents challenges for 
the normalization and interpretation of 450k array data, as addressed below. 
4.1.5 450k array and an epigenome-wide association study 
 Using the Illumina 450k array allows us to test for association of methylation at 
each measured locus with a phenotype of interest. This type of study is called an 
"epigenome-wide association study" or EWAS, in analogy to a genome-wide association 
study (GWAS)—though the 450k array is really genome-"scale," and not genome "wide," 
since by design the probes are densely clustered in some regions and absent in others 
(Chadwick, Sawa et al. 2015). In our study, we are interested in the detection of 
methylation differences that mark a history of prenatal exposure to maternal immune 
activation. 
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 Previous work using this technology has demonstrated that prenatal insults can 
epigenetically alter offspring. For example, prenatal exposure to tobacco smoke changes 
a newborn's DNA methylation in a set of locations across the genome, which forms an 
epigenetic signature reflecting prior exposure (Breton, Byun et al. 2009, Joubert, Haberg 
et al. 2012). This signature of prenatal exposure to maternal smoking persists through the 
first few years of childhood (Ladd-Acosta, Shu et al. 2016) and into adolescence (Lee, 
Richmond et al. 2015). 
 The conceptual framework presented below demonstrates three possible ways that 
infection, maternal immune activation, and brain and blood DNA methylation are related 
(Figure 4.1) (Ladd-Acosta 2015). Maternal immune activation is a useful construct to 
understand the detected associations between infections, fever, and immune markers such 
as CRP and autism. MIA may reflect a common pathway by which different prenatal 
inflammatory insults converge to affect the developing fetus. In model 1, MIA is 
responsible for epigenetic alterations in the developing brain, which are themselves 
causally related to or necessary for ASD development. It is most likely that the disease 
tissue of interest in the case of ASD is brain, not blood. MIA may additionally be 
responsible for epigenetic changes detectable in whole blood, but these may not be 
reflective of any changes present simultaneously in brain. If this is the case, changes in 
DNAm in the blood would be useful as a biomarker of MIA exposure, but would not 
necessarily themselves illuminate ASD pathogenesis.  
 In model 2, blood DNAm may reflect aspects of brain DNAm; differentially 
methylated regions generated in brain as a result of MIA exposure may spill over into 
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blood and be detectable (Davies, Volta et al. 2012). If this is the case, the magnitude of 
difference observed in blood between unexposed and exposed children is likely to be less 
than that present in the brain, but would still shed light on relevant epigenetic regions for 
understanding ASD pathology. 
 In model 3, neither brain nor blood DNAm are in the causal pathway of ASD 
development, but merely serve as biomarkers of an exposure that is causally related. 
Additionally, while not represented in the conceptual framework, is it possible that 
epigenetic changes are a consequence of ASD, and thus not in the causal pathway; they 
still could be associated with MIA exposure, however, if MIA is related to ASD risk. This 
possibility is difficult to assess without repeated DNAm measures at different ages. 
 In summary, DNA methylation differences in whole blood are most likely to serve 
as biomarkers of an exposure associated with autism spectrum disorder. They may also 
serve as proxies for the disease tissue of interest, if epigenetic changes in brain to some 
degree influence peripheral blood epigenetics. Differentiating between these two 
possibilities requires further investigation of a differentially methylated site with 
functional biological assays or comparison in different tissue types. 
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Figure 4.1: Three models for the potential relationship between infection, MIA, brain 
















1. Blood DNA methylation (DNAm) is a biomarker of MIA
2. Blood DNAm reflects brain DNAm, 








3. Blood and brain DNAm are biomarkers of MIA, 
                               but not in the causal pathway
4.2     Methods 
4.2.1 Study to Explore Early Development  
 Johns Hopkins and Kennedy Krieger comprise the Maryland site of the Centers 
for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) in 
the Study to Explore Early Development (SEED), one of six national SEED sites (Figure 
4.2). SEED is a national, CDC-funded case-control study with thorough phenotyping, 
retrospective data on prenatal exposures along with medical records, coupled with 
genotyping and epigenotyping arrays. The first phase of SEED (SEED I) collected data 
from over 2800 families (Schendel, Diguiseppi et al. 2012). Children were eligible for the 
ASD case group if they were born in a catchment area between 9/1/2003 and 8/31/2006 
and utilized relevant ASD services such as early intervention, special education, 
hospitals, and clinics. ASD cases were thus 2-5 years old at the time of recruitment. 
General population controls from the same area and born in the same period were 
randomly sampled from state vital records. Potential cases and controls were invited to 
participate in the study and consenting families were enrolled, followed by clinical ASD 
diagnoses and extensive biological and epidemiological data collection. 
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Figure 4.2: Centers for Autism and Developmental Disabilities Research and 
Epidemiology (CADDRE) and Data Coordinating Center for the Study to Explore Early 
Development (SEED), phase one.  
4.2.2 Exposure assessment  
 We modeled prenatal exposure to maternal immune activation as exposure to 
infection during the perinatal period, according to maternal self-report provided via 
structured telephone interview at the time of enrollment in SEED. Thus exposure was 
assessed retrospectively, when the children were aged 2-5 years. 
 The SEED maternal exposure interview specifically asked about history of 36 
different infections at any time during pregnancy and during each trimester. The most 
frequent categories of specific infections were genitourinary infection (bacterial 










UTI) and respiratory infection (influenza, pneumonia, URI). There was also an 
opportunity for open-ended response for "other conditions," which were matched to 
appropriate ICD codes by the SEED Data Coordinating Center. ICD codes for infections 
were then extracted from these "free text" responses.  
 History of an infection was asked for the three months prior to conception 
(preconception or T0), during the first trimester (T1), during the second trimester (T2), 
during the third trimester (T3), or while breastfeeding. A dichotomous "yes/no" variable 
was generated for each time period based on maternal report of any kind of infection 
(viral, bacterial, or fungal; any organ system). Trimester-specific exposure was not 
mutually exclusive; a mother could report exposure for multiple trimesters. A 
dichotomous variable for "any infection at any time" during pregnancy was created based 
on the T1, T2, T3 variables.  
4.2.3 Autism outcome  
 Autism outcome was assessed in SEED participants in a multistep process 
described in detail in prior literature (Wiggins, Reynolds et al. 2015). First, potential 
study participants were contacted by phone. During this invitation phone call, the family 
was asked to complete a brief ASD screener, the Social Communication Questionnaire 
(SCQ; Rutter, Bailey et al. 2003) (also see Chapter 3 of this dissertation). A score equal 
to or greater than 11 or a prior ASD diagnosis was used to identify children for 
comprehensive developmental and ASD-specific evaluation. Children with no prior ASD 
diagnosis and an SCQ below 11 were asked to complete a shorter study visit with 
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cognitive, social, and motor developmental testing. A study algorithm based on prior 
literature, best practice guidelines, and clinical experience was developed to identify four 
groups of children: (1) ASD, (2) suspected ASD but incomplete study evaluation, (3) 
developmental disability or DD, and (4) population control.  
 We generated a binary variable based on these research classifications of ASD 
status. Children were given a '1' if they were identified as an ASD case or a suspected 
ASD case, and a '0' if they were a population control. No children in the DD group were 
selected for DNA methylation measurement, and are not included in the current analysis. 
  
4.2.4 Epigenetic outcome data 
 Genomic DNA from whole blood was isolated using the QIAsymphony midi kit 
(Qiagen) at the Johns Hopkins Biological Repository (SEED Biorepository) as specified 
by the manufacturer. We bisulfite treated 500 ng of gDNA using the EZ DNA methylation 
kit Zymo Research Corp, Orange, CA, USA) according to the manufacturer’s 
recommendations, as specified for downstream processing with 450K. To obtain genome-
scale methylation measurements, bisulfite treated DNA samples were processed on the 
Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) at the Johns 
Hopkins SNP Center, in accordance with the manufacturer’s recommendations, to obtain 
methylation data at 485,512 loci. Samples were randomized across and within plates to 
minimize potential batch and confounding effects. Sample replicates were included 
across plates for quality control to ensure methylation measurement reproducibility. 
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 Quality control measures for the SEED 450k data were applied at both the sample 
and locus (probe) levels. As is standard in genetic and epigenetic analyses, these 
measures included removing sex-discordant, duplicate, or poorly performing samples; 
and removing poorly performing probes.  
4.2.5 Statistical analyses 
 All statistical analyses were performed using R-3.1.x and 3.2.x and Bioconductor 
3.0, specifically the packages minfi and Bumphunter, which are designed for the handling 
and analysis of epigenetic data obtained from the 450k platform (Gentleman, Carey et al. 
2004, Jaffe, Murakami et al. 2012, Aryee, Jaffe et al. 2014, Huber, Carey et al. 2015).  
 Main effect analysis 
 Epigenetic data, ASD case status, and available covariate data were linked using a 
unique study family ID. The subset of children with epigenetic data, ASD case status, and 
all covariates was used. The association between child risk of ASD and maternal 
infection exposure prior to pregnancy, during each trimester or at any time during 
pregnancy, or while breastfeeding was assessed using unadjusted and adjusted logistic 
regression. Models were adjusted for child sex, study site (California, Colorado, Georgia, 
Maryland, North Carolina, and Pennsylvania), and the child's age in months at the time of 
their clinic visit. The threshold for significance for each association was a p value <0.05 
and an odds ratio 95% confidence interval excluding 1.  
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 Epigenetic data preprocessing 
 Raw intensity data (.idat files) were imported using the read.450k.exp() function 
in minfi. Beta values were obtained by dividing the methylated probe intensity by the 
overall probe intensity (the sum of the methylated and unmethylated probe intensities); 
beta values represent percent methylation, from 0 to 100% methylated. Beta values were 
then logit-transformed to obtain M-values, which are normally distributed and more 
appropriate for our statistical methods (Du, Zhang et al. 2010). Data were then 
normalized with noob, which uses background probes and dye-bias correction to 
normalize data based on technical variation (Triche, Weisenberger et al. 2013). 
 Batch correction 
 Because a second batch of SEED samples was run several years after the first 
batch, statistical control for the unmeasured confounders associated with different run 
dates had to be performed. We used two different strategies for batch correction: ComBat 
(Chen, Grennan et al. 2011) and surrogate variable analysis with the R package sva 
(Leek, Johnson et al. 2012). While ComBat directly adjusts for the known batches, sva 
will detect latent sources of variation in a study sample; the latent variation can then be 
visualized against known sources of technical variability, including batch. These two 
methods of batch correction were performed in parallel, and the downstream effects on 
single-site association methods and genomic control were compared. 
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 This epigenome-wide association study used both single site association methods 
as well as regional methods (Rakyan, Down et al. 2011).  
 Single site association analysis 
 Differentially methylated positions (DMPs) were identified using linear models, 
both unadjusted and adjusted for appropriate confounders, as accounted for by the 
surrogate variables estimated by sva. Potential confounders of the relationship between 
maternal infection and offspring methylation include technical variation, such as that due 
to batch or sample position on the 450k array, as well biological variation unrelated to our 
question of interest, including cell type composition, sex, and ancestry.  
 Epigenetic analyses conducted in whole blood are complicated by the 
heterogenous cell population in the sample. We generally wish to ensure that any detected 
methylation differences are not driven by a change in the relative proportion of the cells 
comprising the sample. There are two strategies to address this: (1) cell types in a sample 
are measured with a laboratory assay and then compared across exposed and unexposed 
individuals, to ensure that cell type proportions are stable despite exposure status, (2) cell 
type composition is estimated based on a subset of probes in the 450k platform that have 
been validated to predict relative cell proportions (Jaffe and Irizarry 2014). If not adjusted 
for, differences in cell type proportions among exposed and unexposed samples could 
result in a spurious association between exposure and methylation. Because we were 
interested in epigenetic differences that are not caused by differences in the frequency of 
one particular cell type over another, we ensured that the estimated surrogate variables 
adjusted for cell type. 
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 Similarly, because we were interested in epigenetic differences related to infection 
exposure and not the individual's sex, we also ensured that the surrogate variables 
accounted for sex. 
 Additionally, if a study is not homogenous with regard to ancestry, it is important 
to assess for the possibility of confounding by population stratification. We found that our 
estimated surrogate variables did not account for ancestry. However, in SEED, principal 
components of ancestry have been derived from genotyping data; we included the first 
three principal components of ancestry in a sensitivity analysis to ensure that our results 
were stable. 
 The model for the single site association analysis was structured so that 
methylation at a single probe site was the outcome, represented as a linear combination of 
variables representing the exposure of interest and the potential confounders:  
Using the lmFit() and eBayes() functions in minfi, an empirical Bayes method was used 
to obtained moderated t-statistics where the sample variances were moved towards a 
pooled value, allowing more stable inferences (Smyth 2004). Model performance was 
evaluated by assessing genomic inflation; appropriate control of genomic inflation 
(lambda ≤ 1.05) suggests that a valid model has been developed to fit the study data. 
Essentially, over 455,000 linear models were run estimating the association between 
prenatal exposure to infection at a particular time point and methylation at a given probe 
site. The p-values for the association between prenatal infection exposure and 
methylation at each probe site were extracted and DMPs ranked based on significance. P-
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M-value = B0 + B1infection + B2x2 + … + Bnxn
values were adjusted for multiple testing within the model, generating False Discovery 
Rates (FDR) or q-values using the Benjamini-Hochberg correction. We took a q-value < 
0.05 to be evidence for significance, so we expect that out of the null hypotheses we 
reject, 5% will be false discoveries. Based on the number of tested probes and an alpha 
level of 0.05, we also calculated a Bonferroni significance threshold (1.0973e-07). 
  
 Regional association analysis 
 Next, we used a region-finding approach that takes advantage of probe clustering 
on the 450k platform to detect larger areas of consistent methylation differences between 
cases and controls (differentially methylated regions, DMRs) (Jaffe, Murakami et al. 
2012). This is conducted with the bumphunter() function as implemented in the minfi 
package, and was performed with adjustment for the same set of surrogate variables used 
in the single-site association analysis. Parameters for bumphunting were set with a max 
distance between probes within a cluster of 250 bp; significance was estimated by family-
wise error rates (FWER) for 1000 bootstraps. Empirical p-values and FWER were 
estimated for the first percentile of differentially methylated regions, on the basis of 
length + area under the curve as well as area alone. The properties of the empirical p-
values are not well understood, and so we based our assessment of significance on the 
FWER. The family wise error rate is the proportion of null bootstraps for which any 
DMR has a value as or more extreme than the DMR of interest (see Appendix B for an 
example of an Epigenome Wide Association Study, utilizing both single site and regional 
analysis). 
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4.3     Results 
4.2.1 Sample description 
 The frequencies of exposed and unexposed children in SEED for infection during 
pregnancy, trimester-specific infection, and before and after pregnancy (while 
breastfeeding) are shown in Table 4.1. The epigenetic analytic sample included 620 males 
and 309 females. Two subjects were missing data on ASD case status, but among the 
remaining subjects there were 500 population controls and 427 ASD cases. Five subjects 
were missing data on age, but the mean age among the remaining 924 subjects was 59.3 
months (4.9 years) with a range of 34.6 to 70.7 months (2.9 to 5.9 years). The epigenetic 
sample reflects the age and sex distribution of the larger SEED sample (Wiggins, Levy et 
al. 2015). There were 171 subjects from the California SEED site; 200 from the Colorado 
site; 141 from the Georgia site; 163 from the Maryland site; 124 from the North Carolina 
site; 128 from the Pennsylvania site; and two subjects without an annotated study site.  
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Table 4.1: Prenatal exposures for children with epigenetic data in 
SEED 
4.2.2 Analysis of the main effect 
 The subset of children with epigenetic data, ASD case status, and all covariates 
was used (n=924). Two children with epigenetic data were missing information on ASD 
case status, and three children with epigenetic data were missing information on study 
site or age at clinic visit. In this subset of children with epigenetic data and infection 
exposure data, after adjustment for child sex, child age at study participation, and study 
site, we found a significant association between child ASD status and maternal infection 
in the three months prior to conception; and during trimester 1, 2, or 3 (Table 4.2). 
No, unexposed Yes, exposed
Infection in 3 months prior to 
conception
841 (90.5%) 88 (9.5%)
Infection at any time in 
pregnancy
589 (63.4%) 340 (36.6%)
Trimester 1 799 (86.0%) 130 (14.0%)
Trimester 2 754 (81.2%) 175 (18.8%)
Trimester 3 718 (77.3%) 211 (22.7%)
Infection while breastfeeding 815 (87.7%) 114 (12.3%)
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Table 4.2: Unadjusted and adjusted OR for ASD risk after prenatal 
infection exposure with 95% confidence intervals 
a adjusted for child sex, child age at clinic visit, and study site 
Bold denotes statistically significant associations 
4.2.3 Epigenetic data description 
 The 450k array was run on 1014 samples, including placenta and liver control 
samples and 12 cross-array duplicate samples. After data preprocessing and quality 
control measures, 970 samples and 455,664 probes remained for further analysis (Figure 
4.3). To run a complete case analysis, our analytic sample was less the 41 individuals for 
whom we have no infection exposure information (final analytic sample size = 929). 














































and batch two (6/18/15 − 7/2/15; 355 samples)—and were balanced on infection 
exposure status (Table 4.3).  








Table 4.3: Distribution of infection exposure by 450k batch 
4.2.4 Batch Correction 
 We noted significant p-value deflation in both completely unadjusted data (Figure 
4.4) and data corrected for batch with ComBat (Figure 4.5; data shown for the analysis of 
any infection at any time during pregnancy, though the same pattern was seen for the 
other exposure variables). With a single-site association analysis, the expected versus 
observed p-values can be compared with a qq plot (Casella and Berger 2002). An 
estimate of the p-value inflation can be assessed with the lambda statistic; in genome-
wide association studies, significant p-value inflation can be observed and the expectation 
is that adjustment for appropriate confounders will decrease the lambda < 1.05 to 
minimize false positive discovery. It was unexpected here to see deflation, rather than 
inflation. Correction for batch with ComBat and subsequent direct adjustment for 
confounders (including sample sex and estimated cell type composition) did not alleviate 
the p-value deflation. 
 We then pursued using sva (surrogate variable analysis) to estimate surrogate 
variables for latent sources of variation in the data, including batch. For exposure to any 
infection at any time during pregnancy, 30 surrogate variables were estimated. Then each 
surrogate variable was regressed on potential explanatory variables, including batch, 
Batch unexposed exposed
1 363 (63.2%) 211 (36.8%)
2 226 (63.7%) 129 (36.3%)
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array plate, array row position, sample sex, and estimated cell types (CD8 T cells, CD4 T 
cells, natural killer cells, B cells, monocytes, and granulocytes) (Figure 4.6). The first 18 
surrogate variables adequately captured technical sources of variation (plate, batch, row 
6) and biological sources of variation different from the main question we were interested 
in (sex, cell type composition) (Figure 4.7). We also found that there was a significant 
association between three of the surrogate variables and ASD case status, indicating that 
including the surrogate variables in our analysis also accounted for variation in 
methylation that is due to the ASD case-control design of SEED (Figure 4.8). 
 We did note that the surrogate variables were not associated with ancestry (see 
Figure 4.8, demonstrating that the surrogate variables estimated for third trimester 
infection exposure are not significantly associated with ancestry principal components 
derived from SNP array data). In a sensitivity analysis, we adjusted for the first three 
ancestry principal components in addition to the first 18 surrogate variables; for third 
trimester infection exposure, the two differentially methylated were loci were still the top 
ranked probes, and the first still had a q-value < 0.05. Accounting for ancestry did not 
substantially alter our results. 
 Moving forward, we adjusted for the first 18 surrogate variables when testing the 
association between infection during or prior to pregnancy and DNA methylation in 
offspring at age 2-5 years. This method of adjustment improved the p-value deflation 
observed in the completely unadjusted data and in the data corrected for batch with 
ComBat (Figure 4.9 cf. Figure 4.4 and Figure 4.5; Table 4.4).  
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Figure 4.4: qq plot for the single site association analysis of any infection at any time 
during pregnancy, without batch correction or adjustment for confounders. Lambda is 
estimated to be 0.75, which quantifies the decrease in observed -log10(p-values) 
compared to the expectation. 
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Figure 4.5: qq plot for the single site association analysis of any infection at any time 
during pregnancy, with batch correction performed via ComBat but without adjustment 
for other confounders. Lambda is estimated to be 0.86, which quantifies the decrease in 
observed -log10(p-values) compared to the expectation. 
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Figure 4.6: Heat map showing the degree of significance of the association between a 
surrogate variable (1-30, vertical axis) estimated for the comparison of subjects exposed 
and unexposed to any infection at any time during pregnancy, and an explanatory variable 
(horizontal axis). Blue shading increases as the p-value for the association increases 














































































Figure 4.7: Associations that meet the Bonferroni threshold for significance are marked 
in red (p-value < 0.000139; corrected for testing 30 surrogate variables against 12 
explanatory variables, or 360 tests). Note, no surrogate variables are significantly 
associated with variable "array," which represents the specific sample well, or "Any 
pregnancy inf" (infection, any time during pregnancy), which is the source of biological 
variation we set out to protect in estimating the latent sources of technical and unwanted 
biological variation. The first 18 surrogate variables adequately capture variation 
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Figure 4.8: Associations that meet the Bonferroni threshold for significance are marked 
in red. These surrogate variables were estimated for the comparison of third trimester 
infection exposed and unexposed children. The surrogate variables do account for 
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Figure 4.9: qq plot for the single site association analysis of any infection at any time 
during pregnancy, with batch correction and adjustment for other confounders performed 
via sva. Lambda is estimated to be 0.98. 
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Table 4.4: Lambda values for the single site analysis for each 
exposure variable 
4.2.5 Single-site association analysis (Differentially Methylated Positions) 
 After adjustment for the first 18 surrogate variables, we estimated the association 
between methylation at a particular locus and each exposure variable. For children 
exposed to any infection at any time during gestation, we did not find any differentially 
methylated positions (Table 4.5). For children whose mothers reported an infection in the 
three months prior to their conception, we found a single differentially methylated probe 
(Table 4.6). This was located at genomic position chr5:172903876. For children exposed 
to any infection during trimester 1 or trimester 2, we did not find any differentially 
methylated positions (Table 4.7, Table 4.8). For children exposed to any infection during 
trimester 3, we found two differentially methylated positions (Table 4.9): chr3:12947823 
Unadjusted
Adjusted for first 
18 surrogate 
variables
Infection in 3 months prior to 
conception
0.76 1.10
Infection at any time in 
pregnancy
0.75 0.98
Trimester 1 0.70 0.99
Trimester 2 0.76 1.00
Trimester 3 0.84 1.06
Infection while breastfeeding 0.61 1.01
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within the gene body of IQSEC1, and chr1:110306507 within the gene body of EPS8LS. 
For children whose mothers reported an infection while breastfeeding, we did not find 
any differentially methylated positions; however, the top ranked probe (q-value < 0.1) is 
also within the gene body of IQSEC1, though upstream of the probe identified in the 
trimester 3 infection exposure analysis (Table 4.10). We performed a BLAT analysis of 
the hybridization sequence of the three significantly differentially methylated probes, and 
found that the full sequence unambiguously mapped to the region expected based on the 
Illumina probe annotation (obtained using the getAnnotation() function in the minfi 
package) (Table 4.11).  
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Table 4.5: Top ranked 450k probes for any infection at any time 
during pregnancy 
 a Difference in mean percent methylation levels between patients exposed and unexposed 
to infection during gestation. Positive values reflect relative hypermethylation and negative 
values relative hypomethylation in individuals exposed to infection compared to those unexposed. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi Bioconductor package. 
Chromosome Position Gene ∆Ma P value Adjusted q-value
Annotated 
SNPb
chr17 3828268 ATP2A3 -0.43 2.46E-06 0.64977
chr1 181683239 CACNA1E 0.62 2.85E-06 0.64977
chr4 137732125 -0.37 6.05E-06 0.91944
chr8 47120700 0.33 1.31E-05 0.99996
chr8 145579317 FBXL6; C8ORFK29 -0.12 1.56E-05 0.99996
chr8 35685207 1.26 1.71E-05 0.99996
chr2 158175831 ERMN -0.14 2.19E-05 0.99996
chr16 81040735 CENPN -0.12 2.71E-05 0.99996
chr8 2585976 -3.00 2.92E-05 0.99996
chr14 24458099 DHRS4L2 0.54 3.01E-05 0.99996
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Table 4.6: Top ranked DMPs after maternal infection exposure 3 
months prior to conception 
 a Difference in mean percent methylation levels between patients exposed and unexposed 
to infection during gestation. Positive values reflect relative hypermethylation and negative 
values relative hypomethylation in individuals exposed to infection compared to those unexposed. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi Bioconductor package. 
Chromosome Position Gene ∆Ma P value Adjusted q-value
Annotated 
SNPb
chr5 172903876 -2.68 1.15E-08 0.005
chr12 54385625 MIR196A2 -1.95 3.05E-07 0.069
chr14 89715336 FOXN3 -3.01 1.14E-06 0.161 rs115466766
chr20 36767986 TGM2 -0.48 1.67E-06 0.161
chr20 981673 RSPO4 -3.69 1.77E-06 0.161 rs11906926
chr1 21504121 EIF4G3 -2.12 2.25E-06 0.171
chr20 34287060
ROMO1; 
NFS1 1.99 4.70E-06 0.238
chr6 28864188 1.39 5.22E-06 0.238
chr15 25312161
SNORD116-7;
SNORD116-5 -1.42 5.43E-06 0.238
chr7 6268584 CYTH3 1.14 6.05E-06 0.238
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Table 4.7: Top ranked DMPs after maternal infection exposure 
during trimester 1 
 a Difference in mean percent methylation levels between patients exposed and unexposed 
to infection during gestation. Positive values reflect relative hypermethylation and negative 
values relative hypomethylation in individuals exposed to infection compared to those unexposed. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi Bioconductor package. 
Chromosome Position Gene ∆Ma P value Adjusted q-value
Annotated 
SNPb
chr8 101225344 SPAG1 2.00 2.91E-06 0.65434
chr1 145415441 HFE2 0.76 6.03E-06 0.65434
chr8 101225252 SPAG1 2.14 7.43E-06 0.65434
chr5 86709126 CCNH 0.88 8.07E-06 0.65434
chr22 19436867 C22orf39 0.50 1.09E-05 0.65434
chr6 42018203 TAF8 0.59 1.09E-05 0.65434
chr7 134001865 SLC35B4 0.14 1.11E-05 0.65434
chr7 155534636 RBM33 -0.19 1.31E-05 0.65434
chr4 184021351 WWC2; C4orf38 -0.53 1.41E-05 0.65434
chr8 72987762 TRPA1 0.28 1.61E-05 0.65434
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Table 4.8: Top ranked DMPs after maternal infection exposure 
during trimester 2 
 a Difference in mean percent methylation levels between patients exposed and unexposed 
to infection during gestation. Positive values reflect relative hypermethylation and negative 
values relative hypomethylation in individuals exposed to infection compared to those unexposed. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi Bioconductor package. 
Chromosome Position Gene ∆Ma P value Adjusted q-value
Annotated 
SNPb
chr14 90240124 HCG26 -0.29 1.42E-07 0.06473
chr6 31438151 C21orf63 -2.18 1.80E-06 0.41114 rs9267136
chr21 33784769 MDP1 -0.04 6.12E-06 0.85501
chr14 24685281 GABBR1 -0.08 1.42E-05 0.85501
chr6 29578496 0.28 1.62E-05 0.85501
chr11 64270338 WNT16 -0.73 1.62E-05 0.85501
chr7 120969079 MSH4 0.69 2.11E-05 0.85501
chr1 76262373 EPN1 -0.70 2.14E-05 0.85501
chr19 56196747 MRPL12 0.03 2.15E-05 0.85501
chr17 79670933 HCG26 -0.14 2.32E-05 0.85501
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Table 4.9: Top ranked DMPs after maternal infection exposure 
during trimester 3 
 a Difference in mean percent methylation levels between patients exposed and unexposed 
to infection during gestation. Positive values reflect relative hypermethylation and negative 
values relative hypomethylation in individuals exposed to infection compared to those unexposed. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi Bioconductor package. 
Chromosome Position Gene ∆Ma P value Adjusted q-value
Annotated 
SNPb
chr3 12947823 IQSEC1 -0.66 3.02E-08 0.01378
chr1 110306507 EPS8L3 -0.87 1.59E-07 0.03633
chr19 51220202 SHANK1 -0.15 5.12E-07 0.06654
chr16 84746995 USP10 -0.54 6.50E-07 0.06654
chr11 130013355 APLP2 0.31 7.81E-07 0.06654
chr17 38468610 RARA -0.66 8.76E-07 0.06654
chr8 37758453 RAB11FIP1 1.22 2.78E-06 0.18120
chr17 40175841 NKIRAS2 1.02 3.47E-06 0.19754
chr2 10182525 KLF11 -1.09 4.63E-06 0.23236
chr17 62252524 TEX2 2.00 5.56E-06 0.23236
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Table 4.10: Top ranked DMPs after maternal infection exposure 
while breastfeeding
 a Difference in mean percent methylation levels between patients exposed and unexposed 
to infection during gestation. Positive values reflect relative hypermethylation and negative 
values relative hypomethylation in individuals exposed to infection compared to those unexposed. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi Bioconductor package. 
Chromosome Position Gene ∆Ma P value Adjusted q-value
Annotated 
SNPb
chr3 13063165 IQSEC1 1.01 2.44E-07 0.08581
chr6 6971315 -0.31 3.77E-07 0.08581
chr6 28831393 0.62 2.83E-06 0.33016
chr10 104210692 C10orf95 0.30 2.90E-06 0.33016
chr12 8219358 C3AR1 2.41 4.71E-06 0.34278
chr7 2644645 IQCE -0.43 6.12E-06 0.34278
chr13 73356092 PIBF1;DIS3 0.52 6.78E-06 0.34278
chr6 33384537 CUTA 1.04 6.91E-06 0.34278
chr13 43395572 -1.21 7.04E-06 0.34278
chr8 117778752 UTP23 0.11 8.06E-06 0.34278
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Table 4.11: BLAT (BLAST-like alignment tool) analysis 
  
 For the three probes that were differentially methylated based on infection 
exposure, we plotted the percent methylation for four groups: ASD cases who were 
exposed; ASD cases who were unexposed; population controls who were exposed; and 
population controls who were unexposed. For the probe that was differentially 
methylated based on maternal preconception infection, cases and controls were separated 
based on their preconception (T0) exposure status (Figure 4.10). There were 52 children 
with ASD who were T0 exposed; 375 children with ASD who were T0 unexposed; 36 
population controls who were T0 exposed; and 464 population controls who were T0 
unexposed. For the two probes that were differentially methylated based on trimester 3 
(T3) exposure, we separated ASD cases and population controls based on their T3 
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were T3 exposed; 314 children with ASD who were T3 unexposed; 98 population 
controls who were T3 exposed; and 402 population controls who were T3 unexposed. 
 Next, we subset the data to those children whose mothers reported never having 
an infection during their pregnancy (n=589) and to those children whose mothers 
reported an infection during trimesters 1, 2, and 3 (n=59) and visualized the methylation 
at each of the three positions identified as significant in the full sample (Figures 4.13 - 
4.15). 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Figure 4.10: DNA methylation of children age 2-5 enrolled in SEED on chromosome 5 
at position 172903876, as measured by a probe on the 450k array. 927 children are 
plotted based on maternal report of preconception infection and ASD case status. Median 
percent methylation for each exposure-ASD group is marked by a short horizontal line. 
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Figure 4.11: DNA methylation of children age 2-5 enrolled in SEED on chromosome 3 
at position 12947823, as measured by a probe on the 450k array. 927 children are plotted 
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Figure 4.12: DNA methylation on chromosome 1 at position 110306507 as measured by 
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Figure 4.13: DNA methylation on chromosome 5 at position 172903876, among children 
whose mothers were never sick during their pregnancy (n=589) and children whose 
mothers reported being sick every trimester of their pregnancy (n=59). On average, 
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Figure 4.14: DNA methylation at chr3:12947823, among children whose mothers were 
never sick during their pregnancy (n=589) and children whose mothers reported being 
sick every trimester of their pregnancy (n=59). On average, children whose mothers were 
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Figure 4.15: DNA methylation at chr1:110306507, among children whose mothers were 
never sick during their pregnancy (n=589) and children whose mothers reported being 
sick every trimester of their pregnancy (n=59). On average, children whose mothers were 
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4.2.6 Regional analysis (Differentially Methylated Regions) 
 Next, we used a region finding approach for our six exposure variables (Tables 
4.12-4.17). While none of the identified regions are statistically significantly different 
between exposure groups, there are several regions that were identified in the top ranked 
DMRs across multiple comparisons: a 57 bp region in the promoter of SDHAP3 (Figure 
4.16), a 775 bp region at the 5' end of RUFY1 (Figure 4.17), and a 120 bp region 
overlapping an exon of PIEZO1 (Figure 4.18).  
Table 4.12: Top ranked DMRs for any infection at any time during 
pregnancy 
 a Number of base pairs that the DMR covers. 'ss' indicates that the DMR was composed 
of a single probe site, rather than a cluster of probes. 
b Nearest annotated gene.	
Chromosome Position Distancea Geneb Location FWER FWER area
chr21 43989949 ss SLC37A1 inside intron 0.16700 1
chrX 70712215: 70712810 595 TAF1 inside intron 0.57800 0.855
chr7 22481962 ss STEAP1B inside intron 0.58300 1
chr6 41068553: 41068752 199 NFYA inside exon 0.75100 0.962
chr3 27674461: 27674472 11 EOMES downstream 0.79000 1
chr19 57742112: 57742444 332 AURKC overlaps 5' 0.80400 0.987
chr5 178986131: 178986906 775 RUFY1 overlaps 5' 0.84200 0.999
chr5 1594676: 1594733 57 SDHAP3 promoter 0.89100 1
chr9 115771599 ss ZNF883 inside intron 0.89400 1
chr12 131118426: 131118654 228 RIMBP2 inside intron 0.95100 1
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Table 4.13: Top ranked DMRs for any infection prior to conception 
 a Number of base pairs that the DMR covers. 'ss' indicates that the DMR was composed 
of a single probe site, rather than a cluster of probes. 
b Nearest annotated gene.	
Chromosome Position Distancea Geneb Location FWER FWER area
chr5 1594676:1594733 57 SDHAP3 promoter 0.30800 0.954
chr1 75198211:75199117 906 CRYZ overlaps 5' 0.31300 0.559
chr14 24779793:24780734 941 LTB4R2
overlaps exon 
upstream 0.44800 0.75
chr2 54086854:54087343 489 ASB3 overlaps 5' 0.49900 0.795
chr12 7781004:7781431 427 APOBEC1 downstream 0.59700 0.984
chr3 182817190:182817584 394 MCCC1 overlaps 5' 0.68700 0.945





TRIM34 overlaps 5' 0.83900 1
chr15 100821466:100821466 ss ADAMTS17 inside exon 0.85300 1
chr20 46415320:46415320 ss SULF2 inside exon 0.89300 1
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Table 4.14: Top ranked DMRs for any infection exposure during 
the first trimester 
 a Number of base pairs that the DMR covers. 'ss' indicates that the DMR was composed 
of a single probe site, rather than a cluster of probes. 
b Nearest annotated gene. 
Chromosome Position Distancea Geneb Location FWER FWER area
chr6 33049983: 33050124 141 HLA-DPB1 inside intron 0.20800 0.999
chr19 13875014: 13875137 123 MRI1 promoter 0.41300 0.999
chr5 135415948:135416613 665 VTRNA2-1 covers 0.41800 0.698
chr1 75198211: 75199117 906 CRYZ overlaps 5' 0.43100 0.715
chr6 30039374: 30039524 150 RNF39
overlaps exon 
upstream 0.45900 0.751
chr14 24779793: 24780734 941 LTB4R2
overlaps exon 
upstream 0.62000 0.903
chr8 101224915:101225361 446 SPAG1
overlaps exon 
upstream 0.62300 0.966
chr6 29648590: 29649092 502 ZFP57 upstream 0.69300 0.966
chr11 124613956 ss NRGN inside intron 0.83800 1
chr6 28945182: 28945507 325 ZNF311 downstream 0.91500 0.994
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Table 4.15: Top ranked DMRs for any infection during the second 
trimester 
 a Number of base pairs that the DMR covers. 'ss' indicates that the DMR was composed 
of a single probe site, rather than a cluster of probes. 
b Nearest annotated gene.	
Chromosome Position Distancea Geneb Location FWER FWER area
chr6 32064212:32064660 448 TNXB inside exon 0.31700 0.627
chr10 49654342 ss ARHGAP22 inside exon 0.63700 1
chr3 195489708:195490309 601 MUC4
overlaps exon 
downstream 0.64100 0.884
chrX 70712215:70712810 595 TAF1 inside intron 0.73800 0.933
chr6 30039027:30039206 179 RNF39 inside exon 0.81500 0.957
chr8 10049871 ss MSRA inside intron 0.85700 1
chr17 5403053:5403516 463 LOC728392
overlaps two 
exons 0.89600 1
chr1 240620177 ss FMN2 inside intron 0.90200 1
chr11 66317822 ss ACTN3 inside intron 0.90200 1
chr8 143751796:143751801 5 PSCA inside exon 0.93700 1
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Table 4.16: Top ranked DMRs for any infection during the third 
trimester 
a Nearest annotated gene.	
Chromosome Position Distance Genea Location FWER FWER area
chr6 30039376: 30039476 100 RNF39
overlaps exon 
upstream 0.42800 0.726
chr16 88803931: 88804051 120 PIEZO1
overlaps exon 
downstream 0.48600 1
chr6 29648590: 29649092 502 ZFP57 upstream 0.49000 0.767
chr8 143751796:143751801 5 PSCA inside exon 0.50700 1
chr6 32551749: 32552453 704 HLA-DRB6 overlaps 5' 0.53300 0.842
chr5 178986131:178986906 775 RUFY1 overlaps 5' 0.61500 0.877
chr6 29648379: 29648525 146 ZFP57 upstream 0.72500 0.955
chr5 1594676: 1594733 57 SDHAP3 promoter 0.74100 0.995
chr1 110254709:110254896 187 GSTM5 overlaps 5' 0.75200 0.991
chr1 248100345:248100614 269 OR2L13 overlaps 5' 0.75600 0.961
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Table 4.17: Top 10 ranked DMRs for any infection while 
breastfeeding 
 a Number of base pairs that the DMR covers. 'ss' indicates that the DMR was composed 
of a single probe site, rather than a cluster of probes. 
b Nearest annotated gene.	
  
 
Chromosome Position Distancea Geneb Location FWER FWER area
chr8 1140574 ss ERICH1-AS1 downstream 0.13000 1
chr1 248100228:248100614 386 OR2L13 overlaps 5' 0.13400 0.473
chr1 205818956:205819609 653 PM20D1 overlaps 5' 0.15400 0.532
chr15 28200653 ss OCA2 inside intron 0.53100 1
chr2 113992762:113993313 551 PAX8 covers exon(s) 0.63100 0.884
chr1 146549909:146549940 31 NBPF13P downstream 0.73000 1
chr4 165878037:165878219 182 TRIM61 inside intron 0.77300 0.988
chr17 57053: 57120 67 RPH3AL downstream 0.86400 1
chr17 6558064: 6558440 376 MIR4520-1 close to 3' 0.94200 1
chr5 1594676: 1594733 57 SDHAP3 promoter 0.94900 1
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Figure 4.16: A 57 bp region in the promoter of SDHAP3 that was in the top 10 ranked 
regions for the comparison of any infection during pregnancy, preconception infection, 
infection during T3, and infection while breastfeeding, though FWER > 0.1 for all 
comparisons. Plotted is the comparison of preconception maternal infection exposed 
























































































































































































































































































































































































































































































































































































































































































Figure 4.17: A 775 bp region at the 5' end of RUFY1 that was in the top ranked regions 
for the comparison of any infection at any time during pregnancy and infection during 
T3, though FWER > 0.1 for all comparisons. Plotted is the comparison of third trimester 




















Figure 4.18: A 120 bp region overlapping an exon of PIEZO1 that was in the top 10 
ranked regions for the comparison of any infection prior to conception and infection 
during the third trimester, though FWER > 0.1 for all comparisons. Plotted is the 











































































































































































































































































































4.4     Discussion  
 We tested for associations between prenatal infection exposure and DNA 
methylation in childhood blood in an agnostic, genome-scale approach. Such an 
epigenome-wide approach is superior to a candidate region study, as it tests for 
associations we may not expect based on our current imperfect understanding of the 
science. We represented maternal immune activation as infection during pregnancy for 
two reasons: (1) infection is likely to be the most common cause of MIA, as its reported 
prevalence is up to 60% in both retrospective and prospective interviews of pregnant 
women (Collier, Rasmussen et al. 2009), and (2) it is a prenatal exposure that is 
commonly collected in epidemiological studies, allowing for comparison with the 
literature. 
 We found no probes that were differentially methylated due to exposure to any 
infection at any time during pregnancy; exposure to any infection during the first or 
second trimester; or exposure to any infection when breastfed. We also found no regions 
that had a family wise error rate less than 0.05 for differential methylation in areas of 
probe clustering, for any of the six exposures of interest.  
 However, we found a single differentially methylated probe (q-value < 0.05, p-
value < 1.0973e-07), among children whose mothers reported an infection in the three 
months prior to their conception. This was located at position chr5:172903876, which is 
in an open sea intergenic region that was included on the 450k array due to the presence 
of an enhancer site. The ENCODE project predicts that this position is near an enhancer-
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like region in human astrocytes, a non-neuronal cell type found predominantly in 
synapses in the brain and spinal cord that may be involved in autism etiology 
(Consortium 2012, Blanco-Suarez, Caldwell et al. 2017). It is possible that this exposure 
is a proxy for general maternal health prior to conception, rather than specific to 
infection; it is also possible that report of an infection prior to conception actually 
overlaps with very early pregnancy. 
 We also found two probes that were differentially methylated in children who 
were exposed to an infection during the third trimester of their gestation. The first is at 
position chr3:12947823 (q-value < 0.05, p-value < 1.0973e-07), which is within the gene 
body of IQSEC1. IQSEC1 is thought to be involved in synaptic transmission, as both a 
scaffolding and signaling protein (Um 2016). The second is at position chr1:110306507 
(q-value < 0.05), within the gene body of EPS8LS; this gene is not well studied but is 
likely involved in actin regulation, and the region is predicted to be an enhancer in 
muscle and skin tissues and hematopoietic stem cells (Offenhauser, Borgonovo et al. 
2004, Consortium 2012). While the absolute difference in percent methylation was 
modest when comparing exposed and unexposed in the full sample, the differences were 
more marked when looking specifically at children whose mothers reported infections 
throughout pregnancy compared to those whose mothers had no infections. This may 
reflect a dose-response relationship between a cumulative prenatal infection exposure and 
methylation at the identified sites. Additionally, small absolute differences in DNA 
methylation may still have profound effects on RNA expression. They could also 
represent a significant change in a rare cell population that nonetheless has important 
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biological functions (for example, a change in TH17 cells). Small absolute changes in 
DNA methylation in response to prenatal environmental exposures may be the expected 
response; DNA methylation perturbations on the order of magnitude encountered in 
cancer research may not be compatible with life in a developing fetus (Breton, Marsit et 
al. 2004).  
 DNA methylation was measured in whole blood, which may not be an appropriate 
indicator of DNA methylation in brain tissue across the genome (Hannon, Lunnon et al. 
2015, Bakulski, Halladay et al. 2016). However, a number of probe sites on the 450k 
platform show strong correlation between blood and brain regions, including prefrontal 
cortex, across individuals; while the absolute degree of methylation may or may not be 
comparable between blood and brain, inter-individual differences in methylation are 
conserved across tissues. While methylation in whole blood at positions chr3:12947823 
and chr1:110306507 is not tightly correlated with brain DNA methylation in matched 
samples, it is at position chr5:172903876 (Hannon, Lunnon et al. 2015) (Table 4.18 and 
Figure 4.19; see the Blood Brain DNA Methylation Comparison Tool at http://
epigenetics.essex.ac.uk/bloodbrain/). Although this tool is limited by its reliance on blood 
and brain samples from individuals 71 years of age and older, it does suggest that the 
differential methylation detected at chr5:172903876 in whole blood among the children 
whose mothers reported an infection prior to their pregnancy may reflect differential 
methylation in the child's brain as well. This would correspond to the second 
hypothesized model in our introduction for the relationship between blood and brain 
DNA methylation. 
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 There are several challenges that these data present, including potential exposure 
misclassification due to the retrospective maternal self-report of infection. In SEED, 
exposure data were collected retrospectively at the time of enrollment, which means that 
mothers may have been recalling their pregnancy exposures up to five years after 
delivery. This raises the possibility of recall bias, which may or may not be differential by 
ASD case status, though we would not suspect differential recall based on methylation 
levels. Indeed, we saw strong associations between several categories of infection 
exposure and ASD risk in the main effect analysis; we are not able to rule out that these 
associations are due to recall bias, though mothers in SEED were asked about a number 
of different exposures during their pregnancies, and not just about infection. 
 We also know that self-reported infection exposure is not ideal and may not 
reflect the same underlying construct as an infection diagnosis recorded in the medical 
record. Prospectively collected information on infections meeting standard case 
definitions, along with serologic confirmation of infection, during periconception, 
pregnancy, and the early postpartum period would in this case be the gold standard. We 
do have access to prenatal and labor and delivery records for SEED mothers, but an 
analysis based on their medical records has yet to be performed; although this method of 
exposure assessment may also be limited, as mothers may have had infections or fevers 
that were treated at home and never noted in their medical record. There may be more 
significant methylation differences related to in utero infection exposure that we were not 
able to detect due to a non-ideal exposure assessment. 
!149
Table 4.18: Correlations between DNA methylation in whole blood 
and four brain regions for the three significant infection-exposure 
DMPs  
PFC, prefrontal cortex; EC, entorhinal cortex; STG, superior temporal gyrus; CER, cerebellum 













































Figure 4.19: Correlation between methylation in whole blood at position 
chr5:172903876 and four brain regions, prefrontal cortex (PFC), entorhinal cortex (EC), 
superior temporal gyrus (STG) and cerebellum (CER), according to the Blood Brain 
DNA Methylation Comparison Tool (http://epigenetics.essex.ac.uk/bloodbrain/). 
 The derived variable available to us for this analysis collapsed many different 
infection types into variables reflecting exposure to any infection during specific time 
periods. The differential methylation that we found is thus detected based on a 
heterogeneous exposure; stronger associations between methylation and specific loci 
could exist when examining particular infection-methylation relationships. However, 
using more homogeneous exposure categories in the present study would have decreased 
our sample size and power to detect any association. 
 Multiple testing corrections is difficult to perform with epigenetic data, because of 
the known correlation between methylation at different probe sites. We did perform 
correction for multiple testing within each exposure category, calculating false discovery 
rates and performing a Bonferroni adjustment. However, we tested six different 
exposures, though these exposures are highly correlated (Table 4.19) and unlikely to be 
independently distributed. A strict Bonferroni cutoff (calculating the number of tests as 
six times the number of tested probes for each model) is likely to be inappropriate and 
overly conservative in this situation. 
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Table 4.19: Pearson's product-moment correlation between 
exposure variables 
  
 In our sample, we were unable to control for possible confounding or interaction 
with treatment for infection or fever. One previous study of the link between MIA 
exposure and ASD development did find an association between antibiotic use and ASD 
risk; however, they were unable to distinguish if this effect was observed because 
antibiotic use served as a proxy of MIA and infection, the true cause, or because it was 
independently contributing to disease (Atladottir, Henriksen et al. 2012). Another study 
found that anti-pyretics such as Tylenol actually attenuated an association between MIA 
and ASD (Zerbo, Qian et al. 2015). Unfortunately this kind of information is not 
T0 AP T1 T2 T3 BF
Infection in 3 months 
prior to conception 
(T0)
1
Infection at any time 
in pregnancy (AP)
0.20 1
Trimester 1 (T1) 0.44 0.53 1
Trimester 2 (T2) 0.28 0.63 0.37 1
Trimester 3 (T3) 0.21 0.71 0.32 0.34 1
Infection while 
breastfeeding (BF)
0.33 0.23 0.33 0.24 0.29 1
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currently available to us. It does however, suggest future directions and extensions for our 
work. 
 Future work will include analyses to detect differential methylation in children 
who were exposed to maternal immune activation during gestation, using other markers 
or exposures of MIA. These will include fever during pregnancy, biomarkers of 




Chapter 5: Conclusions and future directions 
 This dissertation represents an effort to understand the biological consequences of 
exposure to an inflammatory environment in utero on a child's later development. First, 
we reviewed what is currently known about the genetic and environmental risk factors for 
Autism Spectrum Disorder (ASD), including prenatal exposure to maternal immune 
activation (Chapter 1). Then, we tested for an association between maternal immune 
activation during pregnancy and later development of ASD in the child (Chapter 2). We 
found that self-reported flu or genitourinary infections during pregnancy were not 
associated with an increased risk of the exposed child developing ASD, but that fever 
exposure was significantly associated. We found suggestive evidence that fever exposure 
during the third trimester might be particularly relevant for ASD risk, though we were 
limited by imprecise effect estimates due to sample size. The significant association 
between in utero exposure to fever and ASD risk was robust to sensitivity analyses for 
outcome and exposure misclassification. 
 Currently, epidemiologic studies of MIA have focused more on exposure to 
infections like influenza than fever itself. Our study is only the third we are aware of that 
looks specifically at ASD risk after exposure to maternal fever during gestation, and the 
first that looks in a predominantly low-income, black American population. We suggest 
that future studies of prenatal risk factors for ASD collect information on fever during 
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pregnancy, including more detailed information on fever timing, severity, duration, and 
treatment, including the use of anti-pyretics or antibiotics.  
 We also explored ways to maximize the information obtained from electronic 
medical records for research phenotypes, to benefit future research on ASD risk factors, 
including MIA exposure, with large clinical cohorts (Chapter 3). We were able to 
identify ICD-9-CM diagnoses that are most predictive of a child's score on an ASD 
screening questionnaire, the Social Communication Questionnaire (SCQ), using a 
machine learning technique called Random Forests (RF). As would be expected, the 
presence of the diagnosis code for current or active ASD (299.00) is the strongest 
predictor of SCQ score, but several other diagnoses provided useful information, 
predominantly conditions related to developmental delay, language disorder, and 
behavioral disorders. Incorporating information on these related diagnoses in ASD case 
definition within an EMR data set could improve the sensitivity and specificity of 
outcome classification. We thus explored the use of Latent Class Analysis (LCA), using 
as observed characteristics what RF identified as the most predictive ICD-9-CM 
diagnoses for SCQ score or the presence of a prior 299.00 diagnosis. LCA shows promise 
as a method that identifies false positive or negative ASD cases, though we anticipate 
future ASD evaluation data from the Boston Birth Cohort to formally assess sensitivity 
and specificity compared to a gold standard. Future directions for this work include 
validating the patterns observed with RF and LCA; the Boston Birth Cohort continues to 
increase the numbers of completed SCQ and SRS questionnaires among study 
participants. Additional SCQ results will allow us to test the model in a training data set, 
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while SRS results will allow us to test for ICD-9-CM diagnoses' predictive abilities for a 
quantitative autism phenotype. 
 Next, we explored the hypothesis that epigenetics plays an important role in the 
interface between environment and expression of the genome or disease risk, and tested 
whether there are detectable epigenetic alterations in the white blood cells of young 
children who were exposed to maternal immune activation in utero (Chapter 4). We 
found evidence suggesting that epigenetic biomarkers of infection exposure—that 
occurred years prior, during gestation—can be detected in the whole blood of 2-5 year 
old children. Epigenetic changes resulting from prenatal exposures may be robust to 
postnatal exposures and persist through the first years of life, and perhaps even through 
adolescence. The set of loci or regions with differential methylation after exposure to 
prenatal infections could serve as a signature of past exposure regardless of disease 
status. This would be useful to exploit in future studies where we could predict exposure 
status based on measured DNA methylation levels, and then use it to test for primary 
associations between infection exposure and the outcome of interest. 
 We also found evidence that in this retrospective case-control study, maternal 
report of an infection during her pregnancy is associated with increased risk of ASD in 
her child. While this might be related to recall bias or differences in exposure assessment, 
as it is not consistent with the results from Chapter 2 which had prospective data on 
infection exposure and asked separately about exposure to flu or genitourinary infections, 
it does raise the possibility that DNA methylation could be a mediator of a causal 
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Appendices 
Appendix A: Primary Data Collection 
1. Experience with data management, quality assurance, and quality control in the Boston 
Birth Cohort:  
A. extraction of ICD-9-CM codes from electronic medical records, both from 
children during their pediatric care at the Boston Medical Center, and from 
the duration of their mother's prenatal care at the BMC 
B. QA/QC in the construction of a nested case-control study from the 
Children's Health Study pediatric cohort/construction of the analytic dataset 
2. Experience with data management, quality assurance, and quality control in a Kabuki 
Syndrome project with collaborators at the School of Medicine: 
A. QA/QC at the probe- and sample-level for epigenetic data, including 
reconciliation of predicted vs. recorded patient sex, annotation of mutation 
status  
B. normalization of data prior to further analysis 
3. Experience with data collection, management, quality assurance, and quality control in 
whole genome sequencing project of a strabismus family with collaborators at the 
School of Medicine: 
A. study design and data collection (choice of family members based on 
genetic distance and homogeneity of phenotype) 
B. data management and QA/QC of next generation sequencing data in 
preparation for analysis 
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Appendix B: Epigenome-wide Association Study of Kabuki Syndrome 
 This appendix describes work currently under review at the American Journal of 
Human Genetics, with contributions from co-authors Nara Sobreira, Li Zhang, Christine 
Ladd-Acosta, Chrissie Ongaco, Jane Romm, Kimberly F Doheny, Debora Bertola, Chong 
A Kim, Ana BA Perez, Maria I Melaragno, David Valle, Vera A Meloni, and Hans T 
Bjornsson. 
Kabuki syndrome: New genes and variants with evidence for interplay 
between histone and DNA methylation machineries 
 Abstract 
 Kabuki syndrome (KS) is a monogenic disorder caused by loss of function 
variants in either of two genes encoding histone-modifying enzymes. We performed 
targeted sequencing in a cohort of 27 probands with a clinical diagnosis of KS. Of these, 
12 had causative variants in the two known KS genes. In 2, we identified presumptive 
loss of function de novo missense variants in KMT2A, a gene that encodes another 
histone modifying enzyme previously exclusively associated with Wiedermann-Steiner 
syndrome. Surprisingly, we also find alterations in DNA methylation among individuals 
with a KS diagnosis relative to matched normal controls regardless of whether they carry 
variant in KMT2A or KMT2D or not. Furthermore, we observed characteristic global 
abnormalities of DNA methylation that distinguished patients with a loss of function 
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variant in KMT2D or missense changes in either KMT2D or KMT2A from normal 
controls. Our results provide new insights into the relationship of genotype to 
epigenotype and phenotype and indicate cross-talk between histone and DNA 
methylation machineries exposed by inborn errors of the epigenetic apparatus.
 Kabuki syndrome (KS; MIM 147920, 300867) is a pleiotropic disorder 
characterized by intellectual disability, postnatal growth retardation and dysmorphic 
facial features1,2. Defects of B cell differentiation are also frequent3. In about 75% of KS 
individuals, the disorder is inherited as an autosomal dominant trait caused by loss of 
function (LOF) variants in KMT2D1 (previously known as MLL2); in another 6% of the 
cases, the disorder shows X-linked dominant inheritance caused by LOF variants in 
KDM6A2. The explanation for the remaining ~20% of KS cases is unknown. 
KMT2D encodes lysine-specific histone methyltransferase (KMT2D) that 
catalyzes methylation of H3K4. KDM6A encodes a lysine-specific demethylase 
(KDM6A) that catalyzes removal of methyl groups from H3K27me3. Thus, both KS-
associated genes regulate histone tail methylation. Little is known about the target genes 
for KMT2D and KDM6A in normal human cells and their relevance to the KS 
phenotype4.  
 Wiedemann-Steiner syndrome (WSS; MIM 605130) is a rare autosomal dominant 
disorder caused by heterozygous loss of function variants in the KMT2A gene5. Jones et 
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al. identified heterozygous, de novo nonsense or indel variants in KMT2A in 5 out of 6 
individuals with a phenotype characterized by hypertrichosis cubiti, excessive hair on the 
back with a whorl-like distribution, long eyelashes, thick or arched eyebrows with a 
lateral flare, and down-slanting and vertically narrow palpebral fissures, sacral dimple, 
height bellow the 10th centile, mild to moderate intellectual disability and behavioral 
difficulties5. 
 Here we studied a large KS cohort to expand our knowledge of genotype-
phenotype relationships in KS. We performed targeted sequencing and genome-wide 
epigenomic analyses to: (1) identify novel genetic variants associated with KS, and (2) 
characterize KS-associated epigenomic patterns, generally, as well as the relationship 
between specific genetic variants identified in KS patients and epigenomic profiles. We 
examined 27 probands with a KS phenotype seen at Escola Paulista de Medicina, Sao 
Paulo and at Universidade de Sao Paulo, Brazil submitted to the Baylor-Hopkins Center 
for Mendelian Genomics (BHCMG) through the online submission portal PhenoDB6 as 
well as 9 samples from control individuals that were matched on age, sex and ethnicity. 
The clinical diagnosis was based on the presence of the most common features seen in 
KS7-8. We performed targeted next-generation sequencing of 9 genes (Table B.1), 
including the 2 genes known to cause KS (KMT2D and KDM6A, Table B.2); 2 genes 
known to cause ICF syndrome (DNMT3B and ZBTB24), a recognized genocopy of KS 
(Table B.2); and 5 candidate genes (KDM6B, MEN1, KMT2A, KMT2B, HCFC1) known 
to interact with or have overlapping function with known KS genes.  
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Table B.1: Genes selected for targeted sequencing 
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 We designed probes for targeted sequencing (TruSeq Custom Amplicon kit, 
Illumina) with the online Illumina DesignStudio software for all candidate genes 
including exon-intron boundaries. We prepared the sequencing library according to the 
manufacturer´s protocol and sequenced one library pool of 28 samples (27 individuals 
and 1 control) in a single run on a MiSeq sequencer (Illumina, 2 X 251 bp paired end 
reads). Alignment of NGS data to the human reference genome and variant calling were 
performed using software provided by Illumina. All variant calls were based on RefSeq 
transcript and NCBI human genome assembly build 37. We then used the Analysis Tool 
of PhenoDB9 to prioritize rare heterozygous and homozygous functional variants 
(missense, nonsense, splice site variants and indels) and excluded variants with a MAF > 
0.01 in the Exome Variant Server (release ESP6500SI-V2) or 1000 Genomes Project10 
and variants present in dbSNP 126, 129, or 131. Next we generated a heterozygous, 
homozygous and a compound heterozygous variant list for each subject and every 
candidate single nucleotide variant and indel were verified by inspection in Integrative 
Genomics Viewer11. 
 In 12 KS probands, we identified KMT2D variants: 3 with unique de novo 
heterozygous variants (Table B.3). Eight of the 12 KMT2D variants we identified are not 
present in the Exome Aggregation Consortium (ExAC) database, three variants are 
present as heterozygous variants in one individual each and one is present as a 
heterozygous variant in three individuals. In a fourth individual (KS11) we found a 
missense variant in KMT2D (p.N4572S) and a missense variant in KMT2B (p.E2354K). 
The KMT2D variant is rare (0.0008% in ExAc), does not involve a known protein domain 
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and has not been previously associated with KS, while the KMT2B variant is novel and 
alters a conserved residue (E2354). KMT2B is a histone methyltransferase that also 
targets H3K4, raising the possibility that in KS11 either or both of these variants 
contribute to the KS phenotype. The phenotype of individual KS11 does not seem to be 
atypical and fits the clinical diagnosis of KS. 
Table B.3: Summary of variants identified with targeted next-
generation sequencing among 26 individuals with clinically defined 
Kabuki syndrome 








Amino acid  
change Exon
Known KS genes
KS4 KMT2D c.14515+1G>T 47 N 0 +
KS7 KMT2D c.C12268T p.Q4090X 39 N 0 +
KS9 KMT2D c.5124_5125del p.T1708fs 21 N 0 +
KS11 KMT2D c.A13715G p.N4572S 41 N 0.0008% ̶
KS12 KMT2D c.11582_11583insGCAp.Q3861delinsQQ 39 N 0.005% +
KS13 KMT2D c.C185T p.P62L 3 Mother  (not present) 0.002% +
KS14 KMT2D c.1329_1332del p.P443fs 10 N 0.0009% +
KS15 KMT2D c.6595delT p.Y2199fs 31 Y (de novo) 0 +
KS19 KMT2D c.15920_15921insT p.S5307fs 49 Mother  (not present) 0 +
KS21 KMT2D c.13207_13208del p.N4403fs 39 Y (de novo) 0 +
KS22 KMT2D c.C12304T p.Q4102X 39 Y (de novo) 0 +
KS24 KMT2D c.C11800T p.Q3934X 39 N 0 +
Other candidate genes sequenced
KS8 KMT2A c.G3019T p.G1007C 3 Y (de novo) 0 +
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KS, Kabuki Syndrome; KMT2A, lysine (K)-specific methyltransferase 2A; KMT2D, lysine (K)-specific 
methyltransferase 2D; HCFC1, host cell factor C1; DNMT3B, DNA methyltransferase 3 beta; ZBTB24, 
zinc finger and BTB domain containing.  
aKS11 was removed from the methylation analysis because it had variants in both KMT2B and KMT2D, 
and was unique in that the KMT2D variant was a missense variant of unknown functional consequence.  
bFor KS1-3, 6, 16-17, 20, 26-28 no mutation was found.  
cPlus and minus signs indicate a sample was included or excluded from DNA methylation analyses, 
respectively. KMT2D transcript identifier is NM_003482, KMT2A transcript identifier is NM_001197104, 
HCFC1 transcript identifier is NM_005334, ZBTB24 transcript identifier is NM_001164313, KMT2B 
transcript identifier is NM_014727, DNMT3B transcript identifier is NM_006892.  
dIn one female individual (KS5) we identified a heterozygous variant in HCFC1 (MIM 309541), a gene 
known to be responsible for an X-linked disorder phenotypically distinct from KS (Table S2). 
 We also found two individuals with a typical KS phenotype (KS8 and 29) who 
had normal KMT2D and KDM6A sequence but had novel de novo heterozygous missense 
variants in KMT2A, a histone methyltransferase gene previously associated with 
Wiedemann-Steiner syndrome (WSS). WSS is a disorder with overlapping features with 
KS5 such as vertically narrow palpebral fissures, strabismus, broad nasal bridge/tip, 
external ear deformity, short stature, hypotonia, small hands, hip abnormalities, 
developmental delay, intellectual disabilities, seizures, feeding difficulties, hypertrichosis, 
heart anomalies, urological anomalies, and recurrent infections (Table B.2). Review of 
the phenotype of the two individuals with the KMT2A variants confirmed the clinical 
diagnosis of KS (Figure B.1a and B.1b). The comparison of their facial features to the 
patients diagnosed with WSS revealed significant facial similarities with the patients 
KS29 KMT2A c.5803-1G>A 22 Y (de novo) 0 +
KS5 HCFC1 c.C3795T p.S1265L 17 N 0.07% ̶
KS10 ZBTB24 c.G146A p.R49Q 2 Mother  (not present) 0.6% ̶
KS11 KMT2B c.G7060A p.E2354K 30 N 0 ̶
KS18 DNMT3B c.A1211G p.Y404C 11 N 0.8% ̶
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described by Jones et al. (WSS-5)5, Mendelssohn et al. (2014)12 and Stellacci et al. 
(2016)13. These results suggest a significant phenotypic overlap between KS and WSS 
suggesting that pathological variants in KMT2A should be considered in KS individuals 
who lack variants in KMT2D or KDM6A. Interestingly, the proteins encoded by the 
KMT2A and KMT2D (WSS and KS, respectively) genes have many of the same domains 
(Figure B.1c). We also identified an individual (KS18) with a heterozygous variant in 
DNMT3B and one individual (KS10) with a heterozygous variant in ZBTB24. Both of 
these genes have previously been associated with ICF syndrome, an autosomal recessive 
known genocopy of KS (Table B.2). These patients have a typical KS phenotype without 
any atypical features or history of recurrent infections. Individual KS7 had a KMT2D 
p.Q4090X variant and an atypical feature, hypoplasia/aplasia of the medial and/or distal 
phalanges of the toes bilaterally. Similarly, individual KS15, with the KMT2D p.Y2199fs 
variant, had shortening of the medial phalange of the 2nd and 5th fingers bilaterally and 
syndactyly of the 4th and 5th toes bilaterally. Skeletal anomalies are characteristics of KS 
but they most commonly affect the hands, not the feet and toes. In thirteen KS probands 
(48%) we failed to identify likely pathogenic variants in any of the 9 genes. This negative 
result is similar to that (36%) of a recent large sequencing study of patients with KS12. 
Direct Sanger sequencing of PCR amplified products validated all variants and confirmed 
appropriate Mendelian segregation in available family members (Table B.3).  
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Shared facial features in patients with variants in two Trithorax orthologs (KMT2A
and KMT2D). Facial features (left) in two patients identified as KS29 (A) and KS8 (B) 
led to a clinical diagnosis of Kabuki syndrome. Here we have summarized the observed 
phenotype (right). These two patients suggest that there is phenotypic overlap between 
Kabuki and Wiedemann-Steiner syndromes, two disorders that are caused by variants in 
two independent Trithorax orthologs (KMT2A and KMT2D). The domain structure of the 
two orthologous proteins (C). Domain structure is based on InterPro. 
 To further elucidate potential mechanisms of the primary histone alterations 
occurring in KS, we measured DNA methylation levels across the genome in a total of 44 
samples including 27 KS and 9 age- and sex-matched control samples. 1125 ng of 
genomic DNA was prepared, for each sample, in a total volume of 45µl and bisulfite 
treated using the EZ DNA Methylation kit (Zymo Research Corp, Orange, CA, USA), as 
specified by the manufacturer for use with 450K arrays. To obtain genome-scale 
methylation measurements, bisulfite treated DNA was processed on the Infinium 
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HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) at the Johns Hopkins 
SNP Center in accordance with the manufacturer’s recommendation. The Infinium 
HumanMethylation450 BeadChip measures DNA methylation levels at 485,512 loci 
across the genome. A total of 44 samples, including 27 KS samples and 9 non-KS 
controls were randomized across (4) 12 array BeadChips to minimize potential 
confounding batch effects. For quality control purposes we also included technical 
control samples with known amounts of DNA methylation (0%, 25%, 50%, 75%, and 
100% methylated). All data preprocessing steps and statistical analyses were performed 
using R-3.1.2 and Bioconductor 3.015. Using the ‘minfi’ package16, we applied several 
quality control measures including removal of samples with low overall array intensities 
(n=0), as well as removal of poorly performing probes (n=2,633), defined as having a 
detection p value greater than 0.01 in any sample. Two of the samples had a predicted sex 
that was discordant with the sample annotation, which was reconciled with clinical notes 
before proceeding. After dropping parental controls (n=6) due to the known epigenetic 
changes that occur with aging, thirty-eight samples, including 9 age- and sex-matched 
controls, and 2 samples who were later removed from further analysis due to a change in 
their KS diagnosis, were retained for calculation of principle components for ancestry 
adjustment20. All samples then underwent quantile normalization and beta values were 
logit-transformed to create M-values, which are normally distributed and therefore more 
appropriate for statistical testing17. Because the DNA methylation measurements were 
obtained from whole blood samples with a heterogeneous mix of nucleated white cells, 
we estimated the proportion of B cells, CD4 and CD8 positive T cells, natural killer cells, 
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monocytes, and granulocytes18. Although we did not find significant differences (p<0.05) 
in cell composition between KS and control individuals, we adjusted for cell composition 
estimates in our analyses to identify KS-associated methylation changes. 
 Initial genome-wide analyses comparing all KS samples to controls revealed 
differences in DNA methylation that appeared to be mainly driven by samples with a 
detected mutation in a histone machinery gene (KMT2A/KMT2D) (Figure B.2). Based on 
this observation, the fact that we had a relatively large number of samples with a 
mutation in a histone machinery genes, and because we were interested in identifying 
downstream epigenetic changes related to mutations in chromatin machinery genes, we 
decided to focus our primary genome-wide screening analyses on identifying differences 
in DNA methylation associated with KS among individuals with a molecularly confirmed 
variant in the histone machinery. Therefore, we removed 16 samples from our DNA 
methylation analyses that did not have a variant in the histone methylation machinery 
genes we examined as well as 1 sample that had a variant in more than 1 gene, leaving us 
with 13 KS cases and 9 controls (n=22). This left a total of 13 blood samples obtained 
from individuals with a clinical diagnosis of KS and defects in the histone machinery 
(KMT2A and KMT2D variants) as compared to 9 age and sex matched control 
individuals (Figure B.3). Differentially methylated positions (DMPs) were identified 
using limma19 and linear regression models were adjusted for sex, blood cell 
composition, and ancestral population20. Differentially methylated regions (DMRs) were 
identified using bumphunter21; the analytic model was adjusted for sex, blood cell 
composition, and ancestral population20. DMR significance was assessed using 
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bootstrapping as available in minfi16 and a family-wide error rate threshold of 0.05 was 
applied.  
Figure B.2: An example of a differentially methylated region (DMR) identified by 
comparing all KS samples to normal controls.  
 Differences appear to be driven by samples with a KMT2D/KMT2A variant. We 
therefore decided to focus on molecularly confirmed KS samples for primary genome-
wide screening purposes. Genomic location is plotted on the x-axis and percent 
methylation on the Y-axis. Blue, purple, and black points denote individuals harboring a 
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controls KMT2D/KMT2A KS with no or other mutations
!  
Figure B.3: A flow chart describing sample numbers analyzed in each stage of our 
analysis.  
 Since position on array is a potential source of bias we explored the location of 
our samples. We noted that many of the control samples were processed in rows 5 and 6 
and many of the KS samples were processed in rows 1-4 of the Illumina BeadChip. To 
confirm that the DNA methylation changes related to KS were not solely attributable to 
array position, we plotted DNA methylation values and array row position for the DMRs 
reported here (Figure B.4). We observed overlapping DNA methylation levels among 
samples processed in rows 1-6; thus, DNA methylation values at these KS-related sites 
are not purely driven by row alone. Furthermore, our findings for these regions were 
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validated using bisulfite pyrosequencing, an independent and highly reliable method, 
where array row and location is irrelevant. 
 When we compared DNA methylation in 13 KS probands with 9 age and sex-
matched controls (Figure B.3) we found 57 differentially methylated loci, at an 
FDR<0.05, associated with KS (Table B.4). Two CpG sites in two independent genes 
(CIRBP, FEM1B) show relative hypomethylation among individuals with KS and histone 
machinery variants compared to controls (Figure B.5a-b). Similarly, Figure B.5c-d shows 
an example of two genes (c10orf11, SOX18) that are hypermethylated in KS relative to 
controls. We also used bumphunter21, as an alternative analysis to identify differentially 
methylated regions (DMRs) and found several genomic regions showing KS-related 
differences in methylation (Table B.5). Although none of these regions reached genome-
wide statistical significance in our relatively small sample, several showed striking 
differences in methylation between KS and controls. Figure B.6a provides an example of 




Figure B.4: Plots showing the relationship between DNA methylation level and 
sample row at two KS-associated DMRs, MYO1F DMR (A) and LAMB2 DMR (B).
KS and control samples are denoted by circles and triangles, respectively. Array 
row location is denoted by color with row 1 shown in red, row 2 shown in orange, row 3 
shown in green, row 4 shown in aqua, row 5 shown in blue, and row 6 shown in purple. 
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Table B.4: Differentially methylated positions (DMPs) significantly 
associated (FDR<0.05) with KS patients harboring variants in 
histone methylation machinery genes compared to non-KS controls 





chr19 1272853 CIRBP -7.7% 6.70E-08 0.0167
chr15 68571585 FEM1B -6.2% 6.90E-08 0.0167
chr19 45720949 EXOC3L2 -15.0% 1.62E-07 0.0186
chr2 114196091 CBWD2 -3.6% 1.91E-07 0.0186
chr16 88871329 CDT1 -7.7% 1.93E-07 0.0186
chr6 15506085 JARID2 -10.2% 4.14E-07 0.0317
chr10 77871958 C10orf11 6.5% 5.09E-07 0.0317
chr20 62681428 SOX18 5.4% 5.25E-07 0.0317
chr19 45737623 EXOC3L2 -16.7% 8.29E-07 0.0332
chr10 77872084 C10orf11 9.1% 1.02E-06 0.0332
chr17 80202961 CSNK1D -10.8% 1.03E-06 0.0332
chr4 145655974 HHIP 8.4% 1.06E-06 0.0332
chr15 30206862 7.2% 1.11E-06 0.0332
chr20 62681243 SOX18 15.2% 1.12E-06 0.0332
chr1 152595992 LCE3A 6.7% 1.19E-06 0.0332
chr1 10699604 CASZ1 5.8% 1.24E-06 0.0332
chr11 859670 TSPAN4 -9.0% 1.42E-06 0.0332
chr22 45094531 PRR5 11.9% 1.50E-06 0.0332
chr7 55086890 EGFR 1.9% 1.51E-06 0.0332
chr17 73630199 RECQL5 4.2% 1.52E-06 0.0332 rs185961263
chr3 45077254 CLEC3B 6.7% 1.57E-06 0.0332
chr19 51171712 SHANK1 -4.3% 1.58E-06 0.0332
chr19 1873591 -9.9% 1.58E-06 0.0332
chr17 79816559 P4HB -10.7% 2.04E-06 0.0402
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Table B.4 continued
chr3 96168838 6.1% 2.12E-06 0.0402
chr15 47477911 9.5% 2.16E-06 0.0402
chr18 60264554 -5.2% 2.37E-06 0.0412
chr19 45720771 EXOC3L2 -9.5% 2.40E-06 0.0412
chr16 57918043 CNGB1 5.7% 2.47E-06 0.0412
chr4 5708474 EVC2 -10.0% 2.68E-06 0.0419
chr12 50017412 PRPF40B -4.5% 2.69E-06 0.0419
chr2 20442088 4.9% 2.84E-06 0.0428
chr9 132386878 2.5% 3.02E-06 0.0437
chr15 30216986 11.8% 3.07E-06 0.0437
chr14 91862864 CCDC88C 6.9% 3.27E-06 0.0437
chr15 30175531 9.1% 3.30E-06 0.0437
chr9 44420179 4.1% 3.56E-06 0.0437
chr11 98940816 CNTN5 -6.2% 3.69E-06 0.0437
chr2 105276153 6.6% 3.72E-06 0.0437
chr16 88152486 11.7% 3.74E-06 0.0437
chr2 8978042 KIDINS220 5.8% 3.75E-06 0.0437
chr7 4778881 FOXK1 6.0% 3.84E-06 0.0437
chr10 77871618 C10orf11 10.2% 3.89E-06 0.0437
chr11 850296 TSPAN4 -12.8% 4.11E-06 0.0451
chr19 18260515 MAST3 -8.8% 4.36E-06 0.0461
chr17 79426432 BAHCC1 -4.8% 4.47E-06 0.0461
chr11 910094 CHID1 -3.7% 4.49E-06 0.0461
chr11 71276654 KRTAP5-10 -8.4% 4.76E-06 0.0472 rs188029416
chr11 89169539 NOX4 5.6% 4.79E-06 0.0472 rs76916726
chr19 846179 PRTN3 -4.6% 5.18E-06 0.0486
chr5 176790179 RGS14 9.7% 5.19E-06 0.0486
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a Difference in mean methylation levels between patients with KS and variants in histone 
machinery genes and non-KS control groups. Positive values reflect relative hypermethylation 
and negative values relative hypomethylation in individuals with KS compared to controls. 
b Denotes which probes have an annotated SNP at the measured CpG site and provides 
the SNP identifier. SNP annotation information was based on dbSNP137 and was obtained using 
the getAnnotation() function from the minfi14 Bioconductor package. 
Figure B.5: Differentially methylated positions in individuals with a Kabuki 
syndrome phenotype 
a.      b. 
Table B.4 continued
chr1 147253401 6.4% 5.23E-06 0.0486
chr5 173021074 -5.2% 5.59E-06 0.0499
chr2 132152878 5.8% 5.65E-06 0.0499
chr6 100882035 SIM1 6.7% 5.72E-06 0.0499
chr19 815090 LPPR3 -11.1% 5.81E-06 0.0499
chr22 19710163
GP1BB; 
SEPT5 10.3% 5.89E-06 0.0499
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c.      d. 
Table B.5: Top 10 differentially methylated  
Individuals with Kabuki syndrome phenotype and a variant in a histone 
methylation machinery gene, either KMT2D or KMT2A, show site-specific hyper- 
and hypo-methylation relative to non-KS controls. Genomic loci showing significant 
relative loss of methylation (CIRBP, FEM1B) in KS samples compared to controls (a, b). 
Genomic loci showing significant gain of methylation (c10orf11, SOX18) in KS samples 
compared to controls (c, d). Blue and black points denote KS and non-KS controls, 
respectively. Light green points denote the two individuals with KMT2A variants.  
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Table B.5: Top 10 differentially methylated regions (DMRs) associated with 
individuals with KS and variants in a histone methylation machinery gene 



























































































 To validate these results with an independent assay and to determine whether 
similar changes in DNA methylation exist in KS samples without a known histone 
machinery variant we performed bisulfite pyrosequencing for 36 individuals including 12 
with KMT2D or KMT2A variants and KS diagnosis and 14 without KMT2D/KMT2A 
variants with KS diagnosis and 10 controls. PCR Primers and sequencing primers were 
designed by MethPrimer22 and are available by request. We bisulfite treated all samples 
used for the Genome Scale DNA methylation measurement and available parents 
(Controls = 16, no KMT2D mutation = 17, KMT2D/KMT2A mutation = 13). After 
bisulfite treatment, only a subset of these samples had the minimal amount needed for 
PCR-based studies (Controls = 7, no KMT2D/KMT2A mutation = 12, and KMT2D/
KMT2A mutation = 13) and these were used for the validation studies. Bisulfite treated 
genomic DNA23 was PCR amplified (50-cycles) in a total of 25ul volume and 5ul were 
loaded onto agarose gel to verify single, strong product and an absence of any unused 
primers. The biotinylated PCR product was captured on streptavidin-coated sepharose 
beads (GE Healthcare, Milwaukee, WI) and pyrosequencing reaction were set up using 
the PyroMark Gold Q24 kit (Qiagen), according to the manufacturer’s instructions. Each 
individual pyrosequencing assay was designed with PyroMark Q24 software and the 
percentage of methylation at each CpG site was analyzed with PyroMark Q24 software. 
We set the p-value threshold for significance to <0.05. Consistent with our array-based 
findings, KS individuals with a KMT2D or KMT2A variant show relative 
hypomethylation at the MYO1F locus (Figure B.6b), however, we also noted that patients 
with a KS phenotype but without molecular confirmation also demonstrated relative 
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hypomethylation. Similarly, we also identified hypermethylated DMRs in KS. For 
example, we observed a 20% increase in methylation in KS samples on average, at a 
DMR located in the 5’ UTR region of the LAMB2 gene (Figure B.7a and Table B.5) 
which was similarly validated by pyrosequencing in patients with variants in KMT2D/
KMT2A (Figure B.7b). Again, we observe a similar methylation pattern in patients with a 
KS phenotype but no discovered variants. These results imply shared downstream targets 
among individuals with a KS phenotype despite locus heterogeneity for the causative 
variant.  




Example of a differentially methylated region (DMR), within the MYO1F gene, 
associated with Kabuki syndrome phenotype and histone methylation machinery 
gene variants (KMT2D or KMT2A). A differentially methylated region (DMR), detected 
via the 450K platform, shows less methylation, on average, among individuals with a 








































































panel displays genomic location on the x-axis and percent methylation on the Y-axis. 
Inset top panel shows methylation values assessed using bisulfite pyrosequencing for the 
CpG sites denoted by the solid red line. Blue, green, and black points denote individuals 
harboring a KMT2D variant, a KMT2A variant, and controls, respectively. Red asterisks 
denote significant differential methylation, via bisulfite pyrosequencing, between KS 
samples with histone machinery variants and control samples. The middle panel shows 
individual probe-based nominal p-values for differences in methylation between the two 
groups (KS and control), with the dashed red line at a level of p = 0.01. The bottom panel 
provides gene annotation information for the differentially methylated region. Boxplots 
comparing bisulfite pyrosequencing derived DNA methylation levels among individuals 
with histone machinery variants and KS, individuals with no detected genetic variants in 
our targeted sequencing screen and KS, and control individuals without KS (b). Samples 
from individuals with KS phenotype are shown in blue and control samples are shown in 
white. The x-axis denotes the genetic variant group plotted and the y-axis plots the DNA 
methylation level detected via bisulfite pyrosequencing. Upper and lower hinges of the 
boxplots correspond to the 75th and 25th percentiles. The upper whisker extends to the 
highest value within 1.5 times the interquartile range beyond the upper hinge; the lower 
whisker extends to the lowest value within 1.5 times the interquartile range beyond the 
lower hinge. Outliers beyond the end of the whiskers are represented as points. *p<0.05; 
**p<0.01 
!208




Relative hypermethylation, at the LAMB2 locus, associated with Kabuki syndrome 
phenotype and histone methylation machinery gene variants (KMT2D or KMT2A) 
compared to controls. A differentially methylated region (DMR) detected via the 450K 
platform, shows more methylation, on average, among individuals with a histone 
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Bisulfite pyrosequencing results for Lamb2 locus
Kabuki Syndrome phenotype
controls
panel displays genomic location on the x-axis and percent methylation on the Y-axis. 
Inset top panel shows methylation values assessed using bisulfite pyrosequencing for the 
CpG sites denoted by the solid red line. Blue, green, and black points denote individuals 
harboring a KMT2D variant, a KMT2A variant, and controls, respectively. Red asterisks 
denote significant differential methylation, via bisulfite pyrosequencing, between KS 
samples with histone machinery variants and control samples. The middle panel shows 
individual probe-based nominal p-values for differences in methylation between the two 
groups (KS and control), with the dashed red line at a level of p = 0.01. The bottom panel 
provides gene annotation information for the differentially methylated region. Boxplots 
comparing bisulfite pyrosequencing derived DNA methylation levels among individuals 
with histone machinery variants and KS, individuals with no detected genetic variants in 
our targeted sequencing screen and KS, and control individuals without KS (b). Samples 
from individuals with KS phenotype are shown in blue and control samples are shown in 
white. The x-axis denotes the genetic variant group plotted and the y-axis plots the DNA 
methylation level detected via bisulfite pyrosequencing. Upper and lower hinges of the 
boxplots correspond to the 75th and 25th percentiles. The upper whisker extends to the 
highest value within 1.5 times the interquartile range beyond the upper hinge; the lower 
whisker extends to the lowest value within 1.5 times the interquartile range beyond the 




 We also performed unsupervised analyses, using hierarchical clustering, to 
evaluate epigenetic patterns, more globally, using the top 10% most variably methylated 
probes on the 450K. For the clustering the 482,879 probes that passed QC measures 
where then restricted to autosomal probes to prevent clustering solely on the basis of 
patient sex. 11,587 probes on the X and Y chromosome were removed to leave 471,292 
autosomal probes. Then we subset to the top 10% of variably methylated probes, leaving 
47,130 probes across 22 samples from which a dissimilarity structure was produced using 
the dist() function in R. Hierarchical clustering was performed with the hclust() function 
on this dissimilarity structure with the complete linkage method. As shown in Figure B.8, 
we observed strong clustering of the KS samples with KMT2D loss of function variants 
as well as a cluster of samples primarily comprised of the KMT2D/KMT2A missense 
variants. These clusters did not show association with other covariates (Figure B.8 and 
Table B.6). Thus, DNA methylation patterns, at a more global level appear to be related 
to the type of histone methylation machinery mutation present in KMT2D and KMT2A. 
Although this would support the notion that a Kabuki Syndrome phenotype is associated 
with a particular epigenotype, it also raises the possibility that specific classes of variants 
may have unique epigenetic signatures which could act as a biomarker of the disease 
state; however, further studies will be needed to clarify this. 
 Although the primary defect in KS is a defect in the histone machinery, it is 
noteworthy that we also observe site-specific DNA methylation changes relative to 
controls. DNA methylation abnormalities have also been found in Sotos syndrome (SS, 
117550, 614753)24, another histone methylation machinery disorder. The SS changes 
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appear more extensive, although the published results do not correct for cell composition 
or other relevant covariates (sex and ancestry). NSD1, the protein product of the gene 
most frequently defective in SS, adds both open and closed chromatin modifications 
(H3K36 and H4K20) whereas KMT2A/D only adds open chromatin modifications 
(H3K4). Therefore, it is possible that the increased number of DNA methylation changes 
identified in SS compared to KS reflects biologically meaningful differences related to 
the function of the different histone modifying proteins involved in each disorder. The 
DNA methylation abnormalities found in SS, WSS and KS suggest interactions between 
histone and DNA methylation machineries. Additionally, they provide a potential 
explanation for phenotypic overlap among the Mendelian disorders of the epigenetic 
machinery4 (Table B.2).  
 There has been long standing debate regarding the directionality of epigenetic 
information flow, i.e. whether DNA methylation dictates histone modification25 or 
whether histone modification lead to downstream DNA methylation changes26,27. Cells 
from patients with ICF syndrome (MIM 242860, 614069, 616910, 616911), a condition 
caused by mutations in a de novo DNA methyltransferase and interacting proteins, 
demonstrate global DNA hypomethylation28 but also secondary abnormalities of histone 
modification28. Our data show that individuals with KMT2A/D mutations also have site-
specific DNA methylation changes; thus, providing support for histone modification 
leading to downstream DNA methylation changes. These results together with those 
published for SS and ICF suggests that the information flow is bi-directional forming a 
feedback loop among individual epigenetic machineries. Our data also suggest that DNA 
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methylation signatures could be diagnostic markers for KS as well as specific types of 
KS-related variants. 
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Figure B.8: Hierarchical clustering dendrogram, based on the 10% most variably 
methylated probes, shows differences in DNA methylation patterns based on type of 
genetic variation within the histone machinery genes KMT2A and KMT2D.
 Here we depict loss of function KMT2D variants (red) and KMT2D missense 






















































































































































































































































































KMT2D missense variants, indicating that epigenetic similarities may account for 
phenotypic overlap. 
Table B.6: Estimated amount of each cell type. No patterns emerge 
to suggest cell type composition drives clustering 
CD8 T-cells CD4 T-cells NK B-cells Monocytes Granulocytes
Con1 0.100 0.136 0.034 0.097 0.026 0.623
Con2 0.103 0.113 0.011 0.055 0.228 0.519
Con3 0.042 0.117 0.088 0.026 0.125 0.595
Con4 0.145 0.245 0.000 0.088 0.050 0.478
Con5 0.200 0.228 0.009 0.156 0.013 0.399
Con6 0.072 0.168 0.097 0.059 0.031 0.578
Con7 0.094 0.187 0.032 0.047 0.052 0.596
Con8 0.180 0.214 0.022 0.198 0.039 0.339
Con9 0.144 0.136 0.073 0.189 0.059 0.427
PAT12 0.103 0.065 0.000 0.105 0.088 0.635
PAT13 0.213 0.091 0.042 0.121 0.103 0.433
PAT14 0.016 0.114 0.000 0.235 0.151 0.474
PAT15 0.094 0.237 0.000 0.147 0.064 0.449
PAT19 0.101 0.082 0.001 0.062 0.077 0.679
PAT21 0.157 0.122 0.000 0.095 0.086 0.529
PAT22 0.128 0.218 0.000 0.063 0.045 0.536
PAT24 0.044 0.225 0.032 0.131 0.109 0.438
PAT29 0.072 0.150 0.223 0.040 0.059 0.424
PAT4 0.142 0.143 0.136 0.097 0.097 0.402
PAT7 0.092 0.194 0.034 0.178 0.073 0.429
PAT8 0.097 0.231 0.019 0.160 0.069 0.422
PAT9 0.038 0.137 0.000 0.057 0.092 0.668
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